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ABSTRACT 
 
Two-Armed Molecular Receptors – 
Peptide Recognition and Vesicle Formation 
Driven by Selective Non-Covalent Interactions 
 
Jessica Grun 
 
 
 
This thesis presents examples for applying encoded combinatorial chemistry to trace 
molecular interactions between two-armed receptors and peptidic substrates that could have 
not been predicted by conventional means. Starting from these selective non-covalent 
interactions, applications, like supramolecular self-assembly, were investigated in organic 
and aqueous media. 
In the first part the synthesis of macrocyclic diketopiperazine receptors and their 
binding properties towards peptides is described. Combinatorial on-bead studies showed that 
both macrocyclization of the receptor and choice of the linker-type lead to significant 
changes in the binding properties compared to their flexible open-chain parent 
diketopiperazine receptors. Macrocyclization rigidifies the receptor and should induce a 
higher preorganisation. Thus, the conformations of the macrocyclic receptors were expected 
to differ from the open-chain diketopiperazine receptor prototype. Binding studies revealed 
that macrocyclization led not only to lower binding selectivities but also lower affinities 
toward peptidic guest compared to the open-chain parent receptors. Thus, the flexibility of 
the open-chain receptor allows the arms to better adjust to a peptidic guest and can be 
beneficial for selective and higher binding. 
The second part describes the development of a new class of two-armed receptors 
consisting of a rigid carbazole backbone and peptidic side-chains which allow for structural 
as well as functional variations. Compared to the diketopiperazine template, a third 
functionality is present and allows for attachment of a dye, polymer chain or resin, at the 
opposite site of the recognition modules. Combinatorial binding studies and solid phase 
binding assays showed that these carbazole receptors interact with certain tripeptides, in 
organic solvents, with sequence selectivities and binding affinities that are comparable to 
  
those of diketopiperazine receptors. These two-armed receptors have been the basis for the 
design of receptor libraries to identify selective receptors for interesting peptidic and non-
peptidic substrates.  
In the third part, selective non-covalent interactions between a diketopiperazine 
receptor and peptide-PEG conjugates were used to induce the assembly of vesicles in 
aqueous solution. The vesicles were analysed by a combination of light scattering, electron 
transmission and atomic force microscopy as well as surface pressure measurements. Vesicle 
formation was found to be independent of the ratio of receptor to ligand and relies upon 
selective receptor-peptide interactions. Other peptide-PEG conjugates did not assemble into 
vesicular structures when mixed with the receptor. 
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1 INTRODUCTION 
 
1.1 From Synthetic Receptors to Tweezer-like Receptors 
 
Over the past decade a lot of effort has been made in order to design synthetic 
receptors with specific binding properties towards small peptides.[1-5] Many research groups 
have focused on the study of small synthetic hosts in order to gain insight into the principles 
governing non-covalent molecular interactions such as hydrogen bonds and ionic and 
hydrophobic interactions. Understanding the basis of these interactions by synthesizing 
molecules able to mimic and block the action of natural compounds with a high degree of 
specificity, is of enormous importance in the discovery of new therapeutic agents for the 
treatment of many diseases. Studying the selective recognition of peptides by synthetic 
receptors is not only of importance as a model for the study of biological protein-protein 
complex interactions but also for the development of novel specific chemosensors.[1,6] 
Furthermore, synthetic receptors can be immobilized on a solid phase and used as chiral 
stationary phases for the separation of peptides.[7] In this respect, the discrimination 
between enantiomeric as well as diastereomeric peptides is of particular interest.  
The interaction between two molecules is a very sensitive process and slight 
structural modifications can lead to tremendous changes in the binding properties. The 
example of the antibiotic vancomycin demonstrates this subtlety of intermolecular 
interactions between small molecules.[8] Vancomycin is a macrotricyclic glycoheptapeptide 
which exerts its main bactericidal effect through inhibition of cell wall formation of gram-
positive bacteria. Although rather small in size it binds strongly and selectively to the 
tripeptide N-acyl-Lys-D-Ala-D-Ala, a crucial component in the cell wall crosslinking of gram 
positive bacteria.[9] In the last few years this defence strategy against pathogenic bacteria 
appears to be endangered by the ability of bacteria to evolve rapidly into drug-resistant 
strains. Resistance is effected by the biosynthesis of an altered cell wall precursor ending in 
N-acyl-Lys-D-Ala-D-Lac.[10] Replacement of the terminal D-alanine with D-lactate introduces a 
repulsive electrostatic interaction of the oxygen with vancomycin instead of a hydrogen bond 
resulting in an approximately 1000-fold reduction in binding affinity (Figure 1).[11] This is one 
clear example showing that slight structural modifications (the substitution of a single atom) 
can induce significant changes in the binding properties. The identification of synthetic 
receptors that bind with high affinity to N-acyl-Lys-D-Ala-D-Lac could provide a powerful 
strategy for overcoming vancomycin resistance.[12] 
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Figure 1: Repulsive electrostatic interaction in Vancomycin binding N-acyl-Lys-D-Ala-D-Lac 
 
In recent years, much work in the area of peptide receptors has focused on ‘tweezer-
like receptors’.[13] This simple design for receptors consists of a template with two peptidic or 
sulfonopeptidic recognition elements (Figure 2).[14-19] Within the receptor structure, the 
receptor arms are considered as the selectivity determining modules, while the template 
serves as a rigid, structure-directing module. In spite of their structural flexibility many of 
such two-armed receptors bind peptidic guests with moderate to excellent selectivities and 
affinities. The lack of apparent preorganization within the receptor structure, combined with 
the many degrees of freedom of even simple di- and tripeptides, renders the rational design 
of such receptors for specific peptide sequences an extremely challenging task. During the 
last decade, combinatorial chemistry has become very promising in the search of suitable 
substrates for a given receptor and vice versa.[20,21] 
Yet, most of the examined receptors exhibit drawbacks such as either poor binding 
selectivities, rather laborious syntheses or limited possibilities for tuning the receptor 
structures. 
 
 
 
 
 
Vancomycin
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Figure 2: Examples of two-armed receptors that bind short peptides (dye = disperse red 1) 
 
In order to overcome these problems, we aimed to develop a new class of two-armed 
receptors based on diketopiperazine and carbazole scaffolds that offer facile synthesis, high 
variability and structural rigidity. Furthermore, the use of amino acids as building blocks 
offers the possibility to employ these receptors as models to understand peptide-peptide 
interactions.  
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1.2 Combinatorial Chemistry 
 
The advent of combinatorial chemistry in the early 1990s has revolutionized the 
discovery process of new therapeutics.[20,21] While it was first applied mainly in bioorganic 
and medicinal chemistry, it has since spread to other fields like material science[22] and 
catalyst development.[23-24] 
The principle of combinatorial chemistry is to synthesize a large number of different 
molecules at the same time - instead of synthesizing compounds in a conventional one-at-a-
time manner - and then to identify the most promising compound by high-throughput 
screening, for further development. The characteristics of combinatorial synthesis are that 
different compounds are generated simultaneously under identical reaction conditions in a 
systematic manner, so that in the ideal case the products of all possible combinations of a 
given set of starting materials (building blocks) will be obtained at once. The collection of 
these synthesized compounds is referred to as a combinatorial library. A very simple method 
to create molecular diversity is the “split-and-mix synthesis” that was presented by Furka 
and Lam in 1991.[25-28] Although many other methods have been introduced,[29-31] split and 
mix synthesis is still one of the most elegant approaches to create highly diversified pools of 
small molecules. 
 
 
1.2.1 Split-and-mix synthesis 
 
The concept of split-and-mix synthesis is based on the generation of a large number 
of related compounds simultaneously on solid support. The method works as follows 
(Scheme 1): a sample of resin is divided into a number of x equal portions (step 1), and 
each of these is reacted with a different set of reagents (step 2). After completion of the 
reactions, and subsequent washing to remove excess reagents, the portions are recombined 
and mixed (step 3). After splitting the resin again into equal portions, the modified solid 
support is ready for a next synthesis cycle. Reaction with a further set of activated reagents 
gives the complete set of possible dimeric units as a mixture, and then the whole process 
may be repeated if necessary (for a total of n times). The number of compounds obtained 
arises from the exponential increase of products (xn). In the example illustrated in Scheme 1, 
two cycles (n = 2) with three different reagents each (x = 3) are performed, yielding 32 = 9 
combinations of dimeric products. Since each bead is subjected to only one reaction during 
any cycle, each bead carries only one compound (‘one-bead-one-compound’). X, Y and Z 
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could be amino acids, in which case the final products would be dipeptides, but more 
generally they could be any type of monomeric unit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: Application of the split-and-mix library procedure exemplified for the solid phase synthesis 
of a 9 component dimer library 
 
After the generation of a library, the further steps are the screening for the 
identification of active compounds and subsequently their structural determination. 
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1.2.2 Encoded Split-and-Mix Synthesis 
 
The power of combinatorial libraries is only evident if structural information on active 
components may easily be obtained. The amount of compound on each bead depends on 
the type of resin used and is typically in the order of 100 pmol per bead. With this amount 
linear peptides or oligonucleotides can be analyzed via Edman-sequencing[32] and PCR-
(polymerase chain reaction) techniques, respectively. However, the analysis of non-
sequenceable molecules is not as straightforward. Analytical methods like mass 
spectrometry[33-36] or 13C-NMR and 1H-NMR spectroscopy[37-39] have also been applied for the 
analysis of compounds on single bead. However, these detection methods have some 
limitations like the impossibility to distinguish isomers and enantiomers (for example L- and 
D- amino acids). Moreover, incomplete reactions during the synthesis result in compound 
mixtures which are difficult to analyse. In order to avoid these problems a number of new 
methods have been developed in the last years, in which the information concerning the 
active compound is carried on the bead in the form of a ‘tag’. The idea of encoded 
combinatorial synthesis was to attach molecular tags to the solid support, in each reaction 
vessel of each reaction cycle, which can later be cleaved off the resin and analyzed easily 
and unequivocally.[40] Thus the tags can report the synthetic history of each individual bead.  
The tag molecules should have the following properties: They should be inert under 
various reaction conditions, detectable on a very small scale and they should be easily 
attached and detached from the solid support. 
 
Still et al. reported the first method using such chemically stable moieties.[41] The tags 
consist of polyhalogenated aromatic alcohols which can be detected at subpicomolar 
concentrations using electron capture gas chromatography (EC-GC), which is a very sensitive 
detection method of halogenated compounds. 26 tags can be separated in the EC-GC just by 
varying the length of the hydrocarbon chain and the substitution pattern of the halogenated 
aromatic ring. Two different linkers, one photolabile and one oxidatively labile, were 
developed in order to allow the tag alcohols to be attached, and then detached from the 
beads. Both linkers incorporate a carboxylic acid for attachment to the synthesis beads 
(Figure 3). For the photolabile linker, a photochemically labile ortho-nitrobenzylcarbonate 
was chosen for subsequent detachment of the tags[41a] via irradiation with UV-light, while 
vanilic acid[41b] was chosen as an oxidative-labile linker segment which allows the release of 
the tag alcohols via oxidation with ceric ammonium nitrate (CAN). The tag alcohols are then 
analyzed by EC-GC after silylation of the alcohol function. Amide chemistry was implemented 
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to attach the tags to the beads. These polyhalogenated aromatic reagents acylate the same 
synthesis sites used for the ligand synthesis, but due to the sensitivity of the tag detection 
this competition could be minimised. Only 1-2 % of the active sites on the solid support are 
acetylated with the tag during each reaction step. The tags attached to the oxidatively labile 
linker can be incorporated directly on the solid support via carbine insertion. This has the 
advantage that there is no dependence on the functional group of the solid support and so 
they can be used for any compound library.[41b] 
Since this kind of tagging is the most versatile, we used polyhalogenated tags to 
encode our libraries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Photolabile and oxidative-labile linkers and tag alcohols 
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1.2.3 Synthesis of an Encoded Split-and-Mix Library 
 
As illustrated in Scheme 2, during each synthesis cycle, a different array of tags is 
attached to the beads in each reaction vessel prior to the actual reaction step. The use of 
binary codes of tags instead of only a single tag allows for encoding of a large number of 
compounds.[41a] In the following example, two tags (T1 and T2) encode three reactions 
performed in the first cycle, the two tags T3 and T4 encode the three reactions performed in 
the second cycle. If the analysis of the tags on one bead of the library shows tags T1, T3 and 
T4 the bead was subjected to reagent X in the first step and to reagent Z in the second step 
of the synthesis. Thus, using this binary encoding scheme N different tags can encode 2N-1 
reagents.[41a] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Application of the encoded split-and-mix library procedure exemplified for the 
solid phase synthesis of a 9 component dimer library 
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1.2.4 Screening of Encoded Combinatorial Libraries 
 
A highly efficient way for screening all members of a combinatorial library 
simultaneously for their binding properties is ‘on-bead screening’. This selection system 
allows for the detection of activity by simply looking at the beads that carry the compounds 
of interest. The compound that is screened against the library is in solution while the library 
members are immobilized on the solid support. Intermolecular interactions with members of 
the library can be detected directly if the binding partner in solution carries a marker that 
allows for visual detection. Such markers can be dyes or fluorescent molecules[42] for the 
direct visual detection, enzymes or antibodies that allow for their detection by a color 
reaction[41b,43] or radioactive isotopes that can be detected by photoimaging techniques or 
microradiography.[44-47] In our group, dyes or fluorescent molecules have been employed as 
markers for the screening in aqueous and organic solvents because of their high sensitivity in 
detection. For example, a library is mixed with the solution of a receptor marked with a dye. 
Beads of the library members that interact with the receptor will appear colored and can be 
detected visually through a low power light microscope. After isolation of the colored beads, 
the tags are cleaved and analyzed by EC-GC to reveal the structure of the active compound 
(Scheme 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3: ‘On-Bead Screenings’ of an encoded 
combinatorial library against a colored receptor 
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Screenings are performed using an amount of beads that corresponds to several 
theoretical copies of the tested library. This is mandatory to assure a representative 
screening result because the distribution of individual sequences obeys Poissons statistics, 
thus a sample of 50000 beads of a 50000 membered library does not contain each 
member.[48,49] 
 
 
1.3 Research Project 
 
The work described here is based on three main aspects concerning two-armed 
receptors and their binding properties, which are explained below. 
 
 
1) Our group has recently developed two-armed diketopiperazine receptors that bind 
peptides with high sequence selectivities and binding affinities. These receptors consist of a 
rigid diketopiperazine backbone bearing two peptidic side-chains, the “receptor arms”.[50-54] 
The conformation of the template is well understood. In contrast, the conformation of the 
receptor arms and their orientation towards each other is difficult to elucidate due to their 
high structural flexibility.  
In the first part of this thesis, we have addressed this question by comparing the 
binding selectivities of flexible two-armed receptors with those of macrocyclic receptors in 
which the termini of the receptor arms are connected (Figure 4). If flexible two-armed 
receptors bind their substrates with a somewhat parallel arrangement of the receptor arms, 
connecting the arms should not alter the binding properties significantly. In contrast, the 
binding selectivities should be altered by macrocyclization in the case of a rather “unordered” 
non-parallel arrangement of the receptor arms upon binding of their substrates. The binding 
properties have been investigated by combinatorial screenings and conventional binding 
studies. 
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Figure 4: General concept of macrocyclic receptor prototypes 
 
The following points are discussed: 
- Design and binding properties of four macrocyclic diketopiperazine receptor 
prototypes. 
- Comparison with the binding properties of the corresponding open-chain 
diketopiperazine receptor prototypes. 
- Binding energies of macrocyclic and open-chain diketopiperazine receptor prototypes 
with tripeptides in chloroform. 
 
 
2) Previous studies revealed that an exchange of the diketopiperazine template (e.g. 
simpler diamino scaffold) leads to significantly lower or the entire loss of binding 
selectivity.[52] 
In the second part of this thesis, we investigated an alternative template that would 
offer an additional site for the attachment of receptors to a solid support or a soluble 
polymer. For this purpose, we chose the carbazole template which offers a third functionality 
in addition to those required for tethering of the two peptide arms (Figure 5).[55] The design 
and the binding properties of this new class of two-armed receptors based on a carbazole 
backbone are presented. 
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Figure 5: Two-armed carbazole receptors. 
 
The following points are discussed: 
- Design and binding properties of five carbazole receptor prototypes and comparison 
with the binding properties of the corresponding diketopiperazine receptor prototypes. 
- Binding energies of the two-armed carbazole receptor prototypes and tripepides in 
chloroform. 
- Synthesis of a receptor library on solid support and its screening towards water 
soluble peptidic target molecules. 
 
 
3) We were also interested in the study of the self-assembly process of a 
diketopiperazine receptor with pegylated tripeptides. Combinatorial binding studies had 
revealed that, for example, diketopiperazine receptor 1 binds to the tripeptide Ac-D-Val-D-
Val-D-His-linker-resin (resin = polystyrene) in chloroform solution with high selectivity and a 
binding affinity of ∆G = -4.7 kcal mol-1.[50,54] Due to the low solubility of the non-resin bound 
peptide and in order to understand this highly selective host-guest interaction, we prepared 
the pegylated tripeptide 2[56] to perform NMR studies in chloroform. Upon mixing the 
receptor 1 with the pegylated peptide 2 in chloroform, the formation of a gel was observed, 
demonstrating a supramolecular assembly process (Figure 6). Since a 3D network structure 
occurring via non covalent interactions may explain the gel formation in chloroform, we also 
investigated a possible self-assembly in aqueous solution.  
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Figure 6: Diketopiperazine receptor 1 mixed with the pegylated tripeptide 2 
 
To gain insight into the supramolecular assembly process, the following points are discussed: 
- Synthesis of two selected pegylated tripeptides with different PEG lengths and two 
peptide-PEG conjugates which were not selected by the receptor in combinatorial 
on-bead assay. 
- Dynamic Light Scattering studies of the self-assembled receptor-pegylated tripeptide 
system. 
- Transmission Electron (TEM) and Atomic Force (AFM) Microscopy investigations. 
- Surface pressure measurements. 
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2 DESIGN AND BINDING PROPERTIES OF MACROCYCLIC DIKETOPIPERAZINE 
RECEPTOR PROTOTYPES 
 
2.1 Receptor Design 
 
A receptor class containing members, which are capable of binding any desired 
peptide selectively, should consist of a rigid, structure-directing backbone as well as 
functional groups that allow for the formation of non-covalent interactions such as hydrogen 
bonds, ionic and hydrophobic interactions. Furthermore, the receptor structure should offer 
the possibility for combinatorial structural and functional variations and should be accessible 
by a simple synthesis strategy both in solution and on solid supports, to ultimately permit the 
generation of a combinatorial receptor library using a split-and-mix protocol.[26-27] 
Two-armed diketopiperazine receptors fulfil all of the above-mentioned requirements 
for a versatile class of receptors. The design of the receptor is based on using trans,trans-
diketopiperazine as a rigid scaffold which itself is derived from 4-hydroxyproline. The two 
peptidic receptor arms, which are attached to the scaffold via amide linkage, are built of 
L- as well as D- amino acids and offer structural and functional variety for binding peptide 
sequences. Standard peptide synthesis can be used to assemble these diketopiperazine 
receptors. 
Moreover, conformational analysis demonstrated that the trans,trans-diketopiperazine 
adopts a well-defined turn-conformation that proved crucial for selective peptide binding 
(Figure 7).[52] Thus, exchange of the template leads to significantly lower or entire loss of 
binding selectivity. The analysis of the preferred conformation adopted by the receptors 
arms has not been straightforward due to their structural flexibility. To get an understanding 
of their relative orientation towards each other, we connected the termini of the peptidic 
receptor arms by different linkers and describe the synthesis and binding properties of these 
macrocyclic diketopiperazine receptors. To test for the effect of macrocyclization, the termini 
of the peptidic side-chains were connected by a) a metathesis reaction[57], b) amide bonds 
and c) a disulfide bond.[58] 
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Figure 7: Crystal structure of the trans,trans-diketopiperazine 
 
Macrocyclization was expected to result in improved binding selectivities and 
particularly binding affinities in the case of the open-chain diketopiperazine receptors bind 
with linearly aligned peptidic recognition modules. Conversely, reduced binding affinities 
were expected as a result of macrocyclization in the case of the recognition modules are not 
aligned parallel to each other in the binding conformation (Figure 8). 
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Figure 8: Schematic representation of binding preorganisation 
 
To analyse the effect of macrocyclization on the binding properties of 
diketopiperazine receptors, we chose the open-chain receptor 1 as a receptor prototype. 
This receptor prototype consists of the trans,trans-diketopiperazine backbone and two 
symmetric tripeptide arms containing L-Tyr(dye), L-Gln(Trt) and L-Phe (Figure 9). Tyrosine 
was chosen as first amino acid because its phenolic hydroxyl group offers an attachment site 
for a dye, essential for the screening. As a dye, the red azo-dye Disperse Red 1 is used. We 
chose this specific receptor even though it is not the most selective or the one with the 
highest binding properties but because it is more soluble compared to the receptor 
containing Asn instead of Gln at the second position of the peptidic arms.[50] 
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Figure 9: Macrocyclic dye-marked diketopiperazine receptor prototype 
 
 
2.2 Synthesis of the Symmetric Diketopiperazine Template 
 
The synthesis of the diketopiperazine template 10 (Scheme 4) started from N-Boc-γ-
trans-hydroxy-L-proline-methylester 4 which was obtained from the reaction of the Cesium-
salt of the commercially available N-Boc-γ-trans-hydroxy-L-proline 3 with MeI. Inversion of 
the configuration of the Cγ of 4, under Mitsunobu conditions, yielded N-Boc-γ-cis-hydroxy-L-
proline-methylester. Introduction of the azide-group was accomplished by a SN2 substitution 
with NaN3 of the corresponding mesylate of 5 in 96% yield.[59] Subsequently the N-Boc-γ-
trans-azido-L-proline-methylester 6 was split into two portions. One portion was hydrolized 
and transformed into the pentafluorophenylester 7. In the second portion of 6, the Boc 
group was deprotected using a mixture of TFA/CH2Cl2 yielding the corresponding TFA salt 8. 
Mixing of 7 and 8 in the presence of Hünig’s base yielded the cyclization precursor 9. N-Boc 
deprotection with TFA and addition of Hünig’s base led to the diketopiperazine 10 in 81% 
yield. The reduction of the azide functionalities with Palladium on carbon in the presence of 
Boc2O yielded the well storable N-Boc-protected diketopiperazine 11. 
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Scheme 4: Synthesis of the symmetric diketopiperazine template 
 
 
 
 
 
 
 
 
 
 
(a) i. Cs2CO3 (0.55 eq), MeOH, H2O, r.t., 1 h; ii. MeI (2 eq), DMF, r.t., 30 min, 94 %; (b) i. C6H5CO2H (1.15 
eq), PPh3 (1.16 eq), DIAD (1.1 eq), THF, 0°C then r.t., 2.5 h,; ii. NaOCH3 (0.95 eq), MeOH, r.t., 15 min, 66 
%; (c) i. MsCl (1.2 eq), Et3N (1.2 eq), CH2Cl2, 0°C then r.t., 30 min; ii. NaN3 (5 eq), DMF, 80°C, 2 h, 96 %; 
(d) i. NaOH (1.8 eq) in H2O, THF/MeOH (1:1), r.t., 1.5 h; ii. C6F5OH (1.1 eq), EDC (1.5 eq), CH2Cl2, r.t., 1 h, 
80 %; (e) TFA/CH2Cl2 (1:3), r.t., 1.5 h, quant.; (f) iPr2NEt (2 eq), CH2Cl2, r.t., 16 h, 69 %; (g) i. TFA/CH2Cl2
(1:3), r.t., 1.5 h; ii. iPr2NEt (5 eq), THF, r.t., 16 h, 81 %; (h) Pd/C (10%), H2, Boc2O (4.1 eq), MeOH, r.t., 3 h, 
13 %. 
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2.3 Synthesis of the Two-Armed Diketopiperazine Receptor Precursor 
 
The red azo-dye Disperse Red 1 was attached to the phenolic hydroxyl group of the 
N-Boc-L-Tyrosine-methylester 12 by a Mitsunobu reaction, followed by conversion of the 
methylester into the carboxylic acid to yield the dye-marked tyrosine derivative 13 (Scheme 
5). For the assembly of the receptor, the Boc groups of 11 were removed and the resulting 
diamine was coupled with the dye-marked carboxylic acid of N-Boc-L-Tyrosine to yield 14. 
After N-Boc deprotection with HCl, the remaining amino acids of the arms were assembled 
by standard couplings of N-α-Fmoc-protected amino acids using O-(7-azabenzotriazol-1-
yl)N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU) or O-(1H-6-
chlorobenzotriazole-1-yl)1,1,3,3-tetramethyluronium hexafluorphosphate (HCTU) as coupling 
reagents and tris(2-aminoethyl)amine (TAEA) for Fmoc-deprotection. Using this synthetic 
route the receptor precursor 15 with two identical arms consisting of a dye-marked L-Tyr as 
initial amino acid followed by L-Gln(N-trityl) and L-Phe was prepared. 
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Scheme 5: Synthesis of two-armed diketopiperazine receptor precursor 
 
 
 
 
 
 
 
 
(a) Disperse Red 1 (1 eq), PPh3 (1 eq), DIAD (1.3 eq), toluene, r.t., 16 h, 46 %; (b) NaOH (1.8 eq) in H2O, 
THF/MeOH (1:1), r.t., 1.5 h, quant.; (c) i. TFA/CH2Cl2 (1:3), r.t., 1 h, quant.; ii. 13 (4 aq), HATU (4 eq) in 
DMF, iPr2NEt (4 eq), CH2Cl2, r.t., 1 h, 85 %; (d) i. 4 M HCl in dioxan, MeOH, r.t., 1 h, quant.; (e) Fmoc-L-
Gln(Trt)-OH (4 eq), HATU (4 eq) in DMF, iPr2NEt (4 eq), CH2Cl2, r.t., 1 h, 89 %; (f) TAEA (50 eq), CH2Cl2, r.t., 
1 h, quant.; (g) Fmoc-L-Phe-OH (4 eq), HCTU (4 eq) in DMF, iPr2NEt (4 eq), CH2Cl2, r.t., 1 h, 77 %. 
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2.4 Synthesis of Macrocyclic Diketopiperazine Receptor Prototypes 
 
After the synthesis of the Fmoc-protected macrocyclic receptor precursor 15, we 
envisaged different methods of macrocyclization. The termini of the peptidic side-chains 
were connected by a) ring closing metathesis;[57] b) amide bond formation and c) formation 
of a disulfide bridge.[58] All of the linkers were designed to reduce the conformational 
flexibility of this receptor to test the binding properties towards tripeptides of these rigidified 
macrocyclic receptors. Thus, after Fmoc-deprotection different linking moieties for 
macrocyclization were introduced by standard coupling methods using HATU or HCTU and 
Hünig’s base as coupling reagents and TAEA for Fmoc-deprotection. Specifically, we 
prepared four different macrocyclic receptor prototypes (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Macrocyclic diketopiperazine receptor prototypes (dye = Disperse Red 1) 
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2.4.1 Ring Closing Metathesis 
 
Ring closing metathesis (RCM) has emerged as a powerful tool for the formation of C-
C bonds in chemistry. Of particular significance, this type of metathesis utilizes no additional 
reagents beyond a catalytic amount of metal carbene and the only other product formed in 
the reaction is, in most cases, a volatile olefin, such as ethylene, and the cycloalkene. 
Furthermore, RCM is a very versatile method for the preparation of medium-sized and 
macrocyclic products.[60] It was discovered that neither a conformational predisposition of 
the starting material toward ring closure, nor the ring size formed are particularly relevant 
factors,[61] although this had been previously assumed.[62] The E/Z selectivity depends on the 
ring strain. Ruthenium alkylidene[63] and molybdenum alkylidene[64] are two of the most 
commonly used initiators for RCM, and reports of their use in organic synthesis have 
increased steadily.[65] 
The Grubbs catalysts, based on ruthenium alkylidene, are some of the major catalysts 
employed in this reaction, as they exhibit high reactivity and have a remarkable tolerance 
towards many different organic functional groups. Catalytic activity is not reduced 
significantly by the presence of air, moisture or minor impurities in solvents.[66] However, the 
mere presence of a functional group (ester, ketone, ether, etc.) in the starting material was 
found to be of utmost importance, as well as the proper distance between this key 
substituent and the alkenes to be metathesized.[61a,d] To accomplish our macrocylization, we 
chose the first generation of Grubbs catalyst. 
After Fmoc-deprotection, 5-hexenoic acid was coupled onto receptor precursor 15 
using HATU as coupling reagent. Use of 0.8 eq of Grubbs catalyst at a concentration of 1 mM 
in a mixture of CH2Cl2 and MeOH, led to the macrocyclic receptor 17 in 71 % yield. Addition 
of the catalyst was accomplished over a period of three days to complete the reaction. The 
ring closing metathesis reaction resulted in a 1:2 mixture of the Z and E isomers that were 
separated by preparative HPLC (Scheme 6). 
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Scheme 6: Synthesis of the macrocyclic diketopiperazine receptors 17a and 17b via ring closing 
metathesis 
 
 
 
 
 
 
 
 
 
 
(a) i. TAEA (50 eq), CH2Cl2, r.t., 1 h, quant.; ii. 5-hexenoic acid (4 eq), HATU (4 eq) in DMF, iPr2NEt (4 eq), 
CH2Cl2, r.t., 1 h, 81 %; (b) Grubbs cat. (0.8 eq), CH2Cl2/MeOH, reflux, 3 days, 71 %. 
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2.4.2 Amide Bond Formation 
 
For the amide bond formation, the linkers between the termini of the peptidic side-
chains were designed to have the same number of atoms (ten) as used in the RCM, thus 
allowing to analyze whether the linker would have an influence on the binding properties of 
macrocyclic diketopiperazine receptors with the same ring size. 
After Fmoc deprotection, the free amines of the receptor precursor 15 were coupled 
with an activated dicarboxylic acid. Sebacic acid 18 was chosen and activated as 
pentafluorophenyl (Pfp) esters using Pfp-OH and 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide (EDC) as coupling reagent. The macrocyclic receptor 20 was obtained by 
simultaneous slow addition of the bis-pentafluorophenylester 19 and the free amines of 
receptor 15 to a solution of Hünig’s base at a concentration of 1 mM in THF, in 32% yield 
(Scheme 7). This low concentration was used as a means to avoid intermolecular reactions 
and polymerization of the receptors through sebacic acid, instead of the desired 
macrocyclization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7: Synthesis of the macrocyclic diketopiperazine receptor 20 via amide bond formation 
 
 
 
(a) C6F5OH (2.2 eq), EDC (1.5 eq), CH2Cl2, r.t., 1 h, 47 %; (b) i. TAEA (50 eq), CH2Cl2, r.t., 1 h, quant.; ii. 19
(1 eq), iPr2NEt (4 eq), THF, r.t., 16 h, 32 %. 
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2.4.3 Disulfide Bridge Formation 
 
Disulfide bonds between cysteine residues play an important role in the folding and 
structural stabilization of many peptides and proteins.[67] The introduction of a disulfide 
bridge in our receptor is an important concept in the macrocyclization and should allow for 
reversible opening and closing of the cyclic receptor. Due to the complex functionality and 
reactivity of the individual amino acid side-chains, it is important to have a range of reagents 
available for disulfide bond formation. Various oxidation methods are available now, but 
synthetic methods for selective disulfide bond formation are still limited.[68] We tested sulfide 
oxidation using iodine as oxidant, with cysteine carrying various side-chain protecting groups 
such as acetamidomethyl (Acm), Fmoc and Trt. The best result was obtained with an Acm-
side-chain protected cysteine residue.[58] 
Two macrocyclic receptors were synthesized, one with a disulfide linker containing 
seven atoms, receptor 26, (Scheme 9) and a second with a linker containing fourteen 
additional atoms, receptor 23, thus, forming a larger macrocycle (Scheme 8). 
After Fmoc-deprotection, the free amines of the two-armed receptor precursor 15 
were coupled with an Acm-side-chain protected cysteine residue via an aminocaproic acid 
“spacer” to obtain the open-chain receptor prototype 21. Direct coupling of the protected 
cysteine, i.e. without aminocaproic acid “spacer”, lead to the receptor 24. After Fmoc 
deprotection and acetylation, the disulfide bridge formation was carried out with iodine at a 
concentration of 1 mM in a mixture of dichloromethane, methanol and water. The disulfide 
bridge-containing macrocyclized receptors 23 and 26 were obtained in 40% and 63 % yield, 
respectively. 
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Scheme 8: Synthesis of the macrocyclic diketopiperazine receptors 23 via disulfide bridge formation 
 
 
 
 
 
 
 
a) i. TAEA (50 eq), CH2Cl2, r.t., 1 h, quant.; ii. Fmoc-ε-aminocaproic acid (4 eq), HCTU (4 eq) in DMF, iPr2NEt
(4 eq), CH2Cl2, r.t., 1 h, 85 %; (b) i. TAEA (50 eq), CH2Cl2, r.t., 1 h, quant.; ii. Fmoc-L-Cys(Acm)-OH (4 eq), 
HATU (4 eq) in DMF, iPr2NEt (4 eq), CH2Cl2, r.t., 1 h, 76 %; (c) i. TAEA (50 eq), CH2Cl2, r.t., 1 h, quant.; ii. 
Et3N (3 eq), Ac2O (3 eq), CH2Cl2, 1 h, 75 %; (d) I2 (4 eq) in CH2Cl2/MeOH (8:1.5), CH2Cl2/MeOH/H2O 
(6:2.5:0.42), r.t., 1 h, 40%. 
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Scheme 9: Synthesis of the macrocyclic diketopiperazine receptors 26 via disulfide bridge formation 
 
 
 
 
 
 
 
a) i. TAEA (50 eq), CH2Cl2, r.t., 1 h, quant.; ii. Fmoc-L-Cys(Acm)-OH (4 eq), HCTU (4 eq) in DMF, iPr2NEt (4 
eq), CH2Cl2, r.t., 1 h, 60 %; (b) i. TAEA (50 eq), CH2Cl2, r.t., 1 h, quant.; ii. Et3N (3 eq), Ac2O (3 eq), CH2Cl2, 
1 h, 55 %; c) I2 (4 eq) in CH2Cl2/MeOH (8:1.5), CH2Cl2/MeOH/H2O (6:2.5:0.42), r.t., 1 h, 63%. 
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2.5 Screening of the Two-Armed Diketopiperazine Receptor Prototypes Against 
an Encoded Side-chain Deprotected Peptide Library 
 
The binding properties of dye-marked receptor prototypes were tested by screening 
them against a side-chain deprotected acetylated tripeptide library in chloroform.[50] The 
same library had been used to evaluate the binding properties of diketopiperazine receptor 
1. The library was synthesized on polystyrene resin by encoded split-and-mix synthesis[33-34] 
using standard Fmoc-strategy[69] and had the general structure Ac-AA3-AA2-AA1-
NH(CH2)5CONH-PS. Amino acid couplings were accomplished by reacting 3 eq of N-Fmoc-
amino acid, 3 eq of diisopropylcarbodiimide (DIC) and 3 eq of N-hydroxybenzotriazole 
(HOBt) (dissolved in the smallest amount of DMF) in CH2Cl2 at room temperature for 2 hours. 
N-Fmoc-aminohexanoic acid (Fmoc-Ahx) was chosen as a “spacer” between the peptide 
sequences and the resin. 29 L- and D-amino acids were employed at each position. Thus, the 
library contained maximally 293=24389 different acetylated tripeptides (Figure 11). 
 
 
 
 
 
 
 
 
 
   
Figure 11: General structure of the acetylated tripeptide library on polystyrene resin 
 
In order to ensure a representative screening result, an amount corresponding to at 
least five theoretical copies of the library was used per assay.[48] Upon mixing the library (~ 
5 mg) with dilute solutions of receptors (50-100 µM) in CHCl3 (freshly filtered through 
aluminium oxide) and equilibration for 1 to 3 days, several beads picked up the red color of 
the receptor (Figure 12). The structures of the peptide substrates preferentially bound to the 
receptor prototypes were determinated by isolating the red beads from the assays of each 
receptor and decoding the tags by EC-GC. 
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Figure 12: Picture of a typical binging assay of macrocyclic receptor 23 
with the tripeptide library 
 
 
2.5.1 Screening of Macrocyclic Diketopiperazine Receptor Prototypes 
 
In the assays of receptors 17a and 26, approximately one out of 100 beads picked 
up the bright red color of the receptors and for the receptor 23, one out of ~300. The 
assays of receptors 20 and 23 indicated an even higher level of binding selectivity since only 
one bead out of ~2000 and ~4000 respectively, had turned red. These qualitative results of 
the binding assays revealed that all macrocyclic diketopiperazine receptors are able to bind 
to peptides selectively. Isolation of the colored beads followed by analysis of the encoding 
tag-molecules revealed the amino acid sequences of the selected peptides. 
Table 1 lists the most frequently occurring peptide sequences for each macrocyclic 
receptor prototype (see Figure 10).  
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Table 1: Binding specificities of the macrocyclic receptors for tripeptides within the side-chain 
deprotected library 
Receptors AA3a AA2a AA1a 
freq. 
found 
[%]c 
freq. 
exp. 
[%]c 
Beads 
isolated 
17a 
(metathesis) 
X 
L-AA 
X 
D-AA 
D-AA 
D-/L-Pro 
D-Pro 
D-/L-Lys 
D-Lys 
19 
24 
14 
1.66 
1.61 
0.24 
21 
17b 
(metathesis) 
X 
D-Pro/ L-Lys 
D-Phe/ D-Ser 
L-Pro/ D-/L-Lys 
D-/L-Pro 
D-/L-Lys 
D-/L-Pro 
X 
X 
30 
20 
20 
0.71 
0.48 
0.48 
20 
20 
(amide bond) 
L-AA 
D-Lys 
D-/L-Pro 
D-Pro 
D-/L-Pro 
L-Pro 
35 
23 
0.23 
0.004 
17 
23 
(“spacer” -  
disulfide bridge) 
D-/L-Ala 
D-Gln 
Gly/ L-Leu/ L-Ala 
L-Gln 
D-Hphb 
L-Gln 
L-Ala 
D-Hphb 
D-Hphb 
17 
37 
13 
0.008 
0.07 
0.01 
30 
26 
(disulfide bridge) 
D-/L-Arg 
D-/L-Thr 
D-/L-Pro 
X 
X 
X 
X 
X 
D-/L-Pro 
L-Pro/ L-His 
L-His 
D-/L-Arg 
D-/L-Pro 
X 
D-/L-Gln 
D-/L-Gln 
D-/L-Gln 
D-/L-Gln 
D-/L-Pro 
D-/L-Pro 
L-Arg 
12 
5 
8 
7 
5 
12 
14 
0.48 
0.03 
0.03 
0.23 
0.48 
0.48 
3.45 
92 
a X: Random amino acids. 
b Hph = hydrophobic amino acid can be either Gly, Ala, Val, Leu or Phe. 
c The frequency found column lists the percentage of beads selected in the receptor binding assay for the 
indicated peptide sequence. The frequency expected column lists the expected frequency for the particular 
tripeptide sequence if the beads were picked randomly. The comparison between the percentage of “frequency 
found” and “frequency expected” is a measure for the selectivity level of the receptor. 
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2.5.2 Comparison to the Open-Chain Receptor Prototypes 
 
After having tested the binding properties of macrocyclic dye-marked receptor 
prototypes, the results were compared to the binding properties of the corresponding open-
chain receptors with and without different types of linkers under the same conditions (Figure 
13). Upon mixing a dilute solution of receptor 25 in CHCl3 with the 24389 membered library 
only a few beads (ca. one out of 1500) picked up the color of the dye-marked receptor 
indicating selective binding to certain members within the library. In contrast, the assays of 
receptors 1, 16 and 22 indicated a particularly high level of binding selectivity, since 
approximately one bead out of 5000 was colored. The structures of the peptidic substrates 
bound to the receptors were determined by isolation of the red beads from the assay of each 
receptor and analysis of the encoding tag molecules was achieved by EC-GC (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Open-chain diketopiperazine receptor prototypes (dye = Disperse Red 1) 
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Table 2: Binding specificities of the open-chain receptors for tripeptides within the side-chain 
deprotected library 
Receptors AA3a AA2a AA1a 
freq. 
found 
[%]b 
freq. 
exp. 
[%]b 
Beads 
isolated
1 
D-Ala/ D-Val 
L-Ala/ L-Leu  
D-Gln 
D-Hph 
L-Gln 
D-Hph 
D-His 
D-Hph 
D-Val/ D-Leu 
34 
37 
20 
0.04 
0.04 
0.04 
 
16 
(metathesis 
precursor) 
D-Ala 
D-Ala/ Gly 
L-Hph 
D-Phe 
L-Gln 
L-Gln 
D-Gln 
L-Ser 
L-Ser/ D-/L-Ala
36 
29 
21 
0.004 
0.008 
0.05 
14 
22 
(“spacer” – disulfide 
bridge precursor) 
D-Gln D-Val D-Val 100 0.004 
3 
25 
(disulfide bridge 
precursor) 
D-Gln/ D-Asp 
L-Ala 
D-/L-Pro 
L-AA 
D-Phe 
L-Gln 
D-/L-Pro 
D-/L-Pro 
D-Val 
D-AA 
D-/L-Gln 
D-/L-Pro 
12 
21 
7 
14 
0.008 
0.06 
0.03 
0.23 
42 
a Hph = hydrophobic amino acid can be either Gly, Ala, Val, Leu or Phe. 
b The frequency found column lists the percentage of beads selected in the receptor binding assay for the 
indicated peptide sequence. The frequency expected column lists the expected frequency for the particular 
tripeptide sequence if the beads were picked randomly. The comparison between the percentage of “frequency 
found” and “frequency expected” is a measure for the selectivity level of the receptor. 
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2.5.3 Discussion 
 
The analysis of the red beads revealed that, the sequence D-Hph-D-Hph-D-His, 
selected preferably by the open-chain receptor 1, was not selected by any of the macrocyclic 
receptors nor their open-chain precursors.[50] On the other hand, the sequences D-Gln-D-
Hph-D-Hph and/or L-Hph-L-Gln-D-Hph were recognized by both the macrocyclic receptor 23 
and the open-chain receptors 1, 16, and 22. In the case of macrocyclic receptors 17a, 17b, 
20, and 26, very different amino acids were recognized compared to the open-chain 
receptors 1 and 16. Strikingly, the amino acids D-/L-Pro occured frequently in the 
sequences, along with the hydrophilic amino acids D-/L-Lys and D-Ser for the receptor 17a, 
17b, and 20. Interestingly, receptor 20 has significantly higher binding selectivities 
compared to the isomeric receptors 17a and 17b, with an alkene, instead of an alkan-linker, 
and to receptor 26, with a disulfide bridge in the linker. In the case of the open-chain 
receptor, the selected amino acid sequences are quite different since L-Ser was recognized 
by the receptor 16 and D-/L-Pro by the receptor 25 but not by the receptors 1 and 22. This 
indicates that both the cyclization of the receptor and the choice of the linker-type lead to 
significant changes in their binding properties. 
In contrast, the selectivity is not influenced by the disulfide bridge in the case of the 
receptor 23, which has similar binding properties compared to the receptor 1, because of 
the long distance between the linker and the termini of the peptidic arms. These results 
suggest that the ring size of the macrocycle 23 is large enough to accommodate a similar 
conformation as in the open-chain receptor 1 that allows for binding to the Gln-containing 
peptides. 
In general, macrocyclic receptors bind peptides with lower selectivites compared to 
open-chain diketopiperazine receptors. The selectivities were found to be largely dependent 
on the length of the “spacer” used for the macrocyclization. Macrocyclic receptors, with a 
long “spacer”, have binding properties that are similar to those of open-chain receptors while 
a short “spacer” leads to often drastically modified and typically decreased binding 
selectivities. 
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2.6 Binding Energies of the Macrocyclic Diketopiperazine Receptors and 
Tripeptides in CHCl3 
 
The screening results indicate that macrocyclic diketopiperazine receptors bind with 
selectivity to some resin-bound tripeptides. In order to analyze these selective interactions, 
binding studies to quantify the affinity of the substrates to the receptors were 
performed.[50,51,54,70] For this purpose, the selected tripeptides were re-synthesized on solid 
support (polystyrene, 200-400 mesh, loading 1.1 mmol g-1) by employing the general 
procedure for solid phase synthesis, using the Fmoc-strategy. By using mixtures of N-Fmoc-
aminohexanoic acid and acetic acid (37:63) for the initial resin functionalization, different 
resins with peptide loadings of ~0.3 mmol g-1 were prepared. The loading of each resin was 
determined by the quantitative Fmoc-test.[71] Diisopropylcarbodiimide and 1-
hydroxybenzotriazole (HOBt) served as coupling reagents for the initial coupling as well as 
for the following amino acid couplings. 
For the determination of the binding affinity, a precisely measured amount of the 
solid supported peptide was placed in a 1 ml UV-cuvette and 1 ml of the dye-marked 
receptor of known concentration (for receptors 17a, 17b, 23 and 26, c ~ 14 µM) in CHCl3 
(freshly filtered through aluminium oxide) was added. The mixture was tightly sealed and 
allowed to equilibrate by slight agitation for at least 72 h. After this time, the UV-Vis 
absorbance (for Disperse Red 1 λmax = 480 nm) of the remaining receptor concentration did 
no longer change (Figure 14). 
 
 
 
 
 
 
 
 
  
Figure 14: Solid phase binding assay 
 
 
 
weight ~5mg of beads
carrying the peptide of interest
add receptor solution of known 
concentration in CHCl3, seal the cuvette 
and equilibrate
measure UV-Vis after 
equilibration
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The binding constants and affinities were calculated under the assumption of a simple 
bimolecular receptor-peptide complex and participation of all peptides in the intermolecular 
binding by equation (1). 
 
 
 
 
[RP] = concentration of the receptor-peptide complex at equilibrium 
[R0] = initial receptor concentration 
[R0]-[RP] = concentration of the receptor at equilibrium 
[P0] = initial peptide concentration 
[P0]-[RP] = concentration of the peptide at equilibrium 
 
Equation 1 is valid for obtaining relative binding constants, only if the resin bound 
peptide interacts with the receptor but not the resin itself. We checked this in a control 
experiment using acetylated PS resin containing no peptide. No binding was observed 
indicating the absence of any non-specific receptor-resin interaction. Thus, non-specific 
background absorption of the receptor to the resin matrix can be neglected. After the 
determination of Ka, the binding energy ∆G can be obtained according to equation (2): 
 
 
 
(Gas constant R = 8.314 J mol-1 K-1, temperature T = 298 K) 
All measurements were repeated multiple times to ascertain the accuracy of the binding 
affinities within an error of ±0.1 kcal mol-1. 
  
Using this protocol, the binding affinities of macrocyclic receptors towards the 
selected peptides are lower compared to the binding affinity with which receptor 1 binds to 
its selected peptide. Indeed, the association constants (Ka = 19±4 to 90±17 M-1, ∆G = -1.7 
to -2.7±0.1 kcalmol-1) are ~50 times lower than the binding strength of receptor 1 (Table 3). 
This result is supported by a qualitative color comparison between the darkest beads of the 
macrocyclic receptor assays and those of the parent open-chain receptor 1. None of the 
beads in the assays of the macrocycles was as intensely colored as the darkest beads in the 
assays of the open-chain receptor 1. This indicates a somewhat weaker binding of the 
][]])([[]([
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macrocyclic receptors to their selected peptides, compared to the interaction between the 
open-chain diketopiperazine receptor 1-peptide complexes. 
 The macrocyclization of diketopiperazine receptors, which rigidified the receptor and 
induced a higher preorganisation, leads to significant changes in the binding properties. In 
conclusion, the conformations of macrocyclic receptors are different compared to the open-
chain diketopiperazine receptors and alter the binding selectivities and affinities of these 
receptors. 
 This demonstrates that mimicking the conformation in which the open-chain 
receptors bind their peptidic substrates through macrocyclization, is not trivial. It suggests 
that a certain degree of flexibility in the structure of the receptor is beneficial for allowing the 
receptor to wrap around their peptidic guests. 
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Table 3: Relative binding affinities of macrocyclic receptors toward solid supported peptides: peptide-
NH(CH2)5CONH-PS 
N
H
H
N
N
H
O
O
R1
H
N
N
H
O
O
O
R2
R3
AA3 AA2 AA1
polystyrene
 
Receptors Ac-AA3-AA2-AA1-linker-PS 
Ka 
[M-1] 
∆G 
[kcal mol-1] 
1 
Ac-D-Val-D-Val-D-His-linker-PS 
Loading 0.33 mmol g-1 
2486±480 -4.6±0.1 
17a / 17b 
Ac-D-Lys-D-Pro-L-Lys-linker-PS 
Loading 0.34 mmol g-1 
59±11 -2.4±0.1 
17a / 17b 
Ac-L-Pro-L-Pro-D-Lys-linker-PS 
Loading 0.34 mmol g-1 
90±17 -2.7±0.1 
17a / 17b 
Ac-L-Ser-D-Pro-D-Pro-linker-PS 
Loading 0.36 mmol g-1 
63±12 -2.4±0.1 
17a / 17b 
Ac-D-Phe-L-Lys-D-Pro-linker-PS 
Loading 0.40 mmol g-1 
34±6 -2.1±0.1 
17a / 17b 
Ac-D-Ser-D-Lys-L-Lys-linker-PS 
Loading 0.41 mmol g-1 
38±7 -2.2±0.1 
23 
Ac-L-Ala-L-Gln-L-Ala-linker-PS 
Loading 0.34 mmol g-1 
51±10 -2.3±0.1 
23 
Ac-D-Gln-D-Ala-D-Leu-linker-PS 
Loading 0.33 mmol g-1 
19±4 -1.7±0.1 
26 
Ac-D-Pro-L-Pro-D-Gln-linker-PS 
Loading 0.33 mmol g-1 
25±5 -1.9±0.1 
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3 CARBAZOLE RECEPTORS: DEVELOPMENT OF A NOVEL CLASS OF HIGHLY 
SELECTIVE TWO-ARMED RECEPTORS FOR BINDING SMALL PEPTIDES 
 
3.1 Carbazole Receptor Design 
 
Combinatorial binding studies revealed that diketopiperazine receptors bind peptidic 
substrates with high selectivities and binding affinities of ∆G = -5 to -6 kcal mol-1 in organic 
and aqueous solvents[50,72] and that the tempate plays the most crucial role in allowing or 
preventing an intermolecular interaction of two-armed receptors toward peptides.[52] This 
result is supported by combinatorial binding studies with two-armed molecules based on 
diamines. Therefore, four different diamine templates were used: diaminocyclohexane A, 
bis-aminomethylcyclohexane B, diketodiazabicyclooctane C and 1,7-diaminoheptane D 
(Figure 15). The templates A - D differ not only in the distance of the two amino groups that 
serve as anchors for the peptidic arms but also in their rigidity. While the templates A and C 
are rigid, the direction of the amino groups is not fixed in B. The diaminoheptane D is 
completely flexible and was chosen because the distance between the two amino groups is 
the same as in the diketopiperazine template. Screening against the deprotected tripeptide 
library revealed that none of these two-armed molecules interact with any of the 24389 
peptides within the tripeptide library (see Chapter 2.5). Thus, exchange of the template 
leads to significantly lower or entire loss of binding selectivity.[52] 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 15: Diamines used as templates for two-armed molecules 
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Nevertheless, we were still interested in an alternative template since using the 
diketopiperazine template only allows for attachment of a dye moiety or linking to a solid 
suport via the side-chains of one of the amino acids. Attachment via a third functionalization 
site, that is opposite to the recognition elements, could be beneficial for reducing possible 
influence of the dye or resin onto the conformation and thereby binding properties of the 
receptor. 
We felt that carbazole template could be such an alternative since the attachment 
sites for the receptor modules are separated by at least ~7.5 Å from each other by the rigid 
aromatic moiety and the third functionality is present in this template (Figure 16). 
 
 
 
 
 
 
 
 
  
Figure 16: Diketopiperazine and carbazole templates for two-armed molecules 
 
To test the binding properties of receptors based on a carbazole template, four dye-
marked receptor prototypes 39 - 42 were synthesized, with side-chains which are identical 
to those of the parent diketopiperazine receptors 1 and 27 (Figure 17). These 
diketopiperazine receptors are known to bind tripeptides, D-Hph-D-Hph-D-His, D-Gln-D-Hph-
D-Hph and L-Hph-L-Gln-D-Hph, in the case of the receptor 1 and D-Hph-D-Hph-D-His, in the 
case of the receptor 2, with high selectivities and binding affinities.[50] The two symmetric 
tripeptidic arms contain L-Tyr(dye) or L-Tyr(tBu) at the first position of the recognition 
elements, L-Gln(Trt) or L-Asn(Trt) in the middle, and L-Phe at the end. 
Receptor 39 is analogue to diketopiperazine receptor 1, while receptor 40 has the 
dye no longer attached to the side-chains but to the additional functionalized site, the “tail” 
of the carbazole template. Since the solubility of these two receptors in organic solvent (e.g. 
CHCl3) turned out to be rather low, we also prepared receptors 41 and 42 with solubilizing 
polyethylene glycol (PEG) moieties attached to the carbazole “tail”.[56] Receptor 39, 41 and 
42 were designed to allow for a direct comparison of the binding properties of two-armed 
receptors based on the carbazole or diketopiperazine templates (receptor 1 and 27). 
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Comparison of the binding properties of receptor 40 with those of receptors 39 or 41 should 
allow for an analysis of the influence of the dye moiety on the binding properties. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Dye-Marked carbazole receptor prototypes (dye = Disperse Red 1) 
 
 
3.2 Synthesis of the Symmetric Carbazole Template 
 
The synthesis of the carbazole template 34 (Scheme 10) started from the 
dibromocarbazole ethyl ester 30, which was obtained by an SN2 reaction of ethyl 
bromoacetate 29 with the commercially available 3,6-dibromocarbazole 28. In another 
reaction, N-Boc-allylamin 32 was hydroborated with 9-borabicyclo[3.3.1]nonane (9-BBN) 31 
and coupled via a Suzuki-Miyaura cross-coupling to dibromcarbazole ethyl ester 30 in the 
presence of tetrakis(triphenylphosphine)palladium (Pd[PPh3]4), leading to the N-Boc-
protected carbazole 34 in 14 % yield.[55,73] 
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Scheme 10: Synthesis of the symmetric carbazole template 
 
 
3.3 Synthesis of Two-Armed Carbazole Receptor Prototypes 
 
The two-armed carbazole receptor prototypes 39 – 42 were dye-labelled in two 
different ways: the first with the dye-marked L-tyrosine 13 coupled on free amines of the 
carbazole template, and the second with the amine-functionalized Disperse Red 1[74] 
introduced on carbazole “tail”. The template was also functionalized with a PEG chain with 
an average molecular weight of 750 g mol-1 (H2N-(CH2CH2O)≈16CH3).[56] 
The synthesis of the amine-functionalized dye started from Disperse Red 1 which was 
activated as mesylate 35, followed by the introduction of the azide-group by an SN2 
substitution with NaN3 to obtain derivative 36 in 88 % yield (Scheme 11).[75] The reduction 
of the azide functionality under Staudinger conditions led to the amine-functionalized 
Disperse Red 1 37 in 96 % yield.[76] After the hydrolytic saponification of 34, the amine-
functionalized dye was coupled using HCTU and Hünig’s base to obtain the dye-marked 
template 38. 
(a) K2CO3 (2 eq), Ethyl bromoacetate 29 (2.2 eq), DMF, 65°C, 5 h, 81 %; (b) 9-BBN 31 (1.2 eq) in THF (0.5 
M), r.t., 16 h, quant.; (c) 33 (2.4 eq), [Pd(PPh3)4] (10 Mol%), KOH (1 M)  in H2O, toluene, 120 °C, 16 h,
14 %. 
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Scheme 11: Synthesis of the amine-functionalized dye 37 and the dye-marked template 38 
 
After N-Boc deprotection of 34 and 38 respectively, the carbazole receptor 
prototypes were assembled by a similar synthetic route as described for the diketopiperazine 
receptors, using HCTU as coupling reagents and TAEA for Fmoc-deprotection. Acetylation 
with Ac2O in the presence of Et3N, after the final Fmoc-deprotection, led to the carbazole 
receptors 39 and 40 (Figure 18). In the case of the receptor containing a PEG chain, after 
assembling the peptidic arms on compound 34, the ethyl ester functionality was converted 
to a PEG chain substituted amide via the same method as used for the amine-functionalized 
dye to obtain receptors 41 and 42. 
Using this synthesis route, four receptor prototypes 39 – 42 with closely related yet 
distinctly different structures were prepared. The two identical arms of each receptor 
consisted of a dye-marked L-Tyr or L-Tyr(tBu), as initial amino acid, followed by either L-
Asn(N-trityl) or L-Gln(N-trityl) and as last amino acid, L-Phe. Thus, the structural differences 
(a) MsCl (2 eq), Et3N (2 eq), CH2Cl2, r.t., 1 h, quant.; (b) NaN3 (2 eq), DMSO, 80 °C, 3 h, 88 %; (c) PPh3 (1.6
eq), H2O (2 eq), THF, r.t., 38 h, 96 %; (d) i. NaOH (1.4 eq) in H2O, THF/MeOH (1:1), r.t., 4 h, quant.; ii. 37
(0.8 eq), HCTU (1.6 eq) in DMF, iPr2NEt (1.6 eq), CH2Cl2, r.t., 1 h, 67 %. 
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of the four prototypes were as subtle as a single methylene group (e.g. 41 and 42), the 
position of the dye (e.g. 39 and 40) or the presence of a PEG chain (e.g. 41 and 42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Dye-marked carbazole receptor prototypes 39 - 42 
 
 
3.4 Selective Binding of the Two-Armed Carbazole Receptors of Side-Chain 
Deprotected Peptides 
 
The binding properties of the two-armed receptors 39 – 42 towards a resin-bound 
tripeptide library with the general structure Ac-AA3-AA2-AA1-NH(CH2)5CONH-PS (PS = 
polystyrene resin), were examined in chloroform: the same library as for the analysis of the 
binding properties of the dye-marked diketopiperazine receptors 1 and 27 was used 
(Chapter 2.5). Each combinatorial binding assay was carried out with an amount of the 
library that corresponded to at least five theoretical copies in order to ensure the 
representative screening results.[48] 
Upon mixing dilute solutions (50 or 100 µM) of receptors 39 – 42 in CHCl3 with the 
24389 membered library, approximately one bead out of 3500 was colored, indicating a high 
level of selectivity comparable to what we previously observed for the diketopiperazine 
receptors. Isolation of the colored beads of the assays of receptors 39 – 42 followed by 
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analysis of the encoding tag-molecules revealed the amino acid sequences of the selected 
peptides (Table 4). 
 
Table 4: Binding specificities of diketopiperazine receptors 1, 27 and carbazole receptors 39 – 42 for 
tripeptides within the side-chain deprotected library Ac-AA3-AA2-AA1-NH(CH2)5CONH-PS 
Receptors AA3a AA2a AA1a 
freq. 
found 
[%]b 
freq. 
exp. 
[%]b 
Beads 
isolated 
1 
D-Ala/ D-Val 
L-Ala/ L-Leu  
D-Gln 
D-Hph 
L-Gln 
D-Hph 
D-His 
D-Hph 
D-Val/ D-Leu 
34 
37 
20 
0.04 
0.04 
0.04 
 
27 D-Val/ D-Ala D-Hph D-His 100 0.04  
39 
D-Gln 
D-Gln 
D-Phe 
D-Hph 
D-Val 
D-Hph 
60 
40 
0.004 
0.06 
5 
40 
L-Ala 
D-Val 
D-Gln 
L-Gln 
D-Ala/ D-Leu 
D-Hph 
D-Ala 
D-His 
D-Hph 
40 
20 
20 
0.004 
0.008 
0.06 
15 
41 
D-Hph 
D-Gln 
L-Hph 
D-Hph 
D-Hph 
L-Gln 
D-His 
D-Hph 
D-Hph 
36 
34 
12 
0.06 
0.06 
0.06 
42 
42 D-Val/ D-Phe D-Hph D-His 100 0.04 5 
a Hph = hydrophobic amino acid can be either Gly, Ala, Val, Leu or Phe. 
b The frequency found column lists the percentage of beads selected in the receptor binding assay for the 
indicated peptide sequence. The frequency expected column lists the expected frequency for the particular 
tripeptide sequence if the beads were picked randomly. The comparison between the percentage of “frequency 
found” and “frequency expected” is a measure for the selectivity level of the receptor. 
 
 These screening results indicate that two-armed carbazole receptors bind certain 
resin-bound tripeptides with considerable selectivity and have similar binding selectivities as 
diketopiperazine receptors. Carbazole receptor 42 and diketopiperazine receptor 27 select 
exclusively peptides with D-His followed by two hydrophobic D-amino acids (D-Hph). 
Receptors 39 – 41, with the Gln instead of Asn in the peptidic arms, have binding properties 
that are similar to those of diketopiperazine receptor 1. Receptor 39 binds two of the three 
peptide motives that are also selected by receptor 1 preferentially. The motif, D-Hph-D-Hph-
D-His, selected by receptor 1 is, however, not selected by the carbazole receptor 39. 
Carbazole receptors 40 and 41 bind the same peptide sequences as diketopiperazine 
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receptor 1. This demonstrates that the carbazole template induces similar binding 
selectivites of two-armed receptors as diketopiperazine. 
Binding properties of receptors 39 and 41 with the dye in the peptidic side-chains 
are similar to those of receptor 40 with the dye placed at the “tail” position of the carbazole 
template. This suggests that the dye is only functioning as an “innocent” spectator and is not 
playing a crucial role in the intermolecular interaction between two-armed receptors and 
their peptidic guests. 
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3.5 Binding Energies of the Two-Armed Carbazole Receptor Prototypes and 
Tripeptides in CHCl3 
 
 In order to obtain a measure for the strength of the observed intermolecular 
association, we determined the binding affinities of carbazole receptors 39 – 42 towards the 
peptide, Ac-D-Val-D-Val-D-His-resin, which was selected in the one-bead assay (Table 5). 
The peptide was synthesized on polystyrene resin (200-400 mesh, loading 1.1 mmol g-1) 
employing the general procedure for solid phase synthesis using the Fmoc-strategy. The final 
resin loading, after the peptide couplings, was determined by the quantitative Fmoc-test to 
be ~0.3 mmol g-1 (see Chapter 2.6).[71] The association constant was determined by solid 
phase binding of the receptors. 
 
Table 5: Binding affinities measured for diketopiperazine receptors 1, 27 and carbazole receptors 39 
– 42 towards the peptide selected in the on-bead assay and immobilized on PS-resin 
N
H
H
N
N
H
O
O
R1
H
N
N
H
O
O
O
R2
R3
AA3 AA2 AA1
polystyrene
 
Receptors Ac-AA3-AA2-AA1-linker-PS 
Ka 
[M-1] 
∆G 
[kcal mol-1] 
1 
Ac-D-Val-D-Val-D-His-linker-PS 
Loading 0.33 mmol g-1 
2486±480 -4.6±0.1 
27 
Ac-D-Val-D-Val-D-His-linker-PS 
Loading 0.28 mmol g-1 
15000±2900 -5.7±0.1 
39 
Ac-D-Val-D-Val-D-His-linker-PS 
Loading 0.33 mmol g-1 
2760±530 -4.7±0.1 
40 
Ac-D-Val-D-Val-D-His-linker-PS 
Loading 0.33 mmol g-1 
2482±480 -4.6±0.1 
41 
Ac-D-Val-D-Val-D-His-linker-PS 
Loading 0.33 mmol g-1 
1852±360 -4.4±0.1 
42 
Ac-D-Val-D-Val-D-His-linker-PS 
Loading 0.33 mmol g-1 
1063±200 -4.1±0.1 
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 Binding selectivities of diketopiperazine receptors and carbazole receptors were found 
to be comparable. Also, the binding affinities of diketopiperazine receptor 1 and carbazole 
receptors 39 – 41 are comparable. These results, furthermore, demonstrated that the 
position of the dye does affect neither the binding selectivity nor the binding affinity 
properties of the receptors and that the carbazole receptors 39 – 41 are not only highly 
selective for certain tripeptides, but also show a high binding affinity towards the selected 
peptide. 
 However, differences in the binding strength were observed for diketopiperazine 
receptor 27 and carbazole receptor 42. Diketopiperazine receptor 27 was found to bind to 
Ac-D-Val-D-Val-D-His, that was selected preferentialy by both receptors in combinatorial on-
bead assays, with a binding energy of ∆G = -5.7±0.1 kcal mol-1 (Ka = 15000 M-1). In 
contrast, the corresponding carbazole receptor 42 binds this sequence less tightly with ∆G = 
-4.1±0.1 kcal mol-1 (Ka = 1063 M-1). 
Nevertheless, the carbazole template is a choice alternative and these results justified 
the synthesis of a receptor library, since the carbazole receptor prototypes showed the 
desired properties described in chapter 2.1. 
 
 
3.6 Two-Armed Carbazole Receptor Library 
 
For the preparation of our two-armed receptor library, the symmetric carbazole 
scaffold 43 was chosen as initial target molecule, since it would provide an anchor point to 
the solid support. 
After hydrolytic saponification of the carbazole template 34, the N-Boc protected 
carbazole 43 was linked through an amide bond to the amino functionalized Tentagel S resin 
(loading 0.26 mmol g-1) using (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyAOP) and Hünig’s base as coupling reagents (Scheme 12).[77] 
Cleavage of the Boc protecting group of 44 was performed by shaking the resin with a 30% 
v/v mixture of TFA/CH2Cl2 at r.t. for 30 minutes. After neutralization and washing steps, the 
resin was dried in vacuo. The loading of the resin was determined by quantitative Fmoc-test, 
by coupling Fmoc-Gly-OH on an accurate measured amount of resin. The determined loading 
of the resin was 0.43 mmol g-1.[71] 
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The two symmetric ‘arms’ of the receptor library were built following the protocol for 
encoded split-and-mix synthesis using the standard Fmoc-procedure for peptide coupling 
(Scheme 12). Upon achieving synthesis of tripeptidic arms, one part of the resin was 
acetylated with Ac2O in the presence of Et3N, after the final Fmoc-deprotection, to yield the 
two-armed tripeptide carbazole library. The other part was coupled one-more time, using the 
same split-and-mix protocol, to lead to a two-armed tetrapeptide library, after final Fmoc-
deprotection and acetylation. Using a part of each library, the side-chain protecting groups of 
peptides were cleaved by a 95:2.5:2.5 (v/v/v) mixture of TFA/H2O/TIS at r.t. for 1 h to 
obtain the corresponding deprotected carbazole libraries. 
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Scheme 12: Synthesis of the tripeptide and tetrapeptide two-armed carbazole receptor libraries 
 
 
(a) KOH (14 eq) in H2O, THF, 60 °C, 23 h, quant.; (b) 43 (1 eq), PyAOP (1.2 eq), iPr2NEt (2.4 eq), DMF, r.t., 
4 h; (c) i. TFA/CH2Cl2 (30% v/v), r.t., 30 min; ii. Encoded split-and-mix synthesis: AA-couplings; (d) i. 
Piperidine/DMF (20% v/v), r.t., 10 min; ii. Encoded split and-mix-synthesis: AA-couplings. 
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In the synthesis of the carbazole receptor libraries, 15 different D- and L- amino acids 
were employed in each position of the two peptidic arms. D- and L- amino acids were 
alternated in each position: e.g. for AA1, L-Ala was used, for AA2, D-Ala and for AA3, L-Ala 
(Figure 19). Thus, the libraries contained a maximum of 153 = 3375 different carbazole 
receptors with tripeptide arms and 154 = 50625 receptors with tetrapeptide arms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Combinatorial variation of the amino acids used for the synthesis of the carbazole 
receptor libraries 
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3.7 On-bead Screening of the Carbazole Receptor Library Against Biologically 
Important Peptides 
 
3.7.1 Angiotensin II and Alzheimers’ Peptide Derivatives Labelled with 
Fluorophores 
 
In preliminary screenings of our carbazole receptor library, segments of Angiotensin 
II and Alzheimer’s peptides were tested for binding to the receptors.  
The goal of this screening is to find a selective receptor for the octapeptide 
Angiotensin II, which is responsible of an enhancement of the blood pressure and 
consequently leads to hypertension[78] and for a segment of β-amyloid peptide, Aβ4–10, which 
is a targed for therapeutically active antibodies raised against the self-aggregation of  
Aβ1–42.[79] 
In order to perform screening assays with the deprotected tripeptide two-armed 
carbazole library, different peptides derived from Angiotensin II were labelled with a small 
fluorescent marker, the aminobenzoic group (Abz), a derivative of anthranilic acid. To 
improve the solubility in water and to reduce the influence of the fluorophore on the binding 
selectivity of peptides, the aminobenzoic group was attached at the N-terminal ends of the 
peptides via a tetraethylene glycol unit as “spacer”. Using the Abz group, four different 
peptides were prepared on solid support using the standard Fmoc-strategy (Rink Amide AM 
resin or Wang resin): two peptides containing only the four C-terminal amino acids of 
Angiotensin II, 45 – 46, and two peptides with all eight amino acids (full length Angiotensin 
II), 47 – 48. One peptide in each sub-group was functionalized, at the C-terminus of the 
sequence, with a free carboxylic function (peptides 45 and 47), the other with an amide 
group (peptides 46 and 48). Our goal was to investigate the influence of these functional 
groups on potential binding selectivities and to discriminate between peptides of different 
lengths (Figure 20).[80] 
To answer the question whether carbazole receptors are able to bind Alzheimer’s 
peptides selectively, three fluorophore-labelled peptide derivatives 49 – 51 were screened 
against the side-chain deprotected acetylated carbazole library. To that effect, dansyl (DNS), 
carboxyfluorescein (FAM) and nitrobenzofurazan (NBD) groups were introduced in 
Alzheimer’s peptide derivatives. Five glycine residues, between the epitope Aβ4-10 and the 
fluorophores, served as “spacer” to reduce the influence of the fluorophore on the binding 
selectivity of the peptide. Przybylski et al. achieved the synthesis of the FAM-marked peptide 
50 and the synthesis of peptides 49 and 51 was performed on solid support (Rink Amide 
AM resin) under standard Fmoc-strategy (Figure 20).[80] 
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Figure 20: Screening assays of carbazole receptor library against fluorophore labelled peptides 
 
 
3.7.2 Screening Assays of the Carbazole Receptor Library Towards 
Fluorophore-Labelled Peptides 
 
A stock solution of each peptide (45 – 48 and 49 – 51) was prepared in a 10:90 
(v/v) mixture of DMSO/H2O, which allowed for solubilization of peptides, at a concentration 
of 1 mM. The fluorophore-marked peptides were screened against approx. 7 mg of the 
carbazole receptor library at a concentration of 100 µM in PBS buffer (10 mM, pH = 7.2) to 
approach physiological conditions. To obtain the desired concentration, the stock solutions of 
each peptide were added to this PBS buffer/carbazole receptor library mixture. The assays 
were allowed to shake at r.t. for 24 h. In these assays, with peptides 45 – 48, 49 and 51 
no fluorescent beads were observed. These peptides were also not recognized by any 
receptors in the carbazole library even after prolonged incubation (48 h), increasing the 
temperature (37 °C) or the concentration from 100 µM up to 200 µM, or using the two-
armed tetrapeptide carbazole library. No higher concentrations have been used to run more 
screening assays with the different fluorophore-labelled peptides. 
In the case of the FAM-marked peptide 50, after equilibration for 24 h, several beads 
were found to be fluorescent. Since this result was not consistent with the other assays, 
some control experiments were performed using the fluorophores only (fluorescein and 5(6)-
carboxyfluorescein) against the carbazole receptor, or a peptide library, under identical 
conditions as in the previous assays. In all assays, selective binding was observed, indicating 
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that the fluorophore moiety is responsible for the high interaction compared to the peptide 
(Figure 21). 
 
 
 
 
 
 
 
 
 
    
Figure 21: Binding assays of FAM-marked peptide 50 and fluorescein  
with the carbazole receptor library 
 
These preliminary studies indicate that care has to be taken with the fluorophore as a 
marker in aqueous solution.[81] In order to avoid such undesired interactions, radiolabelling 
can be used instead. The use of 3H or 14C allows for marking the receptor without altering its 
structure. Interactions between radiolabelled receptor and ‘on-bead’ libraries can be detected 
by phosphoimaging[44,45] techniques or by microradiography.[46,47a,b] Nevertheless, the 
combinatorial synthesis of receptor libraries does provide a powerful method for identifying 
selective receptors for a chosen dye-labelled guest. 
The screening assays were unfortunately not successful. However, other screening 
assays could be performed with these peptides in other buffers, for example 0.1 M Tris 
buffer (pH 7.2), or in organic solvents, like MeOH or CHCl3. Nonetheless, in the future other 
biologically interesting targets could be screened. Other molecules can be envisaged, either 
with a peptide backbone (e.g. glycopeptides, PNA, RGD motif[82]) or different from peptides 
(e.g. oligonucleotides, cholesterol,[83] ATP,[84] c-di-GMP[85]). Some modifications on the 
carbazole library could be introduced to study molecular recognition, for example, the 
introduction of boronic acids that provide effective sugar binding sites[86] or a hydrophobic 
part like a phenylazobenzoyl derivative or macrocyclization of the receptor.  
 
 
Assay with 50 Assay with fluorescein 
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4 VESICLE FORMATION IN AQUEOUS SOLUTION DRIVEN BY SELECTIVE NON-
COVALENT INTERACTIONS 
 
In recent years synthetic vesicles have been developed for application, for example, 
in drug delivery or gene therapy.[87] The vesicular structure, generated by biological 
membranes for transport, consists of a spherically closed lipid bilayer, which 
compartmentalizes an inner aqueous pool from the physiological medium. Many approaches 
for the self-assembly of mechanically stable nanocontainers used amphiphilic block 
copolymers consisting of a hydrophilic (e.g. polyethylene glycol (PEG) or polymethacrylic acid 
(PMA)) and a hydrophobic (e.g. polystyrene (PS), polybutadiene) polymer block.[88] The 
formation of vesicles can be viewed as a two-step self-assembly process, in which the 
amphiphile first forms a bilayer, which then, in a second step, closes to form the vesicle. In 
the classical description, the factor determining the shape of self-assembled amphiphile 
structures is the size of the hydrophobic part relative to the hydrophilic part. It determines 
the curvature of the hydrophobic-hydrophilic interface.[89] 
Recently, also hydrophobic and hydrophilic polypeptides have been utilized as 
amphiphilic block copolymers. Given the pH sensitivity of some amino acids, the resulting 
vesicles are responsive to their environment.[90] Another elegant approach used the 
formation of metal-bisterpyridine complexes for the formation of vesicles. Hydrophobic and 
hydrophilic polymers were functionalized with terpyridine ligands at their termini and 
assembled into vesicles upon addition of metal ions.[91] 
Here, selective non-covalent interactions between a diketopiperazine receptor and its 
pegylated tripeptidic guest were used to induce the assembly of vesicles in aqueous solution. 
The vesicles were analyzed by a combination of light scattering, electron transmission and 
atomic force microscopy as well as surface pressure measurements. 
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4.1 Self-Assembly Process between Diketopiperazine Receptor and Pegylated 
Peptides in Aqueous Solution 
 
In order to obtain a measure of the strength of the observed intermolecular 
interactions, we envisaged to determine the binding affinities of diketopiperazine receptor 1 
towards the peptide, Ac-D-Val-D-Val-D-His-resin, selected in the on-bead assays, by solution 
phase binding assays, e.g. NMR spectroscopy. However, these studies of the binding mode 
of this receptor-peptide complex were thwarted by the poor solubility of the non-solid-
supported peptide Ac-D-Val-D-Val-D-His-NH2 in CHCl3. 
Initially, we attempted to increase the solubility of the peptide by conjugation with 
hydrophobic and/or sterically demanding residues like octylamine, 3,3-diphenylpropylamine 
or 3,4-dibenzyloxyphenethylamine, designed to hinder intermolecular aggregation of the 
peptides. However, none of these residues rendered the modified peptides significantly more 
soluble in chloroform. Hence, we started to explore the possibility of conjugation with PEG 
chains of different lengths as solubilizing moieties. 
First, the peptide-PEG conjugate 2 was synthesized by conjugation in solution phase, 
by coupling of the peptide with a carboxylic acid at the C-termini with a PEG bearing a 
terminal amino group. For this purpose, the peptide, Ac-D-Val-D-Val-D-His(Trt)-OH, with a 
carboxylic acid at the C-termini and acid labile protecting groups on the side-chain functional 
groups, were prepared on a hyper acid labile solid support (2-chlorotrityl chloride resin), 
using the standard Fmoc-strategy. After cleavage of the peptide from the resin under mildly 
acid conditions (CF3CH2OH/AcOH/CH2Cl2 1:1:8, v/v/v), the side-chain protected peptide was 
coupled with an amino-functionalized polyethylene glycol (H2N-(CH2CH2O)≈16CH3 = H2N-
PEG750). However, use of the coupling reagents EDC/HOBt, HATU/Hünig’s base, O-
benzotriazol-1-yl-N,N,N’,N’,tetramethyluronium tetrafluoroborate (TBTU)/Hünig’s base or an 
activated pentafluorophenyl ester led to considerable epimerization at the chiral center of the 
C-terminal amino acid histidine. Only the use of 3-(diethyoxy-phosphoryloxy)-3H-
benzol[d][1,2,3] triazin-4-one (DEPBT) and Hünig’s base as coupling reagents proceeded 
without detectable epimerization for the coupling of peptide, Ac-D-Val-D-Val-D-His(Trt)-OH, 
based on analysis by 1H-NMR spectroscopy.[56] After the coupling and the side-chain 
deprotection, the pegylated peptide 2 was soluble in CHCl3 at a concentration of at least 100 
mM.  
However, when we mixed peptide 2 with receptor 1 in CDCl3 in an NMR tube to study 
the binding mode, the formation of a gel was observed, indicating the assembly of 
supramolecular aggregates. Since a 3D network structure occurring via non-covalent 
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interactions may explain the gel formation in chloroform, we also investigated a possible self-
assembly in aqueous solution. 
For this purpose, the pegylated peptides Ac-D-Val-D-Val-D-His-NH-PEG750 2 was re-
synthesized using a different strategy allowing to reduce the risk of epimerization and 
bypassing the matter of low yields obtained in the first coupling between the Fmoc-D-His-OH 
and the 2-chlorotrityl chloride resin otherwise. Ac-D-Val-D-Val-D-His-NH-PEG3200 55, which 
were selected by the diketopiperazine receptor 1, and Ac-Lys-Lys-Lys-PEG850 56 or Ac-Val-
Val-Gly-PEG850 57, that did not bind to receptor 1, were also prepared. Two strategies were 
pursued to obtain the pegylated peptides: (a) conjugation in solution phase for the pegylated 
peptide 2 and (b) synthesis of the peptide-PEG conjugates 55 - 57 on solid phase. 
 
 
4.1.1 Solution Phase Synthesis of the Pegylated Peptide 2 
 
The first strategy started with the synthesis of Ac-D-Val-D-Val-OH 52 on solid support 
(Wang resin) under standard Fmoc-strategy, using DIC/HOBt as coupling reagents (Scheme 
13). After the final Fmoc-deprotection and acetylation with Ac2O in the presence of Et3N, the 
peptide was removed from the solid support using a 95:2.5:2.5 (v/v/v) mixture of 
TFA/H2O/TIS at r.t. for 2 h, leading to the peptide 52 with a carboxylic acid at their C-
termini. In a second part, the Fmoc-protected D-His(Trt) was coupled on a polyethylene 
glycol bearing a terminal amino group (H2N-(CH2CH2O)≈16CH3 = H2N-PEG750) using DEPBT 
and Hünig’s base as coupling reagents at r.t. for 3 h, yielding the Fmoc-protected D-His(Trt)-
PEG conjugate 53. After purification by flash chromatography and Fmoc-deprotection of 53, 
the amine-functionalized D-His(Trt)-PEG conjugate was reacted with peptide 52 using DEPBT 
and Hünig’s base at r.t. for 3 h, leading to the protected pegylated peptide 54, which could 
be purified by flash chromatography on silicagel (gradient of CH2Cl2/MeOH/Et3N from 
99.5:0.5:0.1 to 96:4:0.1 (v/v/v)). The pegylated peptide 2 was isolated by precipitation with 
diethyl ether after side-chain deprotection, followed by an ion exchange chromatography 
(Dowex® 1x2-400, Dowex-1-chloride, strongly basic anion). 
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Scheme 13: Synthesis of the peptide-PEG conjugate 2 in solution phase 
 
 
4.1.2 Solide Phase Synthesis of the Peptide-PEG Conjugates 55 - 57 
 
The second strategy involved the synthesis of the peptides on a polystyrene (PS) 
based solid support where an amino-functionalized PEG chain is attached via an acid labile 
benzylether linker (TentaGel® PAP-NH2: <Mw> = 3200 g mol-1 or TentaGel-N-NH2: <Mw> = 
850 g mol-1) (Scheme 14).[92] Peptide 55 was prepared on solid support bearing PEG3200 and 
56 – 57, bearing PEG850. The syntheses were performed by following the standard Fmoc-
strategy using HCTU/Hünig’s base as coupling reagents. Side-chain deprotection and 
simultaneous peptide-PEG conjugate cleavage from the solid support were achieved with a 
99:1 (v/v) mixture of TFA/trimethylsilylbromide (TMSBr) at r.t. for 6 h. The pegylated 
peptides 55 – 57 were isolated by precipitation with diethyl ether, followed by an ion 
exchange chromatography. As judged by NMR-spectroscopy, HPLC, and MS analysis the 
purity of peptide-PEG conjugates 55 – 57 was ≥ 90%. This second approach yields peptide-
PEG conjugates where the PEG chain terminates with a hydroxy group, in comparison to the 
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methylether obtained by the conjugation of the peptides with PEG in solution phase.[56] The 
risk of epimerization is significantly reduced since only single amino acids are coupled, hence 
avoiding the risk of oxazolidinone formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 14: Synthesis of the peptide-PEG conjugates 55 – 57 on solid support 
 
 
4.1.3 Receptor-Ligand Self-Assembly 
 
Upon mixing of 2 or 55 with diketopiperazine receptor 1 in chloroform, the formation 
of an organogel was observed, as was expected (Figure 22). Gel formation was not observed 
with the peptide-PEG conjugates 2 and 55 themselves, or when receptor 1 was mixed with 
non-functionalized PEG or non-selected peptide-PEG conjugates 56 and 57. Thus, the 
supramolecular assembly into an organogel is driven by selective non-covalent interactions 
between receptor 1 and Ac-D-Val-D-Val-D-His. 
(a) amino acid (2 eq), HCTU (2 eq) in DMF, iPr2NEt (4 eq), CH2Cl2, r.t., 2 h; (b) 20 % piperidine in DMF, r.t., 
10 min; (c) repeat (a) and (b) till completion of peptide formation; (d) Ac2O (5 eq), Et3N (5 eq), CH2Cl2, r.t., 1 
h; (e) i. TFA/TMSBr (99:1), r.t., 6 h; ii. ion exchange chromatography (Dowex® 1x2-400, H2O). 
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Next, the supramolecular assembly properties between receptor 1 and the peptide-
PEG conjugates 2 and 55 were studied in water. Whereas peptide-PEG conjugates 2 and 55 
were fully soluble in water, receptor 1 was not. To allow for a supramolecular assembly to 
form between receptor 1 and pegylated peptide 2, 1 was dissolved in THF (0.4 mM) and 2 
(2 mM, pH 5.5) in water. In the case of the assembly between 1 and 55, the receptor was 
diluted in THF at 4.4 mM and the peptide-PEG conjugate in water at 57 µM (pH 5.5). For the 
studies, we prepared different peptide/receptor ratios using an accurate amount of both the 
stock solutions of receptor 1 and the respective peptides. If necessary, the solution was 
diluted with water to reach a final THF content of maximally 9% and a receptor/ligand 
complex concentration of maximally 1 mg ml-1. 
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Figure 22: Diketopiperazine receptor 1 mixed with pegylated peptides 2 and 55 – 57 in CHCl3 and 
with 2 and 55 in H2O 
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4.2 Dynamic Light Scattering (DLS) Investigations 
 
Dynamic Light Scattering (DLS),[93] also known as Quasi Elastic Light scattering 
(QELS) and Photon Correlation Spectroscopy (PCS), has the potential to yield a great deal of 
information about particles, including their size, over the size range from a few nanometers 
to a few microns, and some notion of concentration. Such information is useful in many 
scientific fields, and the techniques of DLS can provide such information relatively quickly 
and inexpensively, compared with other methods. The most direct applications for the 
method are for those who are interested in diffuse properties of a given solution, such as 
bacteria or proteins in suspension. The concept uses the idea that small particles in a 
suspension move in a random pattern. 
According to the semi-classical light scattering theory when light (laser) impinges on 
matter, the electric field of the light induces an oscillating polarization of electrons in the 
molecules. The molecules then serve as secondary source of light and subsequently radiate 
(scatter) light. The frequency shifts, the angular distribution, the polarization and the 
intensity of the scattered light are influenced by the size, shape and molecular interactions in 
the scattering material. In dynamic light scattering, one measures the time dependence of 
the light scattered from a very small region of a solution, over a time range from tenths of a 
microsecond to milliseconds. These fluctuations in the intensity of the scattered light are 
related to the rate of diffusion of molecules in and out of the region being studied and the 
data can be analyzed, to directly give the diffusion coefficients of the particles doing the 
scattering. Traditionally, rather than presenting the data in terms of diffusion coefficients, 
the data are processed to give the size of the particles (radius or diameter). The relation 
between diffusion and particle size is based on theoretical relationships for the Brownian 
motion of spherical particles, which describes the way in which very small particles move in 
fluid suspension, where the fluid consists of molecules much smaller than the suspended 
particles. The hydrodynamic diameter or Stockes radius, Rh, derived from this method is the 
effective radius of an irregularly shaped particle that is used when describing the manner in 
which particles in suspension diffuse through the suspending medium. Assuming that our 
vesicles behave as hard spheres, the diffusion coefficient D could be related to the 
hydrodynamic radius Rh using the Stockes-Einstein equation: 
 
 
where k is the Boltzmann constant (k = 1.3806x10-23 J K-1), T is the temperature and η is the 
solvent viscosity. 
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For a hard sphere, the hydrodynamic radius Rh is equivalent to the gyration radius Rs 
(radius of the sphere). However, for other particles, we can consider Rh as the radius of a 
hypothetical hard sphere that diffuses with the same speed as the particle under 
examination. A faster one represents a smaller particle and a slower one represents a larger 
particle.[93] 
To gain insight into our supramolecular assembly process between the 
diketopiperazine receptor 1 and the pegylated peptides 2 and 55, the choice of this method 
was relevant. 
Dynamic light scattering revealed the formation of well defined nanometer-sized 
structures demonstrating that receptor 1 forms supramolecular assemblies with the peptide-
PEG conjugates 2 and 55 also in aqueous environment. The measurements showed that the 
peptide-PEG conjugate 2 with a molecular weight of PEG of ~750 g mol-1 yielded particles 
with a mean apparent hydrodynamic radius of 50 nm whereas peptide-PEG conjugate 55 
with a molecular weight of PEG of ~3200 g mol-1 organized itself into structures with a mean 
apparent hydrodynamic radius of 100 nm. In both cases, the particle size does not depend 
on the ligand (peptide) to receptor ratio (Figure 23). No supramolecular assemblies were 
observed by the peptide-PEG conjugates 2 and 55 themselves or when receptor 1 was 
mixed with the peptide-PEG conjugates Ac-Lys-Lys-Lys-PEG850 56 and Ac-Val-Val-Gly-PEG850 
57. Thus, the assembly between receptor 1 and peptide-PEG conjugates 2 and 55 is driven 
by selective non-covalent interactions. The assembly might, furthermore, be strengthened by 
the chemical incompatibility of the hydrophobic receptor and the hydrophilic PEG segment, 
however, the main driving force is the selective interaction between receptor 1 and Ac-D-Val-
D-Val-D-His. 
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Figure 23: The hydrodynamic radii of supramolecular assemblies between receptor 1 and peptide-
PEG conjugates 2 and 55, versus peptide/receptor ratios 
 
 
4.3 Transmission Electron (TEM) and Atomic Force (AFM) Microscopy 
 
To further analyze the properties of the supramolecular assemblies between receptor 
1 and peptide-PEG conjugates 2 and 55, Transmission Electron Microscopy (TEM)[94] and 
Atomic Force Microscopy (AFM)[95] were used. 
TEM is especially useful in studying the structure of cells and in crystallography. It 
operates on the same basic principles as the light microscope but uses electrons instead of 
light. What we can see with a light microscope is limited by the wavelength of light. TEMs 
use electrons as “light source” and their much lower wavelength make it possible to get a 
resolution a thousand times better than with a light microscope. In TEM, a “light source” at 
the top of the microscope emits the electrons that travel through vacuum in the column of 
the microscope (Figure 24). Instead of glass lenses focusing the light in the light microscope, 
the TEM uses electromagnetic lenses to focus electrons into a very thin beam. The electron 
beam then travels through the studied specimens. Depending on the density of the material 
present, some of the electrons are scattered and disappear from the beam. At the bottom of 
the microscope, the unscattered electrons hit a fluorescent screen, which gives rise to a 
“shadow image” of the specimen with its different parts displayed in varied darkness 
according to their density. The image can be studied directly by the operator or 
photographed with a camera.[94] 
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Figure 24: Schematic presentation of 
Transmission Electron Microscopy 
 
TEM analysis of our supramolecular assemblies supported the results from the 
dynamic light scattering studies, showing spherical objects with a size of 100 nm and 200 
nm for receptor 1 with peptide-PEG conjugates 2 and 55, respectively (Figure 25). Their 
macroscopic shape proved to be independent of the ligand to receptor ratio and the 
molecular weight of the polymer. 
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Figure 25: TEM image of self-assembly between receptor 1 and peptides 2 and 55 in dilute aqueous 
solution 
 
 To determine the morphology (vesicles or micelles) of the ligand-receptor driven 
organization of PEG, we studied the assemblies by AFM. 
 The Atomic Force Microscopy (AFM) which was invented in 1986 by Binnig, Quate 
and Gerber, is being used to solve processing and materials problems in a wide range of 
technologies including electronics, telecommunications, biological, chemical, automotive, 
aerospace, and energy industries. The materials being investigated include thin and thick 
film coatings, ceramics, composites, glasses, synthetic and biological membranes, metals, 
polymers, and semiconductors. The basic objective of the operation of the AFM is to 
measure the forces between a sharp probing tip and a sample surface. AFM works by 
scanning a fine ceramic or semiconductor (Si or Si3N4) over a surface much the same as a 
phonograph needle scans a record. The tip is positioned at the end of a cantilever beam 
shaped much like a diving board. As the tip is repelled by or attracted to the surface, the 
cantilever beam deflects. The magnitude of the deflection is captured by a laser that reflects 
at an oblique angle from the very end of the cantilever. A plot of the laser deflection versus 
tip position on the sample surface provides the resolution of the hills and valleys that 
constitute the topography of the surface (Figure 26). The AFM can work with the tip 
Pegylated peptide 2 
Peptide-PEG conjugate 2: 
Receptor 1 = 2:1 
Peptide-PEG conjugate 55: 
Receptor 1 = 1:1 
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touching (contact mode), or the tip can tap across the surface (tapping mode) much like the 
cane of a blind person. Compared with TEM, three dimensional AFM images are obtained 
without expensive sample preparation and yield far more complete information than the two 
dimensional profiles available from cross-sectioned samples.[95] 
 
 
 
 
 
 
 
     
Figure 26: Concept of Atomic Force Microscopy (AFM) 
 
 Figure 27 shows a typical image of AFM with two spherical particles in close contact 
to each other. The hollow objects are indicative of former vesicles from which the interior 
water evaporated upon drying. The data is therefore strong evidence for the vesicular nature 
of the supramolecular assemblies formed between receptor 1 and the peptide-PEG 
conjugates. The observed heights of 4 nm at the center of the collapsed vesicle and 14 nm 
at the rims of the “donut shaped” structure are indicative of an average thickness of ~10 nm 
of two vesicle walls on top of each other. This data suggests a thickness of 5 nm for each 
receptor-peptide-PEG layer. 
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Figure 27: Dry state AFM image of the self-assembly between receptor 1 and peptide-PEG conjugate 
2 resulting from the adsorption of the vesicles from the dilute aqueous solution on silicon water and 
the corresponding height profile 
 
 
4.4 Other Investigations and Conclusions 
 
To characterize the morphology of the supramolecular structure, Static Light 
Scattering (SLS) measurement allows us to determine the mean apparent molecular weight 
and the mean apparent radius of gyration of the macromolecules in the solution. From these 
results, one can go further and deduce for instance the aggregation number of self-
assembled systems or the area occupied by a molecule inside an aggregate. Unfortunately, 
this measurement was not successful due to the absorption by the dye moiety of receptor 1 
at the wavelength of the laser (633 nm). 
To further analyze the structural properties of the vesicles formed, Langmuir-Blodgett 
(LB) studies were performed. These experiments were particularly motivated by the 
observations that a) the vesicle size had proven independent of the ligand to receptor ratio 
and b) the size of the vesicular structures increased from 100 nm to 200 nm when peptide-
PEG conjugate 55 with the longer PEG chain instead of 2 was employed. This is in contrast 
to conventional amphiphilic block polymers. Their size typically decreases when the 
hydrophilic to hydrophobic ratio is increased and might even lead to a change in the 
morphology from, for example, vesicles to micelles.[96]  
The LB-technique is one of the most promising techniques for preparing and studying 
thin films, as it enables the precise control of the monolayer thickness, homogeneous 
deposition of the monolayer over large areas and the possibility to make multilayer 
structures with varying layer composition. This method is used to create a molecular film of 
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amphiphile at the air-water interface. In practice, when a solution of an amphiphile in a 
water insoluble solvent (CHCl3) is placed on a water surface, the solution spreads rapidly to 
cover the available area. As the solvent evaporates, a monolayer is formed. When the 
available area for the monolayer is large, the distance between adjacent molecules is large 
and their interactions are weak. The monolayer can then be regarded as a two-dimensional 
gas. Under these conditions, the monolayer has little effect on the surface tension of water. 
If the available surface area of the monolayer is reduced by a barrier system, the molecules 
start to exert a repulsive effect on each other. This two-dimensional analogue of a pressure 
is called surface pressure. The most important indicator of the monolayer properties of an 
amphiphilic material is given by measuring the surface pressure as a function of the area of 
water surface available to each molecule. This is carried out at constant temperature and is 
known as a surface pressure – area isotherm. Usually an isotherm is recorded by 
compressing the film at a constant rate while continuously monitoring the surface pressure 
(Figure 28). Furthermore, the LB technique provides information about the mean molecular 
area (mma) which is calculated by dividing the trough area by the number of spread 
molecules.[97] 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Schematic illustration of Langmuir-Blodgett technique, isotherm curve and orientation of 
the molecules in different phases 
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The surface pressure measurements demonstrated that the receptor forms a stable 
monolayer at the air-water interface occupying a mean molecular area of 2.2 nm2. This area 
is comparable to that of low molecular weight lipids that self-assemble into liposomes 
(spherical lipid bilayers).[98] This suggests that the receptor organization determines the size 
of the vesicles by assembling into a defined layer. However, the high solubility of the 
peptide-PEG conjugates 2 and 55 did not allow for an analysis of the stoichiometry of 
binding or the kinetics, by using the LB method. 
Our data, so far, suggests that upon binding of the peptide-PEG conjugates to this 
receptor layer, they adapt to the steric organization of the receptors. Whichever ligand to 
receptor ratio or molecular weight of the peptide-PEG conjugate, the same number of 
receptors is available / used for the molecular recognition. A larger PEG chain is forced to 
stretch out, compared to its lower molecular weight analogue which would explain the size 
increase with increased molecular weight of the PEG moiety. 
Taking all of the data together, it is tempting to speculate that the vesicle walls 
consist of receptor-peptide-PEG layers, with the hydrophobic receptors in the inner part and 
the hydrophilic PEG-chains in the parts of the vesicle walls that point to the aqueous outside 
and inside of the vesicles (Figure 29). 
 
 
 
 
 
 
 
 
    
Figure 29: Model of the proposed self-assembly between receptor 1  
and peptide-PEG conjugates 2 or 55. 
 
Furthermore, by changing the pH to acidic condition (pH ~3), the receptor 
precipitated, indicating the destruction of the vesicles. This phenomenon is due to the 
protonation of the histidine moiety, thereby breaking the interaction between the receptor 
and the pegylated peptide. This pH-sensitive behavior is interesting, for example, for the 
encapsulation and the delivery of drugs. 
 
= peptide-PEG conjugate 2 or 55 
= receptor 1
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In conclusion, we have used selective non-covalent interactions between a 
diketopiperazine receptor and its peptidic ligand to induce supramolecular assemblies. Light 
scattering, TEM and AFM studies demonstrate the formation of vesicles upon mixing the 
receptor with the specific peptide-PEG conjugate. Their size is independent of the peptide-
PEG to receptor ratio and the length of the PEG chain, suggesting that the receptor 
organization determines the overall shape of the vesicles. To further understand this high 
interaction, other investigations, like NMR tritration, are performed to determine the 
stoichiometry and the binding energies between the receptor and the pegylated peptides in 
aqueous solution. 
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5 CONCLUSIONS 
 
This thesis discusses the design and synthesis of macrocyclic two-armed 
diketopiperazine receptors and two-armed carbazole receptors. Using encoded combinatorial 
peptide libraries, peptidic ligands were successfully identified for both types of receptors. 
Previous work had demonstrated that two-armed diketopiperazine receptors bind certain 
tripeptides with high binding selectivity and affinitiy. This kind of selective non-covalent 
interactions was the basis for other applications, like supramolecular self-assembly in organic 
and aqueous media. 
 
The first part discusses the effect of macrocyclization on the binding properties of 
diketopiperazine receptors. Several macrocyclic receptors were prepared using different 
linking elements (e.g. ring closing metathesis, amide bond or disulfide bridge formation). 
Their binding properties were evaluated in on-bead screenings against a combinatorial split-
and-mix library of 24389 different peptides. These screenings demonstrated that macrocyclic 
receptors bind peptides with low selectivities compared to their open-chain parent 
diketopiperazine receptors. 
Furthermore, the binding affinities of these macrocyclic receptors were found to be 
weaker, in the range of ∆G = -2 to -3 kcal mol-1, towards their preferred peptides, compared 
to the interactions between flexible diketopiperazine receptors and their selected peptides 
(∆G = -5 to -6 kcal mol-1). The studies also showed that the binding properties of 
macrocyclic receptors depend on the choice of the linker-type, with long “spacers” leading to 
high binding selectivities compared to short “spacers”. This suggests that the conformations 
of macrocycles are different compared to the open-chain diketopiperazine receptor and alter 
the binding selectivites and affinities of these receptors. The flexibility of the open-chain 
receptor allows the arms to better adjust to a peptidic guest. 
 
In the second part of this thesis, the binding properties of two-armed receptors based 
on a carbazole template were examined. The carbazole template was envisioned as an 
alternative template to the diketopiperazine template, offering an additional functionalization 
site for attachment of the receptors to, e.g. a dye, solid support or a soluble polymer, which 
is opposite to the recognition elements. Screenings of several dye-marked carbazole 
receptors against an encoded tripeptide library demonstrated a high level of binding 
selectivity of the carbazole receptors towards certain resin-bound tripeptides in chloroform.  
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Subsequently, solid phase binding affinity studies showed that carbazole receptors 
bind their selected peptides, with binding affinities in the range of ∆G = -4 to -5 kcal mol-1. 
These binding properties are comparable to those of diketopiperazine receptors, 
demonstrating that the carbazole template can be a useful alternative to the diketopiperazine 
template. Moreover, the position of the dye - whether it is attached to the peptidic side-
chains or to the additional functional site of the carbazole template – was found to neither 
affect the binding selectivity nor the binding affinitiy of the receptors. This suggests that the 
dye does not play a crucial role in the intermolecular interaction between two-armed 
receptors and peptides. 
Based on these studies, libraries of carbazole receptors were prepared, with three or 
four variable side-chains, resulting in approximately 3375 carbazole receptors and 50625 
receptors, respectively, for selective binding towards peptides. First screenings against 
fluorophore-marked Angiotensin II or segments of the Alzheimer’s peptides, in aqueous 
solution, were unfortunately not successful. 
 
 The third part discusses the formation of vesicles between a diketopiperazine 
receptor and peptide-PEG conjugates in aqueous solution. The highly selective intermolecular 
interaction between the diketopiperazine receptor and the peptide, Ac-D-Val-D-Val-D-His-
resin (resin = polystyrene), was used to induce supramolecular assemblies by functionalizing 
the peptide with a PEG-chain. In chloroform, the diketopiperazine receptor mixed with the 
pegylated peptide, forms a gel. In aqueous solution, the formation of vesicles was observed 
and studied using Dynamic Light Scattering, Transmission Electron and Atomic Force 
Microscopy, as well as surface pressure measurements. No supramolecular assemblies were 
observed when the receptor was mixed with non-selected peptide-PEG conjugates, 
demonstrating that the assembly is driven by selective non-covalent interactions. 
 The vesicles have a diameter of 100 nm when a small PEG-chain was attached to the 
peptide and 200 nm with a long PEG-chain. Furthermore, the size of the self-assembly 
induced with the peptide-PEG conjugates does not depend on the peptide/receptor ratio. 
This work is the first example of vesicle formation based on selective non-covalent 
interactions. 
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List of Abbreviations 
 
 
9-BBN  9-borabicyclo[3.3.1]nonane 
AA  amino acid 
Abz  2-aminobenzoyl 
Ac  acetyl 
Acm  acetamidomethyl 
Ac2O  acetic anhydride 
AcOH  acetic acid 
AFM  atomic force microscopy 
Ahx  aminohexenoic acid 
Ala  alanine 
anh.  anhydrous 
Asn  asparagine 
aq.  aqueous 
Boc  tert-butoxycarbonyl 
Boc2O  tert-butoxycarbonyl anhydride 
calcd.  calculated 
CAM  ceric ammonium molybdate 
COSY  Correlated Spectroscopy 
Cys  cysteine 
DCC  N,N-dicyclohexylcarbodiimid 
DIAD  diisopropyl azodicarboxylate 
DIC  diisopropylcarbodiimide 
DEPBT  3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one 
DEPT  Distortionless Enhancement by Polarization Transfer 
DLS  dynamic light scattering 
DMAP  N,N-dimethylamino pyridine 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DNS  dansyl 
EC-GC  electron capture gas chromatograpghy 
EDC  1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
ESI  electron spray ionisation 
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eq  equivalent 
EtOAc  ethyl acetate 
FAM  carboxyfluorescein 
Fmoc  9-fluorenylmethoxycarbonyl 
Gln  glutamine 
Gly  glycine 
h  hour(s) 
HATU  O-(7-azabenzotriazol-1-yl)N,N,N’,N’-tetramethyluronium hexafluorophosphate 
HCTU O-(1H-6-chlorobenzotriazole-1-yl)1,1,3,3-tetramethyluronium 
hexafluorphosphate 
His histidine 
HMBC Heteronuclear Multiple Quantum Coherence 
HMQC Heteronuclear Multiple Bond Correlation 
HOBt N-hydroxybenzotriazole 
Hph hydrophobic amino acid 
HPLC high performance liquid chromatography 
LB Langmuir-Blodgett 
Lys lysine 
MALDI-Tof Matrix Assisted Laser Desorption Ionisation – Time of Flight 
MeOH methanol 
min minute(s) 
MS mass spectrometry 
MsCl methanesulfonyl chloride 
NBD nitrobenzofurazan 
NMR nuclear magnetic resonance 
NOESY Nuclear Overhauser Enhancement Spectroscopy 
org. organic 
PAP PEG attached products 
PBS phosphate buffer saline 
PEG polyethylene glycol 
Pfp pentafluorophenyl 
Phe phenylalanine 
ppm parts per million 
PyAOP (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
quant. quantitative 
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r.t. room temperature 
sat. saturated 
soln. solution 
TAEA  tris(2-aminoethyl)amine 
TBTU  O-benzotriazol-1-yl-N,N,N’,N’,tetramethyluronium tetrafluoroborate 
TEG  tetraethylene glycol 
TEM  transmission electron miscroscopy 
TFA  trifluoroacetic acid 
TFE  trifluoroethanol 
THF  tetrahydrofuran 
TIS  triisopropylsilane 
TLC  thin layer chromatography 
TMSBr  trimethylsilylbromide 
TOCSY  Total Correlation Spectroscopy 
Trt  triphenylmethyl (trityl) 
tBu  tert-butyl 
Tyr tyrosine 
UV ultra violet 
Val valine 
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6 GENERAL EXPERIMENTAL CONDITIONS 
 
6.1 Analytical Methods 
 
1H NMR Varian Gemini VXR 400 (400 MHz), Brucker 500 DPX (500 MHz) 
Chemical shifts (δ) are indicated in ppm, relative to SiMe4 (δ = 0.00 ppm) or based on the 
solvent signals of the partially deuterated nuclei of chloroform-d1 (δ = 7.26 ppm), dimethyl 
sulfoxide-d6 (δ = 2.50 ppm) or methanol-d4 (δ = 3.31 ppm). All spectra are interpreted by 
first order, and the coupling constants (J) are given in Hertz (Hz). The classification of the 
signals was achieved by COSY, NOESY and TOCSY. The signals were abbreviated as follows: 
s = singlet, br. s = broad singlet, d = doublet, t = triplet, q = quartet, quint. = quintet, m = 
multiplet, ψ = pseudo. All solvents were purchased from Cambridge Isotope Laboratories, 
Inc. 
 
13C NMR Varian Gemini VXR 400 (101.0 MHz), Brucker 500 DPX (125.6 MHz) 
Chemical shifts (δ) are indicated in ppm and are relative to the following solvent signals: 
chloroform-d1 (δ = 77.1 ppm), dimethyl sulfoxide-d6 (δ = 39.5 ppm) or methanol-d4 (δ = 
49.0 ppm). The spectra are broad-band proton decoupled. The classification of the signals 
was achieved by DEPT, HMQC and HMBC. The signal for quaternary carbons was 
abbreviated as follows: Cq. 
 
Electrospray Mass Spectrometry Brucker esquire 3000plus, Finnigan MAT LCQ (octapole 
mass spectrometer) 
The samples were directly injected as 0.1 mg ml-1 solutions in MeOH/CHCl3 (10:90, v/v). The 
ion source worked via electron ionization. The data are given in mass units per charge (m/z). 
 
MALDI-TOF Mass Spectrometry (matrix-assisted laser desorption ionization time-
of-flight) Voyager-DE PRO BioSpectrometry Workstation from Applied Biosystems. 
2,6-dihydroxyacetophenone and α-cyano-4-hydroxycinnamic acid were used as matrix. 
Sample desorption and ionization was induced by a N2-laser (337 nm, 3 ns pulses). The 
signals are referred to the unfragmented, single charged molecule ions [M-H]- and [M+H]+. 
The data are given in mass units per charge (m/z). 
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UV-Vis Spectroscopy 
Ultra violet – visible absorption spectra were recorded on a Perkin Elmer Lambda Bio UV/Vis 
spectrometer using precision cells made of quartz SUPRASIL® (Hellma, Typ 114-QS, d = 1 
mm). 
 
Electron Capture – Gas Chromatography (EC-GC) 
Gas chromatography of the tags was performed on a Hewlett Packard HP 6890 GC system 
using Agilent Techologies Ultra 1 (crosslinked methyl siloxane) column. As the solvent, DMF 
from Aldrich, was used. The tag alcohols were silylated with N,O-bis(trimethylsilyl)-
acetamide from Aldrich. 
 
Dynamic Light Scattering (DLS) 
Dynamic Light Scattering was performed using an ALV DLS/SLS-5022F compact goniometer 
system from ALV-Laser Vertriebs GmbH equipped with an ALV/CGS-8F goniometer, an ALV-
5000-EPP multiple tau digital correlator, ALC correlator software 3.0 and a 1145P-3083 He-
Ne-laser from JDS Uniphase (22 mW, 633 nm) at scattering angles between 30° and 150°. 
Quartz cuvettes were purchased from Hellma. 
 
Transmission Electron Microscopy (TEM) 
TEM was carried out by Vesna Olivieri at the Microscopy Center (Pharmazentrum) at the 
University of Basel. The analysis were performed employing a Philips EM 400 operated at 80 
kV equipped with a Megaview II charge-coupled device camera (CCD) and controlled with a 
Morgagni 268D control and image acquisition software. The sample was adsorbed on a glow 
discharged, parlodion coated, 150 mesh copper grid. After washing cycles with water, the 
sample was dryed in air. 
 
Atomic Force Microscopy (AFM) 
AFM was carried out by Dipl. Ing. Olivier Casse at the Chemistry Department at the 
University of Basel. The analyses were conducted using a Pico SPM LE from Molecular 
Imaging with silicon cantilevers (C = 10-130 N/m, Nanosensors). Non-contact mode has 
been employed for the investigations of surface topography in dry state. The vesicles were 
deposited from aqueous solution on freshly cleaved mica. Measurements were done in the 
dry state, after evaporation of the solvent. 
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Langmuir-Blodgett Techniques (LB) 
LB was carried out by Dr. Katarzyna Kita at the Chemistry Department at the University of 
Basel. The analyses were performed employing a Langmuir-Blodgett mini-through (Teflon) 
from KSV Ltd. with a total area of 243 cm2. Symmetric compression was carried out by two 
Delrin barriers (compression rate: 10 mm min-1) and the surface pressure was measured by 
Wilhelmy plate method (plate made from ashless Whatman Chr1 chromatography paper, 
perimeter 20 mm, sensitivity: ±0.1 mN m-1). As spreading solvent, chloroform, was used and 
as subphase, bi-distilled water at 20°C (pH 5.5). 
 
 
6.2 Separation and purification methods 
 
Thin Layer Chromatography (TLC) and Flash Chromatography 
Reactions were monitored by thin layer chromatography (TLC) using Merck silica gel 60 F254 
plates. Compounds were visualized by UV, ceric ammonium molybdate (CAM) and ninhydrin. 
TLC retention factors (Rf) are indicated together with the apropriate solvent mixture in 
brackets. Flash chromatography was performed under low pressure (~1.5 bar, membrane 
pump) on silica gel Merck 60 (40-60 µm particle size). The solvents were of technical grade 
and were re-distilled prior to use. The mixture ratios of solvents are referred to the parts of 
the volume. 
 
High Performance Liquid Chromatography (HPLC) Shimadzu Class-VP with UV-Vis 
detection. Reversed-phase HPLC analyses were carried out on Merck LiChrosphere 100 RP-
18e 5µm (250 mm x 4.6 mm) and normal-phase HPLC on a Macherey-Nagel Nucleosil 100.5 
(250 mm x 4.6 mm). As solvents, acetonitrile from Fisher Scientific, methanol and 
dichloromethane from J.T.Backer, were used. 
 
Size Exclusion and Ion Exchange Chromatography 
Size exclusion chromatography was performed on Sephadex LH20 resin purchased from 
Sigma. Ion exchange chromatography was performed using Dowex® 1x2-400 (Dowex-1-
chloride, strongly basic anion) from Sigma-Aldrich.  
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6.3 Further Instruments 
 
Thermomixer Eppendorf Thermomixer confort  
Microscope Olympus Microscope SXZ12 
Camera (from microscope) Olympus Camera Camedia C-3000 Zoom 
 
 
6.4 Solvents and Chemicals 
 
Materials and reagents were of the highest commercially available grade and used without 
further purification. Technical grade solvents for extraction and flash column 
chromatography were distilled prior to use. For all other reactions in water-free environment, 
or for analytical purposes, absolute solvents from Fluka were used without further 
purification. The water used for reactions and HPLC was filtered over Barnstead ultrapure 
water system. TentatelGel-PAP-NH2 was purchased from Rapp Polymere GmbH, Tübingen 
Germany and the Wang resin from Novabiochem. The protected amino acids were purchased 
from Bachem AG and Novabiochem. Coupling reagents were purchased from Fluka, Iris 
Biotech, Bachem AG or Senn Chemicals. 
 
 
6.5 Assignment of C and H for Proline Derivatives 
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Preparation of PBS (phosphate buffer saline) buffer 10 mM, pH 7.20: 
100 mg KCl, 100 mg KH2PO4, 4 g NaCl and 575 mg Na2HPO4 were mixed in 20 ml nanopure 
H2O. The pH of the solution was adjusted to 7.20 with 1 N aq. HCl, and the volume was 
adjusted to 500 ml with nanopure H2O. 
 
Na-phosphate buffer 0.1 M, pH 5.5: 
90 g NaH2PO4, 32.7 g Na2HPO4 and 500 ml of H2O 
 
KMnO4-Dip: 
9 g KMnO4, 60 g K2CO3, 15 ml 5% NaOH and 900 ml H2O 
 
Ninhydrin-Dip: 
0.6 g ninhydrin, 200 ml butanol and 6 ml 99% AcOH 
 
CAM-Dip: 
2.5 g Ce(SO4)2, 75 g (NH4)6Mo7O24 and 500 ml 10% H2SO4 
 
α-Cyano-4-hydroxycinnamic acid matrix: 
10 mg α-cyano-4-hydroxycinnamic in 1:1 (v/v) mixture of water/acetonitrile with 0.3% TFA 
(1 ml) 
 
2,6-Dihydroxyacetophenone matrix: 
1) A small amount of 2,6-dihydroxyacetophenone in 1:1 (v/v) mixture of H2O/acetonitrile 
(1 ml) 
2) 92 mg ammonium tartrate in H2O (1 ml) 
3) 600 µl of 1 mixed with 300 µl of 2 
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NBoc
CO2HHO
NBoc
CO2CH3HO
1. Cs2CO3, H2O/MeOH
2. MeI, DMF
94 %
3 4
7 SYNTHESIS OF THE SYMMETRIC DIKETOPIPERAZINE TEMPLATE 
 
7.1 N-Boc-trans-γ-hydroxy-L-proline methyl ester 4 
 
 
 
 
 
To a solution of 20.0 g (86.45 mmol, 1 eq) N-Boc-trans-γ-hydroxy-L-proline 3 in 
MeOH (100 ml), 15.6 g (47.56 mmol, 0.55 eq) Cs2CO3, dissolved in H2O (20 ml), were 
added. After stirring for 1 h at r.t., MeOH was removed under reduced pressure and the 
residue was co-evaporated 5 times with toluene (20 ml). The resulting precipitate was 
dissolved in DMF (60 ml) and treated with 11 ml (172.93 mmol, 2 eq) MeI. After 30 min in 
the sonicator at r.t., the reaction mixture was first filtered (formation of CsI-salt) and then 
extracted with Et2O (6x160ml). The combined org. phases were dried over Na2SO4, filtered 
and the solvent was removed under reduced pressure. 20.0 g (81.55 mmol, 94%) N-Boc-
trans-γ-hydroxy-L-proline methyl ester 4 were isolated as a white/yellow solid. (1H and 13C 
NMR-spectra show a double set of peaks (~ 1:2) due to the s-cis and s-trans conformers on 
the tertiary amide and the carbamate). 
 
C11H19NO5: 245.13 
 
TLC: Pentane/EtOAc (1/1); Rf: 0.29 (Ninhydrin). 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 4.43 (m, 2H; Hα, Hγ, major + minor), 3.71 (s, 
3H; -CO2CH3, major + minor), 3.53 (m, 2H; Hδ, Hδ’, major + minor), 2.25 (m, 1H; Hβ, major 
+ minor), 2.01 (m, 1H; Hβ’, major + minor), 1.44 (s, 9H; -tBu, minor), 1.45 (s, 9H; -tBu, 
major). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) major = 173.6 (Cq;-CO2CH3), 153.9 (Cq; COBoc), 
80.3 (Cq; -tBu), 69.3 (CH; Cγ), 57.9 (CH; Cα), 54.6 (CH2; Cδ, Cδ’), 52.0 (CH3; -CO2CO3), 39.0 
(CH2; Cβ, Cβ’), 28.2 (CH3; -tBu). 
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1. PPh3, DIAD, PhCO2H, THF
2. NaOCH3, H2O/MeOH
66 %
4 5
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) minor = 173.4 (Cq;-CO2CH3), 154.5 (Cq; COBoc), 
80.2 (Cq; -tBu), 70.0 (CH; Cγ), 57.4 (CH; Cα), 54.7 (CH2; Cδ, Cδ’), 52.2 (CH3; -CO2CO3), 38.4 
(CH2; Cβ, Cβ’), 28.3 (CH3; -tBu). 
 
ESI-MS: m/z: calcd for C11H19NO5Na: 268 [M+Na]+; found: 268. 
 
 
7.2 N-Boc-cis-γ-hydroxy-L-proline methyl ester 5 
 
 
 
 
 
To a suspension of 20.0 g (81.55 mmol, 1 eq) N-Boc-trans-γ-hydroxy-L-proline methyl 
ester 4 in THF (135 ml), 11.5 g (93.78 mmol, 1.15 eq) benzoic acid and 24.8 g (94.4 mmol, 
1.16 eq) PPh3 were added. The mixture was cooled with an ice bath before 17.4 ml (89.70 
mmol, 1.1 eq) DIAD were added and allowed to stir at r.t. for 2.5 h. After removal of the 
solvent under reduced pressure, the oily residue was co-evaporated three times with CH2Cl2 
(70 ml) and then triturated 2 times with a mixture of hexane and EtOAc to yield a white solid 
(triphenylphosphine oxide). The white solid was filtered off and then washed with hexane. 
The hexane-phases were combined and, after removal of the solvent under reduced 
pressure, the residue was purified by flash chromatography (gradient of pentane/EtOAc from 
9:1 to 4:1 (v/v) with 10% CH2Cl2) to afford 27.4 g (78.58 mmol, 96%) of the benzoic acid 
ester of 4 as white solid. The product was subsequently dissolved in MeOH (112 ml) and 
allowed to react with 4.0 g (74.67 mmol, 0.95 eq) NaOCH3 dissolved in MeOH (22 ml). After 
15 min. the solvent was removed under reduced pressure and the residue was diluted in 
CH2Cl2 and washed with water. The aq. phase was extracted again with CH2Cl2 and the 
combined org. phases were dried over Na2SO4. After removal of all volatiles under reduced 
pressure, flash chromatography (gradient of pentane/EtOAc from 3:1 to 2:3 (v/v)) afforded 
12.7 g (51.81 mmol, 66%) N-Boc-cis-γ-hydroxy-L-proline methyl ester 5 as a white solid. (1H 
and 13C NMR-spectra show a double set of peaks (~ 1:1) due to the s-cis and s-trans 
conformers on the tertiary amide and the carbamate). 
 
C11H19NO5: 245.13 
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NBoc
CO2CH3HO
1. MsCl, Et3N, CH2Cl2
2. NaN3, DMF
96 %
5
NBoc
CO2CH3N3
6
TLC: Pentane/EtOAc (1/1); Rf: 0.17 (Ninhydrin). 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 4.33 (m, 2H; Hα, Hγ), 3.78 (s, 3H; -CO2CH3), 
3.61 (m, 2H; Hδ, Hδ’), 2.33 (m, 2H; Hβ), 2.08 (m, 2H; Hβ’), 1.48 (s, 9H; -tBu), 1.37 (s, 9H; -
tBu). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 175.3/175.1 (Cq;-CO2CH3), 154.4/153.6 (Cq; 
COBoc), 80.3 (Cq; -tBu), 71.0/69.9 (CH; Cγ), 57.8/57.6 (CH; Cα), 55.7/55.1 (CH2; Cδ, Cδ’), 
52.6/52.3 (CH3; -CO2CO3), 38.5/35.3 (CH2; Cβ, Cβ’), 28.3/28.1 (CH3; -tBu). 
 
ESI-MS: m/z: calcd for C11H19NO5Na: 268 [M+Na]+; found: 268. 
 
 
7.3 N-Boc-trans-γ-azido-L-proline methyl ester 6 
 
 
 
 
 
To a solution of 12.5 g (50.99 mmol, 1 eq) N-Boc-cis-γ-hydroxy-L-proline methyl ester 
5 in CH2Cl2 (145 ml), 8.5 ml (61.19 mmol, 1.2 eq) Et3N were added. The mixture was cooled 
with an ice bath and then 4.7 ml (61.19 mmol, 1.2 eq) MsCl were slowly added. After 30 
min. the reaction mixture was washed with sat. NaHCO3-soln. and extracted three times with 
CH2Cl2. The combined org. phases were dried over Na2SO4. Filtration and removal of the 
solvent under reduced pressure yielded a yellow oily residue that was dissolved in DMF (145 
ml) and treated with 16.6 g (254.97 mmol, 5 eq) NaN3 at 80°C. After 2 h, the reaction 
mixture was washed with NaHCO3-soln. and extracted three times with Et2O, the combined 
org. phases were dried over Na2SO4. After removal the solvent under reduced pressure and 
drying in vacuo, 13.2 g (48.86 mmol, 96%) N-Boc-trans-γ-azido-L-proline methyl ester 6 
were isolated as a white solid. (1H and 13C NMR-spectra show a double set of peaks (~ 2:3) 
due to the s-cis and s-trans conformers on the tertiary amide and the carbamate). 
 
C11H18N4O4: 270.13 
 
TLC: Pentane/EtOAc (1/1); Rf: 0.7 (Ninhydrin). 
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1. NaOH, THF/MeOH/H2O
2. C6F5OH, EDC, CH2Cl2
85 %
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 4.38 (t, J = 7.1 Hz, 1H; Hα, minor), 4.29 (t, J = 
7.6 Hz, 1H; Hα, major), 4.17 (m, 1H; Hγ, major + minor), 3.71 (s, 3H; -CO2CH3, major + 
minor), 3.66 (m, 1H; Hδ, major + minor), 3.50 (m, 1H; Hδ’, major + minor), 2.30 (m, 1H; 
Hβ, major + minor), 2.14 (m, 2H; Hβ’, major + minor), 1.43 (1s, 9H; -tBu, minor), 1.38 (1s, 
9H; -tBu, major). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) major = 172.9 (Cq;-CO2CH3), 153.0 (Cq; COBoc), 
80.1 (Cq; -tBu), 58.5 (CH; Cα), 57.4 (CH; Cγ), 51.8 (CH2; Cδ, Cδ’), 50.9 (CH3; -CO2CO3), 35.9 
(CH2; Cβ, Cβ’), 27.9 (CH3; -tBu). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) minor = 172.4 (Cq;-CO2CH3), 153.7 (Cq; COBoc), 
80.0 (Cq; -tBu), 59.0 (CH; Cα), 57.1 (CH; Cγ), 52.0 (CH2; Cδ, Cδ’), 51.1 (CH3; -CO2CO3), 35.0 
(CH2; Cβ, Cβ’), 28.0 (CH3; -tBu). 
 
ESI-MS: m/z: calcd for C11H18N4O4Na: 293 [M+Na]+; found: 293. 
 
 
7.4 N-Boc-trans-γ-azido-L-proline pentafluorophenyl ester 7 
 
 
 
 
 
7.0 g (25.91 mmol, 1 eq) N-Boc-trans-γ-azido-L-proline methyl ester 6 were dissolved 
in a 1:1 (v/v) mixture of THF/MeOH (50 ml). After the addition of 2.0 g (46.64 mmol, 1.8 eq) 
NaOH in water (12.5 ml), the mixture was stirred for 1.5 h at r.t. The reaction mixture was 
then carefully acidified with 1 M HCl to pH 3. The mixture was diluted in CH2Cl2 and washed 
with water. The aq. phase was extracted with EtOAc, the org. phases were washed with 
brine and dried over Na2SO4. Filtration and evaporation of the solvent under reduced 
pressure yielded a yellow oily residue which was dissolved in CH2Cl2 (67 ml). 
After addition of 5.3 g (28.50 mmol, 1.1 eq) 2,3,4,5,6-pentafluorophenol and 7.4 g 
(38.87 mmol, 1.5 eq) EDC, the solution was stirred at r.t. for 1 h and then acidified with 1 M 
HCl to pH 3. The reaction mixture was extracted with water and EtOAc. The aq. phase was 
extracted again with EtOAc and the org. phases were washed with brine and dried over 
Na2SO4. Filtration and removal of all volatiles under reduced pressure yielded 8.7 g (20.60 
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mmol, 80%) of the pentafluorophenylester 7 as a white solid. (1H and 13C NMR-spectra show 
a double set of peaks (~ 2:1) due to the s-cis and s-trans conformers on the tertiary amide 
and the carbamate). 
 
C16H15F5N4O4: 422.31 
 
TLC: Pentane/EtOAc (5/1); Rf: 0.7 (Ninhydrin). 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 4.72 (m, 1H; Hα, major + minor), 4.26 (m, 1H; 
Hγ, major + minor), 3.72 (m, 1H; Hδ, major + minor), 3.56 (m, 1H; Hδ’, major + minor), 
2.55 (m, 1H; Hβ, major + minor), 2.38 (m, 1H; Hβ’, major + minor), 1.48 (s, 9H; -tBu, 
minor), 1.46 (1s, 9H; -tBu, major). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) major = 168.5 (Cq;-CO2C6F5), 153.3 (Cq; COBoc), 
82.0 (Cq; -tBu), 58.6 (CH; Cα), 57.3 (CH; Cγ), 51.3 (CH2; Cδ, Cδ’), 36.7 (CH2; Cβ, Cβ’), 28.0 
(CH3; -tBu). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) minor = 168.3 (Cq;-CO2C6F5), 153.9 (Cq; COBoc), 
81.5 (Cq; -tBu), 59.3 (CH; Cα), 57.2 (CH; Cγ), 51.4 (CH2; Cδ, Cδ’), 35.4 (CH2; Cβ, Cβ’), 28.2 
(CH3; -tBu). 
 
ESI-MS: m/z: calcd for C16H15F5N4O4Na: 445 [M+Na]+; found: 445. 
 
 
7.5 TFA-trans-γ-azido-L-proline methyl ester 8 
 
 
 
 
 
5.6 g (20.57 mmol, 1 eq) of the N-Boc protected proline methylester 6 were 
dissolved in a 1:3 (v/v) mixture of TFA and CH2Cl2 (21.3 ml) and allowed to stir at r.t. for 1.5 
h. After removal of all volatiles under reduced pressure the oily residue was triturated with 
Et2O and isolated by decantation followed by removal of all residual volatiles in vacuo to yield 
5.6 g (20.57 mmol, quant.) of the TFA-salt 8 as a white solid. 
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C9H11F3N4O4: 284.2 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 4.56 (m, 1H; Hα), 4.49 (m, 1H; Hγ), 3.81 (s, 
3H; -CO2CH3), 3.76 (m, 1H; Hδ), 3.47 (m, 1H; Hδ’), 2.49 (m, 2H; Hβ), 2.40 (m, 2H; Hβ’). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 168.4 (Cq;-CO2CH3), 59.4/58.2 (CH; Cα), 53.7 
(CH; Cγ), 50.7 (CH2; Cδ, Cδ’), 34.6 (CH2; Cβ, Cβ’). 
 
ESI-MS: m/z: calcd for C9H10N4O2: 170 [M]+; found: 170. 
 
 
7.6 N-Boc-(trans-γ-azido-L-Pro)2-OCH3 9 
 
 
 
 
 
 
 
 
8.7 g (20.57 mmol, 1 eq) of the pentafluorophenol-ester 7 were added to a 5.8 g 
(20.57 mmol, 1 eq) TFA-salt 8 and 6.1 ml (41.14 mmol, 2 eq) iPr2Net solution in CH2Cl2 (27 
ml). The solution was slowly concentrated using a N2 flow and the residual colorless oil 
stirred for 15 h. The reaction mixture was then acidified with 1 M HCl to pH 3 and extracted 
with H2O and EtOAc. The aq. phase was extracted with EtOAc, the org. phases were washed 
with brine and dried over Na2SO4. Filtration and evaporation of the solvent under reduced 
pressure yielded the crude product, which was purified by flash chromatography on silica gel 
(gradient of CH2Cl2/MeOH from 100:0 to 98:2 (v/v)) to yield 5.8 g (14.23 mmol, 69%) of the 
dipeptide 9 as a white solid. (1H and 13C NMR-spectra show a double set of peaks (~ 2:1) 
due to the s-cis and s-trans conformers on the tertiary amide and the carbamate). 
 
C16H24N8O5: 408.41 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.6 (Ninhydrin). 
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1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 4.56 (m, 2H; Hα, major + minor), 4.30 (m, 2H; 
Hγ, major + minor), 3.83 (m, 2H; Hδ, major + minor), 3.67 (1s, 3H; -CO2CH3, minor), 3.66 
(1s, 3H; -CO2CH3, major), 3.62 (m, 2H; Hδ’, major + minor), 2.23 (m, 4H; Hβ, Hβ’, major + 
minor), 1.37 (1s, 9H; -tBu, major), 1.34 (s, 9H; -tBu, minor). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 171.8/171.6/170.8/170.7 (Cq; Cε, -CO2CH3, 
major + minor), 153.9/153.1 (Cq; COBoc, major + minor), 80.8 (Cq; -tBu, minor), 80.1 (Cq; -
tBu, major), 59.7/59.5/59.3/58.9 (CH; Cα, major + minor), 57.7/57.6/56.3/56.0/ (CH; Cγ, 
major + minor), 52.6/52.5 (CH2; Cδ, Cδ’, major + minor), 51.6/51.5/51.3 (CH3; -CO2CO3, 
major + minor), 35.6/34.9/34.1 (CH2; Cβ, Cβ’, major + minor), 28.3 (CH3; -tBu, major), 28.2 
(CH3; -tBu, minor). 
ESI-MS: m/z: calcd for C16H24N8O5Na: 431 [M+Na]+; found: 431. 
 
 
7.7 Cyclo-(trans-γ-azido-L-Pro)2 10 
 
 
 
 
 
 
 
 
5.8 g (14.24 mmol, 1 eq) of the dipeptide 9 were dissolved in a 1:3 (v/v) mixture of 
TFA and CH2Cl2 (46 ml) and allowed to stir at r.t. for 1.5 h. After removal of all volatiles 
under reduced pressure, the oily residue was triturated with Et2O to yield a white solid which 
was isolated by decantation, followed by removal of all residual volatiles in vacuo. The 
residue was dissolved in THF (53 ml), 12.2 ml (71.20 mmol, 5 eq) iPr2NEt were added and 
the mixture was stirred at r.t. for 16 h. The reaction mixture was acidified with 1 M HCl to 
pH 3 and extracted with H2O and CH2Cl2. The aq. phase was extracted with CH2Cl2, the org. 
phases were washed with brine and dried over Na2SO4. After filtration and evaporation of the 
solvent under reduced pressure, the crude product was purified by flash chromatography on 
silica gel (gradient of CH2Cl2/MeOH from 97:3 to 96:4 (v/v)) to afford 3.2 g (11.51 mmol, 
81%) of the diketopiperazine 10 as a white solid. 
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C10H12N8O2: 276.25 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.5 (Ninhydrin). 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 4.47 (dd, J = 10.6, 6.7 Hz, 2H; Hα), 4.36 (m, 
2H; Hγ), 3.71 (dd, J = 12.6, 4.5 Hz, 2H; Hδ), 3.62 (m, 2H; Hδ’), 2.45 (ddd, J = 13.6, 6.6, 1.5 
Hz, 2H; Hβ), 2.30 (ddd, J = 15.7, 10.6, 5.0 Hz, 2H; Hβ’). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 165.7 (Cq; Cε), 58.7/58.6 (CH; Cα, Cγ), 50.8 
(CH2; Cδ, Cδ’), 33.9 (CH2; Cβ, Cβ’). 
 
 
7.8 Cyclo-(trans-γ-N-Boc-L-Pro)2 11 
 
 
 
 
 
 
 
 
 
360 mg (10% of 10) Palladium on carbon were added to a solution of 3.2 g (11.51 
mmol, 1 eq) of the diazide 10 and 10.3 g (47.19 mmol, 4.1 eq) Boc2O in MeOH (123 ml). 
The black suspension was evacuated, flushed with hydrogen and allowed to stir for 3 h at 
r.t. After filtration over celite, the residue was washed with a 10:90 (v/v) mixture of 
MeOH/CH2Cl2. After removal of the solvent under reduced pressure, the residue was purified 
by flash chromatography over silica gel (gradient of CH2Cl2/MeOH from 100:0 to 95:5 (v/v)) 
to afford 4.4 g (1.53 mmol, 13%) of the diketopiperazine 11 as a white solid. 
 
C20H32N4O6: 424.23 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.3 (Ninhydrin). 
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1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 4.42 (ψt, J = 8.6 Hz, 2H; Hα), 4.01 (m, 2H; 
Hγ), 3.61 (m, 2H; Hδ), 3.21 (m, 2H; Hδ’), 2.15 (m, 2H; Hβ), 2.08 (m, 2H; Hβ’), 1.39 (s, 18H; 
-tBu). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 166.4 (Cq; Cε), 155.1 (Cq; COBoc), 58.2 (CH; 
Cα, Cγ), 51.4 (CH2; Cδ, Cδ’), 33.1 (CH2; Cβ, Cβ’), 28.2 (CH3; -tBu). 
 
ESI-MS: m/z: calcd for C20H32N4O6Na: 447 [M+Na]+; found: 447. 
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8 SYNTHESIS OF THE TWO-ARMED DIKETOPIPERAZINE RECEPTOR PRECURSOR 
 
8.1 N-Boc-L-Tyr(dye)-OCH3 58 
 
 
 
 
 
 
 
 
 
 
 
2.0 g (6.77 mmol, 1 eq) N-Boc-L-tyrosine-methylester, 2.1 g (6.77 mmol, 1 eq) 
Disperse Red 1 (dye) and 1.8 g (6.77 mmol, 1 eq) PPh3 were dissolved in toluene (136 ml). 
1.3 ml (6.77 mmol, 1 eq) DIAD were added dropwise in 15 min and the mixture was allowed 
to stir at r.t. for 16 h. After removal of the solvent under reduced pressure, flash 
chromatography over silica gel (gradient of CH2Cl2/Acetone from 100:0 to 97:3 (v/v)) 
afforded 1.9 g (3.16 mmol, 46%) N-Boc-L-Tyr(dye)-OCH3 58 as a red solid. 
 
C31H37N5O7: 591.65 
 
TLC: Pentan/EtOAc (2:1); Rf: 0.3. 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 8.32 (d, J = 9.1 Hz, 2H; Hdye), 7.92 (d, J = 9.1 
Hz, 2H; Hdye), 7.90 (d, J = 9.0 Hz, 2H; Hdye), 7.02 (d, J = 8.6 Hz, 2H; HTyr), 6.81 (m, 4H; 
Hdye, HTyr), 4.95 (br d, J = 8.6 Hz, 1H; -NHBoc), 4.53 (dd, J = 13.7, 6.1 Hz, 1H; Hα), 4.16 (t, J 
= 6.1 Hz, 2H; -N-CH2CH2-O-dye), 3.84 (t, J = 5.9 Hz, 2H; -N-CH2CH2-O-dye), 3.70 (s, 3H; -
CO2CH3), 3.61 (q, J = 7.1 Hz, 2H; -N-CH2CH3dye), 3.05 (dd, J = 14.2, 6.2 Hz, 1H; Hβ), 3.02 
(dd, J = 14.0, 6.0 Hz, 1H; Hβ’), 1.41 (s, 9H; -tBu), 1.29 (t, J = 7.0 Hz, 3H; -N-CH2CH3dye). 
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13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 172.3 (Cq; CO), 156.8/151.2/147.4/143.7/ 
128.6 (Cq; dye, Tyr), 130.4/126.3/124.7/122.6/114.5/111.4 (CH; dye, Tyr), 79.9 (Cq; C-tBu), 
65.3 (CH2; -N-CH2CH2-O-dye), 54.5 (CH; Cα), 52.2 (CH3; -CO2CH3), 49.9 (CH2; -N-CH2CH2-O-
dye), 46.2 (CH2; -N-CH2CH3dye), 37.5 (CH2; Cβ, Cβ’), 28.3 (CH3; C-tBu), 12.3 (CH3; -N-
CH2CH3dye). 
 
ESI-MS: m/z: calcd for C31H37N5O7Na: 614 [M+Na]+; found: 614. 
 
 
8.2 N-Boc-L-Tyr(dye)-OH 13 
 
 
 
 
 
 
 
837 mg (1.41 mmol, 1 eq) N-Boc-L-Tyr(dye)-OCH3 58 were dissolved in a 1:1 (v/v) 
mixture of THF and MeOH (2.6 ml). After the addition of 102 mg (2.55 mmol, 1.8 eq) NaOH 
in water (1 ml), the mixture was stirred overnight at r.t. The reaction mixture was then 
carefully acidified to pH 3 with 1 M HCl. CH2Cl2 and water were added and the mixture was 
extracted. The aq. phase was extracted again with CH2Cl2 and the org. phases were washed 
with brine and dried over Na2SO4. Filtration and evaporation of the solvent under reduced 
pressure yielded 814 mg (1.41 mmol, quant.) N-Boc-L-Tyr(dye)-OH 13 as red solid. 
 
C30H35N5O7: 577.53 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.6. 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 8.32 (d, J = 9.1 Hz, 2H; Hdye), 7.92 (d, J = 9.1 
Hz, 2H; Hdye), 7.90 (d, 2H; Hdye), 7.09 (d, J = 8.7 Hz, 2H; HTyr), 6.81 (m, 4H; Hdye, HTyr), 4.90 
(br d, J = 8.0 Hz, 1H; -NHBoc), 4.53 (m, 1H; Hα), 4.16 (t, J = 5.6 Hz, 2H; -N-CH2CH2-O-dye), 
3.84 (t, J = 5.4 Hz, 2H; -N-CH2CH2-O-dye), 3.60 (q, J = 7.1 Hz, 2H; -N-CH2CH3dye), 3.11 (dd, 
J = 14.1, 5.6 Hz, 1H; Hβ), 3.02 (dd, J = 14.1, 5.4 Hz, 1H; Hβ’), 1.41 (s, 9H; -tBu), 1.28 (t, J 
= 7.0 Hz, 3H; -N-CH2CH3dye). 
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13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 167.1 (Cq; CO), 157.6 (Cq; COBoc), 156.8/ 
151.2/147.4/143.7 (Cq; dye, Tyr), 130.5/126.3/124.7/122.6/114.5/111.4 (CH; dye, Tyr), 
80.3 (Cq; C-tBu), 65.3 (CH2; -N-CH2CH2-O-dye), 54.5 (CH; Cα), 49.8 (CH2; -N-CH2CH2-O-dye), 
46.1 (CH2; -N-CH2CH3dye), 37.0 (CH2; Cβ, Cβ’), 28.3 (CH3; C-tBu), 12.3 (CH3; -N-CH2CH3dye). 
 
ESI-MS: m/z: calcd for C30H35N5O7Na: 600 [M+Na]+; found: 600. 
 
 
8.3 Synthesis of 14 
 
 
 
 
 
 
 
 
 
The Boc-protecting groups of 168 mg (396.7 µmol, 1 eq) of the bis-N-Boc-protected 
diketopiperazine 11 were removed with a 1:3 (v/v) mixture of TFA and CH2Cl2 (2.4 ml) as 
described for the formation of the TFA-salt 11. The residue was dissolved in CH2Cl2 (5.5 ml) 
followed by addition of 150 µl (707.5 µmol, 2 eq) iPr2NEt. The solution was cooled with an 
ice bath before a mixture of 603 mg (1.59 mmol, 4 eq) HATU in DMF (1 ml), 150 µl (707.5 
µmol, 2 eq) iPr2NEt and 916 mg (1.59 mmol, 4eq) N-Boc-L-Tyr(dye)-OH 13 in CH2Cl2 (5.5 
ml), was added and stirred at r.t. for 1 h. The reaction mixture was extracted three times 
with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The aq. phases were extracted again 
with CH2Cl2. The org. phases were extracted with 0.5 M NaOH and CH2Cl2. The aq. phase 
was extracted again with CH2Cl2. The org. phases were washed with brine and dried over 
Na2SO4. After filtration and evaporation of the solvent under reduced pressure the crude 
product was purified by flash chromatography on silica gel (gradient of CH2Cl2/MeOH from 
99.5:0.5 to 99:1 (v/v) with 0.5% of triethylamine) and by another flash chromatography on 
silica gel (gradient CH2Cl2/MeOH from 99.5:0.5 to 97:3 (v/v)) and finally by preparative-TLC 
(CH2Cl2/MeOH, 90:10, v/v) to afford 451 mg (336.6 µmol, 85%) of the diketopiperazine with 
attached N-Boc protected tyrosine 14. 
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C70H82N14O14: 1343.49 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.54. 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 8.30 (d, J = 9.1 Hz, 4H; Hdye), 7.90 (m, 8H; 
Hdye), 7.11 (d, J = 8.3 Hz, 4H; HTyr), 6.81 (m, 8H; Hdye, HTyr), 5.49 (br s, 2H; -NHBoc), 4.32 
(m, 2H; HαTyr), 4.16 (m, 8H; -N-CH2CH2-O-dye, Hα, Hγ), 3.82 (t, J = 5.3 Hz, 4H; -N-CH2CH2-
O-dye), 3.76 (m, 2H; Hδ), 3.60 (q, J = 7.0 Hz, 4H; -N-CH2CH3dye), 3.40 (dd, J = 12.7, 1.9 Hz, 
2H; Hδ’), 2.92 (m, 4H; HβTyr, Hβ’Tyr), 2.26/2.02 (m, 4H; Hβ, Hβ’), 1.38 (s, 18H; -tBu), 1.27 (t, 
J = 7.0 Hz, 9H; -N-CH2CH3dye). 
 
13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 171.3 (Cq; COTyr), 165.9 (Cq; CO), 157.4 (Cq; 
COBoc), 156.7/151.3/147.3/143.6/128.1 (Cq; dye, Tyr), 130.4/124.6/122.5/114.4/111.4 (CH; 
dye, Tyr), 65.3 (CH2; -N-CH2CH2-O-dye), 58.4 (CH; Cα, CαTyr), 50.9 (CH2; Cδ, Cδ’), 49.7 (CH2; -
N-CH2CH2-O-dye), 47.2 (CH; Cγ), 46.0 (CH2; -N-CH2CH3dye), 37.9 (CH2; CβTyr, Cβ’Tyr), 33.5 
(CH2; Cβ, Cβ’), 28.1 (CH3; C-tBu), 12.4 (CH3; -N-CH2CH3dye). 
 
ESI-MS: m/z: calcd for C70H82N14O14: 1343 [M]+; found: 1343. 
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8.4 General Fmoc-strategy for the Synthesis of the Two-Armed 
Diketopiperazine Receptor Precursor in Solution 
 
 
 
 
 
 
 
 
8.4.1 Diketopiperazine Receptor with Attached Fmoc-Protected Gln 
 
451 mg (335.7 µmol, 1 eq) of the diketopiperazine precursor 14 were dissolved in 
MeOH (7.5 ml) and treated with a solution of 4 M HCl in Dioxan (20 ml) at r.t. for 1 h. After 
removal of all volatiles under reduced pressure, the residue was triturated with Et2O to yield 
a red solid which was isolated by decantation and dried in vacuo. The corresponding HCl-salt 
of 14 was then dissolved in dry CH2Cl2 (5 ml) followed by addition of 115 µl (671.4 µmol, 2 
eq) iPr2NEt, ready for the next coupling. 
The solution was cooled with an ice bath before a mixture of 511 mg (1.34 mmol, 4 
eq) HATU in DMF (1ml), 230 µl (1.34 mmol, 4 eq) iPr2NEt and 820 mg (1.34 mmol, 4 eq) 
Fmoc-L-Gln(Trt)-OH in CH2Cl2 (5 ml), was added and stirred at r.t. for 1 h. The reaction 
mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The 
aq. phases were extracted again with CH2Cl2. The org. phases were washed with brine and 
dried over Na2SO4. After filtration and evaporation of the solvent under reduced pressure, 
the crude product was purified by flash chromatography on silica gel (gradient of 
CH2Cl2/MeOH from 99.5:0.5 to 97:3 (v/v)) and preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) to 
afford 697 mg (299.7 µmol, 89%) of the diketopiperazine precursor with attached Fmoc-
protected Gln. 
 
C138H130N18O18: 2328.62 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.68. 
 
ESI-MS: m/z: calcd for C138H129N18O18Na: 2350 [M-H+Na]+; found: 2350. 
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8.4.2 Two-Armed Diketopiperazine Precursor 15 
 
697 mg (299.7 µmol, 1 eq) of N-α-Fmoc-protected receptor precursor were dissolved 
in CH2Cl2 (36 ml) followed by addition of 2.2 ml (14.98 mmol, 50 eq) TAEA, which caused 
the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 min 
and then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) followed by brine. 
The aq. phases were washed once with CH2Cl2 and the org. phases were dried over Na2SO4 
to yield the corresponding diamine after filtration and removal of all volatiles under reduced 
pressure. 
The diamine was dissolved in dry CH2Cl2 (5 ml) followed by addition of 102 µl (599.5 
µmol, 2 eq) iPr2NEt. The solution was cooled with an ice bath before a mixture of 496 mg 
(1.20 mmol, 4 eq) HCTU in DMF (1.5 ml), 205 µl (1.20 mmol, 4 eq) iPr2NEt and 464 mg 
(1.20 mmol, 4 eq) Fmoc-L-Phe-OH in CH2Cl2 (5 ml), was added and stirred at r.t. for 1 h. The 
reaction mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and 
CH2Cl2. The aq. phases were extracted again with CH2Cl2 and the org. phases were washed 
with brine and dried over Na2SO4. After filtration and evaporation of the solvent under 
reduced pressure, the crude product was purified by flash chromatography on silica gel 
(gradient of CH2Cl2/MeOH from 99.5:0.5 to 97:3 (v/v)) and preparative-TLC (CH2Cl2/MeOH, 
90:10, v/v) to afford 606 mg (231.4 µmol, 77%) of the two-armed diketopiperazine 
precursor 15. 
 
C156H148N20O20: 2622.97 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.23. 
 
ESI-MS: m/z: calcd for C156H147N20O20Na: 2644 [M-H+Na]+; found: 2644. 
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9 SYNTHESIS OF MACROCYCLIC DIKETOPIPERAZINE RECEPTOR PROTOTYPES 
 
9.1 Ring Closing Metathesis 
 
9.1.1 Two-Armed Diketopiperazine Receptor Precursor 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 mg (38.2 µmol, 1 eq) of the diketopiperazine receptor precursor 15 were 
dissolved in CH2Cl2 (4.5 ml) followed by addition of 0.2 ml (1.92 mmol, 50 eq) TAEA which 
caused the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 
min and then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5). The aq. 
phases were washed once with CH2Cl2. The org. phases were washed with brine and dried 
over Na2SO4 to yield the corresponding diamine after filtration and removal of all volatiles 
under reduced pressure.  
The diamine was dissolved in dry CH2Cl2 (1 ml) followed by addition of 15 µl (76.5 
µmol, 2 eq) iPr2NEt. The solution was cooled with an ice bath before a mixture of 60 mg 
(152.8 µmol, 4 eq) HATU in DMF (0.5 ml), 15 µl (76.5 µmol, 2 eq) iPr2NEt and 20 µl (152.8 
µmol, 4eq) 5-hexenoic acid in CH2Cl2 (1 ml), was added and stirred at r.t. for 1 h. The 
reaction mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and 
CH2Cl2. The aq. phases were extracted again with CH2Cl2 and the org. phases were washed 
with brine and dried over Na2SO4. After filtration and evaporation of the solvent at reduced 
pressure, the crude product was purified by flash chromatography on silica gel (gradient of 
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CH2Cl2/MeOH from 99.5:0.5 to 96:4 (v/v)), preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) and 
gel filtration (LH 20, CH2Cl2/MeOH, 90:10, v/v) to afford 73 mg (30.9 µmol, 81%) of the two-
armed diketopiperazine precursor 16. 
 
C138H144N20O18: 2370.74 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.70. 
 
1H-NMR (500 MHz, 5% CD3OD in CDCl3, 25°C): δ(ppm) = 8.23 (d, J = 8.4 Hz, 4H; Hdye), 
7.85 (d, J = 8.8 Hz, 8H; Hdye), 7.29 – 7.04 (m, 44H, HTyr, HPhe, HTrt), 6.74 (d, J = 9.0 Hz, 4H; 
HTyr), 6.70 (d, J = 8.6 Hz, 4H; HTyr), 5.66 (ddt, J = 17.0, 10.3 Hz, 2H; HδHex), 4.82 (m, 4H; 
HεHex), 4.49 (dd, J = 10.6, 4.0 Hz, 2H; HαTyr), 4.43 (m, 2H; Hγ), 4.39 (m, 2H; Hα), 4.14 (dd, 
J = 10.4, 4.2 Hz, 2H; HαPhe), 3.98 (m, 4H; -N-CH2-CH2-O-dye), 3.88 (m, 2H; HαGln), 3.68 (t, J 
= 5.5 Hz, 4H; -N-CH2-CH2-O-dye), 3.61 (dd, J = 12.5, 5.9 Hz, 2H; Hδ), 3.50 (q, J = 7.1 Hz, 
2H; -N-CH2-CH3dye), 3.46 (m, 2H; Hδ’), 3.24 (m, 2H; HβTyr), 2.93 (dd, J = 14.2, 4.0 Hz, 2H; 
HβPhe), 2.81 (dd, J = 14.3, 11.0 Hz, 2H; Hβ’Tyr), 2.57 (dd, J = 14.1, 10.1 Hz, 2H; Hβ’Phe), 2.26 
(m, 2H; Hβ), 2.15 (m, 2H; Hβ’), 2.06 (m, 2H;HγGln), 1.96 (m, 2H;Hγ’Gln), 1.83 (m, 4H; HαHex), 
1.76 (m, 4H; HγHex), 1.68 (m, 4H; HβGln, Hβ’Gln), 1.40 (tt, J = 7.1, 6.7 Hz, 4H; HβHex), 1.19 (t, 
J = 7.1 Hz, 6H; -N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, 5% CD3OD in CDCl3, 25°C): δ(ppm) = 175.2/173.9/173.2/171.6/ 
170.9 (Cq; CO), 167.3 (Cq; Cε), 157.1 (Cq; Tyr), 155.5/152.1/147.1 (Cq; dye), 144.2 (Cq; 
Trt), 143.0 (Cq; dye), 137.6 (CH, CδHex), 136.4 (Cq; Phe), 130.2 (Cq; Tyr), 128.9 (CH; CHTyr), 
128.6 (CH; CHPhe), 127.9 (CH; CHTrt), 127.1/124.7/122.1 (CH; dye), 115.1 (CH2; CεHex), 112.3 
(CH; CHTyr), 112.1 (CH; dye), 70.5 (Cq; Trt), 65.2 (CH2; -N-CH2-CH2-O-dye), 58.8 (CH, Cα), 
55.8 (CH; CαPhe), 55.2 (CH; CαGln), 54.6 (CH; CαTyr), 50.1 (CH2; Cδ, Cδ’), 49.9 (CH2; -N-CH2-
CH2-O-dye), 48.0 (CH; Cγ), 46.3 (CH2; -N-CH2-CH3dye), 36.5 (CH2; CβPhe, Cβ’Phe), 35.8 (CH2; 
CβTyr, Cβ’Tyr), 34.9 (CH2; CαHex), 33.6 (CH2; Cβ, Cβ’), 32.9 (CH2; CγGln, Cγ’Gln), 32.8 (CH2; 
CγHex), 25.7 (CH2; CβGln, Cβ’Gln), 24.2 (CH2; CβHex), 12.2 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C138H143N20O18Na: 2392 [M-H+Na]+; found: 2392. 
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9.1.2 Macrocyclic Diketopiperazine Receptor Prototype 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73.3 mg (30.9 µmol, 1 eq) of the diketopiperazine precursor 16 were dissolved in a 
99:1 (v/v) mixture of CH2Cl2 and MeOH (30 ml). The mixture was heated under reflux for 
1 h. A solution of 11 mg (13.3 µmol, 0.4 eq) of Grubbs cat. in CH2Cl2 (2 ml) was added and 
heating was continued for 24 h. The same amount of Grubbs cat. (13.3 µmol, 0.4 eq) in 
CH2Cl2 (2 ml) was added again and reflux maintained for 24 h. After removal of all volatiles 
under reduced pressure, preparative-TLC (MeOH/CH2Cl2, 10:90, v/v) afforded 51.1 mg 
(21.8 µmol, 71%) of a mixture of E- and Z-isomers 17a and 17b as a red solid, which were 
separated by normal-phase HPLC chromatography (Macherey-Nagel Nucleosil 100.5 (250 
mm x 4.6 mm), gradient of CH2Cl2/MeOH from 95:5 to 90:10 (v/v) in 30 min). 
 
C136H140N20O18: 2342.69 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.75. 
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17a: 
1H-NMR (600 MHz, DMSO, 25°C): δ(ppm) = 8.56 (s, 2H; -NHTrt), 8.37 (d, J = 9.1 Hz, 4H; 
Hdye), 8.05 (m, 2H; -NHGln), 7.97 (m, 2H; -NHPhe), 7.95 (m, 2H; -NHPro), 7.94 (d, J = 9.1 Hz, 
4H; Hdye), 7.88 (m, 2H; -NHTyr), 7.84 (d, J = 9.1 Hz, 4H; Hdye), 7.30-7.15 (m, 40H, HPhe, HTrt), 
7.08 (d, J = 8.5 Hz, 4H; HTyr), 6.91 (d, J = 9.2 Hz, 4H; Hdye), 6.79 (d, J = 8.5 Hz, 4H; HTyr), 
5.21 (m, 2H; HδHex), 4.45 (m, 2H; HαPhe), 4.36 (t, J = 7.9 Hz, 2H; Hα), 4.28 (m, 2H; HαTyr), 
4.11 (m, 2H; Hγ), 4.09 (m, 4H; -N-CH2-CH2-O-dye), 4.04 (m, 2H; HαGln), 3.80 (m, 4H; -N-CH2-
CH2-O-dye), 3.62 (m, 2H; Hδ), 3.56 (m, 4H; -N-CH2-CH3dye), 3.18 (br d, J = 11.3 Hz, 2H; Hδ’), 
3.03 (m, 2H; HβPhe), 2.96 (m, 2H; HβTyr), 2.82 (m, 2H; Hβ’Tyr), 2.74 (m, 2H; Hβ’Phe), 2.26 (m, 
4H;HγGln,, Hγ’Gln,), 2.13 (m, 2H; Hβ), 2.05 (m, 2H; Hβ’), 2.00 (m, 4H; HαHex), 1.81 (m, 4H; 
HβGln,), 1.78 (m, 4H; HγHex), 1.72 (m, 4H; Hβ’Gln,), 1.39 (m, 4H; HβHex), 1.17 (t, J = 7.1 Hz, 
6H; -N-CH2-CH3dye). 
 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 157 (Cq; Tyr), 156/151/146 (Cq; dye), 145 
(Cq; Trt), 143 (Cq; dye), 138 (Cq; Phe), 130 (CH; CHTyr), 130 (CH; CδHex), 130 (Cq; Tyr), 126 
– 129 (CH; CHPhe, CHTrt), 125/124/122 (CH; dye), 114 (CH; CHTyr), 112 (CH; dye), 70 (Cq; 
Trt), 65 (CH2; -N-CH2-CH2-O-dye), 57 (CH, Cα), 54 (CH; CαTyr), 53 (CH; CαPhe), 52 (CH; CαGln), 
50 (CH2; Cδ, Cδ’), 49 (CH2; -N-CH2-CH2-O-dye), 47 (CH; Cγ), 45 (CH2; -N-CH2-CH3dye), 37 (CH2; 
CβPhe, Cβ’Phe), 36 (CH2; CβTyr, Cβ’Tyr), 35 (CH2; CαHex), 33 (CH2; Cβ, Cβ’), 32 (CH2; CγGln, Cγ’Gln), 
31 (CH2; CγHex), 27 (CH2; CβGln, Cβ’Gln), 25 (CH2; CβHex), 12 (CH3; -N-CH2-CH3dye). 
 
17b: 
1H-NMR (600 MHz, DMSO, 25°C): δ(ppm) = 8.54 (s, 2H; -NHTrt), 8.35 (d, J = 9.1 Hz, 4H; 
Hdye), 8.06 (m, 2H; -NHGln), 7.93 (m, 2H; -NHPhe), 7.92 (d, J = 9.1 Hz, 4H; Hdye), 7.89 (m, 2H; 
-NHPro), 7.87 (m, 2H; -NHTyr), 7.83 (d, J = 9.3 Hz, 4H; Hdye), 7.30-7.15 (m, 40H, HPhe, HTrt), 
7.07 (d, J = 8.7 Hz, 4H; HTyr), 6.91 (d, J = 9.2 Hz, 4H; Hdye), 6.78 (d, J = 8.5 Hz, 4H; HTyr), 
5.21 (m, 2H; HδHex), 4.44 (m, 2H; HαPhe), 4.37 (t, J = 8.2 Hz, 2H; Hα), 4.23 (m, 2H; HαTyr), 
4.08 (m, 2H; Hγ), 4.05 (m, 4H; -N-CH2-CH2-O-dye), 3.98 (m, 2H; HαGln), 3.76 (m, 4H; -N-CH2-
CH2-O-dye), 3.61 (m, 2H; Hδ), 3.53 (m, 4H; -N-CH2-CH3dye), 3.18 (br d, J = 11.0 Hz, 2H; Hδ’), 
3.02 (m, 2H; HβPhe), 2.95 (m, 2H; HβTyr), 2.82 (m, 2H; Hβ’Tyr), 2.71 (m, 2H; Hβ’Phe), 2.21 (m, 
4H;HγGln, Hγ’Gln,), 2.15 (m, 2H; Hβ), 2.05 (m, 2H; Hβ’), 2.00 (m, 4H; HαHex), 1.80 (m, 4H; 
HβGln,), 1.78 (m, 4H; HγHex), 1.72 (m, 4H; Hβ’Gln,), 1.38 (m, 4H; HβHex), 1.12 (t, J = 6.9 Hz, 
6H; -N-CH2-CH3dye). 
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13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 130 (CH; CHTyr), 130 (CH; CδHex), 130 (Cq; 
Tyr), 126–129 (CH; CHPhe, CHTrt), 126/125/122 (CH; dye), 114 (CH; CHTyr), 111.5 (CH; dye), 
65 (CH2; -N-CH2-CH2-O-dye), 58 (CH, Cα), 55 (CH; CαTyr), 53.5 (CH; CαPhe), 52 (CH; CαGln), 
50.5 (CH2; Cδ, Cδ’), 48 (CH2; -N-CH2-CH2-O-dye), 47 (CH; Cγ), 45 (CH2; -N-CH2-CH3dye), 37 
(CH2; CβPhe, Cβ’Phe), 36 (CH2; CβTyr, Cβ’Tyr), 36 (CH2; CαHex), 32.5 (CH2; Cβ, Cβ’), 32 (CH2; 
CγGln, Cγ’Gln), 27.5 (CH2; CβGln, Cβ’Gln), 26 (CH2; CγHex), 25 (CH2; CβHex), 12 (CH3; -N-CH2-
CH3dye). 
 
ESI-MS: m/z: calcd for C136H140N20O18Na: 2365 [M+Na]+; found: 2365. 
 
 
9.2 Amide Bond Formation 
 
9.2.1 Sebacic Acid Activated as Pentafluorophenol esters 19 
 
 
 
 
 
10 mg (49.4 µmol, 1 eq) sebacic acid 18 were dissolved in CH2Cl2 (0.1 ml) followed 
by addition of 20 mg (108.7 µmol, 2.2 eq) 2,3,4,5,6-pentafluorophenol and 14 mg (74.1 
µmol, 1.5 eq) EDC, and the mixture was allowed to stir at r.t. for 1 h. The reaction mixture 
was then carefully acidified to pH 3 with 1 M HCl and extracted with CH2Cl2. The aq. phase 
was extracted again with CH2Cl2 and the org. phases were washed with brine and dried over 
Na2SO4. Filtration and evaporation of the solvent under reduced pressure yielded the crude 
product which was purified by flash chromatography on silica gel (gradient of EtOAc/Pentane 
from 0.5:99.5 to 2:98 (v/v)) to yield 13 mg (24.7 µmol, 50%) of the activated sebacic acid 
19 as a white solid. 
 
C22H16F10O4: 534.34 
 
TLC: EtOAc/Pentane (2:98); Rf: 0.59 (KMnO4). 
 
1H-NMR (400 MHz, CDCl3, 25°C): δ(ppm) = 2.67 (t, J = 7.0 Hz, 4H; HαSeb), 1.78 (quin, J = 
7.6 Hz, 4H; HβSeb), 1.41 (m, 8H; HγSeb, HδSeb ). 
HO OH
O O
6
C6F5OH, EDC, CH2Cl2
50 %
C6F5O OC6F5
O O
6
18 19
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13C-NMR (101 MHz, CDCl3, 25°C): δ(ppm) = 169.5 (Cq; CO), 33.3 (CH2; CαSeb), 28.9/28.7 
(CH2; CγSeb, CδSeb), 24.7 (CH2; CβSeb). 
 
ESI-MS: m/z: calcd for C22H16N10O4Na: 557 [M+Na]+; found: 557. 
 
 
9.2.2 Macrocyclic Diketopiperazine Receptor Prototype 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 mg (19.1 µmol, 1 eq) of the diketopiperazine receptor precursor 15 were 
dissolved in CH2Cl2 (2.3 ml) followed by addition of 143 µl (955.0 µmol, 50 eq) TAEA which 
caused the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 
min and then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5). The aq. 
phases were washed once with CH2Cl2 and the org. phases were washed with brine and 
dried over Na2SO4 to yield the corresponding diamine, after filtration and removal of all 
volatiles under reduced pressure.  
A solution of the diamine in THF (5 ml) and a solution of 12 mg (22.9 µmol, 1.2 eq) 
of the activated sebacic acid 19 in THF (5 ml) were simultaneously added dropwise over a 
period of 5 h to a solution of 20 µl (114.6 µmol, 6 eq) iPr2NEt in THF (10 ml) at r.t. After 
stirring for another 17 h, the reaction mixture was extracted three times with 0.1 M Na-
phosphate buffer (pH 5.5) and CH2Cl2. The aq. phases were extracted again with CH2Cl2. The 
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org. phases were washed with brine and dried over Na2SO4. After filtration and evaporation 
of the solvent under reduced pressure, the crude product was purified by preparative-TLC 
(CH2Cl2/MeOH, 90:10, v/v) and gel filtration (LH 20, CH2Cl2/MeOH, 90:10, v/v) to yield 14 
mg (6.0 µmol, 32%) of the macrocyclic diketopiperazine receptor 20 as a red solid. 
 
C136H142N20O18: 2344.71 
 
TLC: CH2Cl2/MeOH (90:10); Rf: 0.5. 
 
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.55 (s, 2H; -NHTrt), 8.35 (d, J = 9.1 Hz, 4H; 
Hdye), 8.02 (m, 2H; -NHPro), 8.00 (m, 2H; -NHGln), 7.99 (m, 2H; -NHTyr), 7.93 (d, J = 9.1 Hz, 
4H; Hdye), 7.92 (m, 2H; -NHPhe), 7.83 (d, J = 9.2 Hz, 2H; Hdye), 7.22 (m, 40H, HPhe, HTrt), 7.07 
(d, J = 8.8 Hz, 4H; HTyr), 6.90 (d, J = 9.3 Hz, 4H; Hdye), 6.78 (d, J = 8.6 Hz, 4H; HTyr), 4.42 
(m, 2H; HαTyr), 4.37 (t, J = 8.1 Hz, 2H; Hα), 4.28 (dd, J = 5.7 Hz, 2H; HαPhe), 4.10 (m, 2H; 
Hγ), 4.07 (t, J = 5.1 Hz, 4H; -N-CH2-CH2-O-dye), 4.05 (m, 2H; HαGln), 3.78 (t, J = 4.9 Hz, 4H; 
-N-CH2-CH2-O-dye), 3.59 (m, 2H; Hδ), 3.54 (q, J = 7.1, 4H; -N-CH2-CH3dye), 3.17 (br d, J = 
11.3 Hz, 2H; Hδ’), 3.02 (m, J = 10.2 Hz, 2H; HβTyr), 2.94 (m, J = 8.9 Hz, 2H; HβPhe), 2.76 
(dd, 2H; Hβ’Phe), 2.74 (dd, J = 7.9, 5.7 Hz, 2H; Hβ’Tyr), 2.25 (m, 4H; HγGln, Hγ’Gln), 2.12 (m, 
2H; Hβ), 2.01 (m, 2H; Hβ’), 1.97 (m, 4H; HαSeb), 1.77 (m, 4H; HβGln, Hβ’Gln), 1.30 (m, 4H; 
HβSeb), 1.14 (t, J = 7.0 Hz, 6H; -N-CH2-CH3dye), 1.04 (m, 8H; HγSeb, HδSeb ). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 172.7/171.8/171.5/170.9/170.8 (Cq; CO), 
165.5 (Cq; Cε), 156.9 (Cq; Tyr), 156.2/151.6/146.8 (Cq; dye), 144.8 (Cq; Trt), 142.8 (Cq; 
dye), 137.8 (Cq; Phe), 130.1 (CH; CHTyr), 129.7 (Cq; Tyr), 129.6/128.0 (CH; CHPhe), 
128.5/127.5 (CH; CHTrt), 126.3/125.0/122.5 (CH; dye), 114.0 (CH; CHTyr), 111.7 (CH; dye), 
69.2 (Cq; Trt), 65.2 (CH2; -N-CH2-CH2-O-dye), 58.3 (CH, Cα), 54.6 (CH; CαPhe), 54.3 (CH; 
CαTyr), 52.9 (CH; CαGln), 50.8 (CH2; Cδ, Cδ’), 49.1 (CH2; -N-CH2-CH2-O-dye), 47.2 (CH; Cγ), 
45.3 (CH2; -N-CH2-CH3dye), 37.0 (CH2; CβTyr, Cβ’Tyr), 36.1 (CH2; CβPhe, Cβ’Phe), 35.2 (CH2; 
CαSeb), 32.8 (CH2; Cβ, Cβ’), 32.4 (CH2; CγGln, Cγ’Gln), 28.6/28.5 (CH2; CγSeb, CδSeb), 27.9 (CH2; 
CβGln, Cβ’Gln), 25.1 (CH2; CβSeb), 12.0 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C136H142N20O18Na: 2367 [M+Na]+; found: 2367. 
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9.3 Disulfide Bridge Formation 
 
9.3.1 Two-Armed Diketopiperazine Receptor Precursor 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
310 mg (118.3 µmol, 1 eq) of the diketopiperazine receptor precursor 15 were 
dissolved in CH2Cl2 (10 ml) followed by addition of 0.9 ml (5.92 mmol, 50 eq) TAEA which 
caused the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 
min and then extracted three times by 0.1 M Na-phosphate buffer (pH 5.5). The aq. phases 
were washed once with CH2Cl2 and the org. phases were washed with brine and dried over 
Na2SO4 to yield the corresponding diamine, after filtration and removal of all volatiles under 
reduced pressure.  
The diamine was dissolved in dry CH2Cl2 (3.5 ml) followed by addition of 41 µl (236.6 
µmol, 2 eq) iPr2NEt. The solution was cooled with an ice bath before a mixture of 196 mg 
(473.2 µmol, 4 eq) HCTU in DMF (1 ml), 41 µl (236.6 µmol, 2 eq) iPr2NEt and 167 mg (473.2 
µmol, 4eq) Fmoc-ε-aminocaproic acid in CH2Cl2 (3.5 ml), was added and stirred at r.t. for 1 
h. The reaction mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) 
and CH2Cl2. The aq. phases were extracted again with CH2Cl2. The org. phases were washed 
with brine and dried over Na2SO4. After filtration and evaporation of the solvent under 
reduced pressure, the crude product was purified by flash chromatography on silica gel 
(gradient of CH2Cl2/MeOH from 99.5:0.5 to 96:4 (v/v)) to afford 286 mg (100.5 µmol, 85%) 
of the Fmoc-protected diketopiperazine precursor 59. 
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C168H170N22O22: 2849.28 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.54. 
 
ESI-MS: m/z: calcd for C168H169N22O22Na: 2871 [M-H+Na]+; found: 2871. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 mg (50.3 µmol, 1 eq) of the diketopiperazine receptor precursor 59 were 
dissolved in CH2Cl2 (5 ml) followed by addition of 0.4 ml (2.51 mmol, 50 eq) TAEA which 
caused the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 
min and then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5). The aq. 
phases were washed once with CH2Cl2 and the org. phases were washed with brine and 
dried over Na2SO4 to yield the corresponding diamine, after filtration and removal of all 
volatiles under reduced pressure.  
The diamine was dissolved in dry CH2Cl2 (2 ml) followed by addition of 17 µl (100.6 
µmol, 2 eq) iPr2NEt. The solution was cooled with an ice bath before a mixture of 83 mg 
(201.2 µmol, 4 eq) HCTU in DMF (0.5 ml), 17 µl (100.6 µmol, 2 eq) iPr2NEt and 83 mg 
(201.2 µmol, 4eq) Fmoc-Cys(Acm)-OH in CH2Cl2 (2 ml), was added and stirred at r.t. for 1 h. 
The reaction mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) 
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and CH2Cl2. The aq. phases were extracted again with CH2Cl2. The org. phases were washed 
with brine and dried over Na2SO4. After filtration and evaporation of the solvent under 
reduced pressure, the crude product was purified by flash chromatography on silica gel 
(gradient of CH2Cl2/MeOH from 99.5:0.5 to 94:6 (v/v)) to yield 121 mg (38.0 µmol, 76%) of 
the Fmoc-protected diketopiperazine precursor 21. 
 
C180H190N26O26S2: 3197.72 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.63. 
 
ESI-MS: m/z: calcd for C180H190N26O26S2Na: 3220 [M+Na]+; found: 3220. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 mg (38.0 µmol, 1 eq) of the diketopiperazine receptor precursor 21 were 
dissolved in CH2Cl2 (5 ml) followed by addition of 0.3 ml (1.90 mmol, 50 eq) TAEA which 
caused the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 
min and then extracted three times with phosphate buffer (pH 5.5). The aq. phases were 
washed once with CH2Cl2 and the org. phases were washed and dried over Na2SO4 to yield 
the corresponding diamine, after filtration and removal of all volatiles under reduced 
pressure.  
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The diamine was dissolved in dry CH2Cl2 (5 ml) followed by addition of 16 µl (114.0 
µmol, 3 eq) Et3N and 11 µl (114.0 µmol, 3 eq) Ac2O. After stirring for 30 min, the reaction 
mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The 
aq. phases were extracted again with CH2Cl2. The org. phases were washed with brine and 
dried over Na2SO4. After filtration and evaporation of the solvent under reduced pressure, 
the crude product was purified by preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) and gel 
filtration (LH 20, CH2Cl2/MeOH, 90:10, v/v) to afford 81 mg (28.4 µmol, 75%) of the two-
armed diketopiperazine precursor 22. 
 
C154H174N26O24S2: 2837.32 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.47. 
 
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.58 (s, 2H; -NHTrt), 8.55 (t, J = 6.0, 2H; -
NHAcm), 8.35 (d, J = 8.9 Hz, 4H; Hdye), 8.32 (m, 2H; -NHPro), 8.17 (d, J = 7.1 Hz, 2H; -NHGln), 
8.14 (d, J = 8.4 Hz, 2H; -NHTyr), 7.98 (d, J = 7.9 Hz, 2H; -NHPhe), 7.93 (d, J = 8.9 Hz, 4H; 
Hdye), 7.91 (m, 2H; -NHAhx), 7.89 (m, 2H; -NHCys), 7.84 (d, J = 9.0 Hz, 4H; Hdye), 7.23-7.12 
(m, 40H, HPhe, HTrt), 7.09 (d, J = 8.3 Hz, 4H; HTyr), 6.91 (d, J = 9.2 Hz, 4H; Hdye), 6.79 (d, J 
= 8.4 Hz, 4H; HTyr), 4.51 (m, 2H; HαPhe), 4.43 (m, 2H; HαTyr), 4.37 (m, 2H; HαCys), 4.27 (m, 
2H; Hα), 4.23 (m, 2H; CH2Acm), 4.19 (m, 2H; HαGln), 4.17 (m, 2H; CH2Acm), 4.14 (m, 2H; Hγ), 
4.08 (m, 4H; -N-CH2-CH2-O-dye), 3.78 (m, 4H; -N-CH2-CH2-O-dye), 3.61 (m, 2H; Hδ), 3.55 (q, J 
= 6.8 Hz, 4H; -N-CH2-CH3dye), 3.15 (m, 2H; Hδ’), 2.97 (m, 2H; HβPhe), 2.95 (m, 4H; HαAhx), 
2.87 (m, 2H; HβCys), 2.82 (dd, J = 13.5, 5.3 Hz, 2H; HβTyr), 2.76 (m, 2H; Hβ’Cys), 2.67 (m, 
2H; Hβ’Phe), 2.65 (m, 2H; Hβ’Tyr), 2.29 (m, 4H; HγGln, Hγ’Gln), 2.10 (m, 2H; Hβ), 1.96 (m, J = 
5.7 Hz, 4H; HεAhx), 1.85 (m, 2H; Hβ’), 1.84 (s, 3H; -COCH3), 1.83 (s, 3H; -COCH3), 1.81 (m, 
2H; HβGln), 1.69 (m, 2H; Hβ’Gln), 1.31 (m, 4H; HδAhx), 1.28 (m, 4H; HβAhx), 1.15 (t, J = 6.8 Hz, 
6H; -N-CH2-CH3dye), 1.04 (m, J = 14.9, 7.7 Hz, 4H; HγAhx). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 72.2/171.8/171.6/171.1/170.6/ 
170.0/169.6/169.3 (Cq; CO), 165.7 (Cq; Cε), 156.9 (Cq; Tyr), 156.2/151.7/146.9 (Cq; dye), 
144.9 (Cq; Trt), 142.8 (Cq; dye), 138.1 (Cq; Phe), 130.3 (CH; CHTyr), 129.5 (Cq; Tyr), 129.2 
(CH; CHPhe), 128.5/127.5 (CH; CHTrt), 127.9 (CH; CHPhe), 126.4/125.0/124.9/122.5 (CH; dye), 
113.9 (CH; CHTyr), 111.7 (CH; dye), 69.2 (Cq; Trt), 65.1 (CH2; -N-CH2-CH2-O-dye), 58.1 (CH, 
Cα), 53.9 (CH; CαCys), 53.8 (CH; CαPhe), 53.4 (CH; CαTyr, CαGln), 50.4 (CH2; Cδ, Cδ’), 49.1 
(CH2; -N-CH2-CH2-O-dye), 46.9 (CH; Cγ), 45.3 (CH2; -N-CH2-CH3dye), 40.3 (CH2, CH2Acm), 38.5 
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(CH2; CαAhx), 37.5 (CH2; CβPhe, Cβ’Phe), 37.0 (CH2; CβCys, Cβ’Cys), 35.1 (CH2; CεAhx), 33.0 (CH2; 
Cβ, Cβ’), 32.8 (CH2; CβTyr, Cβ’Tyr), 32.6 (CH2; CγGln, Cγ’Gln), 28.7 (CH2; CβAhx), 28.1 (CH2; CβGln, 
Cβ’Gln), 25.8 (CH2; CγAhx), 24.9 (CH2; CδAhx), 22.6 (CH3; -COCH3), 22.6 (CH3; -COCH3), 12.0 
(CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C154H173N26O24S2Na: 2859 [M-H+Na]+; found: 2859. 
 
 
9.3.2 Macrocyclic Diketopiperazine Receptor Prototype 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 mg (27.4 µmol, 1 eq) of the diketopiperazine receptor precursor 22 were 
dissolved in a 6:2.5:0.42 (v/v/v) mixture of CH2Cl2, MeOH and H2O (22 ml) followed by 
addition of 28 mg (109.6 µmol, 4 eq) I2 in a 8:1.5 (v/v) mixture of CH2Cl2 and MeOH (5 ml). 
After stirring for 1 h, the excess of I2 was quenched with a 1 M ascorbic acid. The mixture 
was then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The aq. 
phases were extracted again with CH2Cl2. The org. phases were washed with brine and dried 
over Na2SO4. After filtration and evaporation of the solvent under reduced pressure, the 
crude product was purified by preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) and gel filtration 
(LH 20, CH2Cl2/MeOH, 90:10, v/v) to yield 30 mg (11.0 µmol, 40%) of the macrocyclic 
diketopiperazine prototype 23. 
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C148H162N24O22S2: 2693.15 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.49. 
 
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.59 (s, 2H; -NHTrt), 8.35 (d, J = 8.9 Hz, 4H; 
Hdye), 8.19 (d, J = 8.1 Hz, 2H; -NHCys), 8.12 (m, 2H; -NHPro), 8.06 (m, 2H; -NHGln), 8.00 (m, 
2H; -NHAhx), 7.95 (m, 2H; -NHPhe), 7.91 (d, J = 8.8 Hz, 4H; Hdye), 7.88 (m, 2H; -NHTyr), 7.83 
(d, J = 8.9 Hz, 4H; Hdye), 7.29-7.12 (m, 40H, HPhe, HTrt), 7.07 (d, J = 8.3 Hz, 4H; HTyr), 6.90 
(d, J = 9.1 Hz, 4H; Hdye), 6.78 (d, J = 8.3 Hz, 4H; HTyr), 4.50 (m, 2H; HαCys), 4.46 (m, 2H; 
HαPhe), 4.33 (m, 2H; HαTyr), 4.31 (m, 2H; Hα), 4.12 (m, 2H; HαGln), 4.10 (m, 2H; Hγ), 4.06 
(m, 4H; -N-CH2-CH2-O-dye), 3.78 (m, 4H; -N-CH2-CH2-O-dye), 3.62 (m, 2H; Hδ), 3.54 (m, 4H; -
N-CH2-CH3), 3.17 (m, 2H; Hδ’), 3.03 (m, 2H; HβCys), 3.00 (m, 2H; HβPhe), 2.95 (m, 4H; 
HαAhx), 2.91 (m, 2H; HβTyr), 2.50 (m, 2H; Hβ’Cys), 2.78 (m, 2H; Hβ’Tyr), 2.71 (m, 2H; Hβ’Phe), 
2.28 (m, 4H; HγGln, Hγ’Gln), 2.13 (m, 2H; Hβ), 1.97 (m, 4H; HεAhx), 1.93 (m, 2H; Hβ’), 1.84 (s, 
6H; -COCH3), 1.81 (m, 2H; HβGln), 1.73 (m, 2H; Hβ’Gln), 1.31 (m, 4H; HδAhx), 1.27 (m, 4H; 
HβAhx), 1.12 (t, J = 6.8 Hz, 6H; -N-CH2-CH3dye), 1.04 (m, 4H; HγAhx). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 172.4/171.8/171.6/170.9/170.7/169.7/169.5 
(Cq; CO), 165.7 (Cq; Cε), 156.9 (Cq; Tyr), 156.2/151.6/146.8 (Cq; dye), 144.9 (Cq; Trt), 
142.8 (Cq; dye), 137.9 (Cq; Phe), 130.2 (CH; CHTyr), 129.6 (Cq; Tyr), 129.1 (CH; CHPhe), 
128.5/126.4 (CH; CHTrt), 127.5 (CH; CHPhe), 126.3/126.1/125.0/122.5 (CH; dye), 113.9 (CH; 
CHTyr), 111.7 (CH; dye), 69.2 (Cq; Trt), 65.1 (CH2; -N-CH2-CH2-O-dye), 58.2 (CH, Cα), 53.3 
(CH; CαTyr), 54.0 (CH; CαPhe), 52.7 (CH; CαGln), 52.0 (CH; CαCys), 50.6 (CH2; Cδ, Cδ’), 49.1 
(CH2; -N-CH2-CH2-O-dye), 47.1 (CH; Cγ), 45.3 (CH2; -N-CH2-CH3dye), 40.9 (CH2;CβCys, Cβ’Cys), 
38.7 (CH2; CαAhx), 37.3 (CH2; CβPhe, Cβ’Phe), 33.6 (CH2; CβTyr, Cβ’Tyr), 35.1 (CH2; CεAhx), 32.9 
(CH2; Cβ, Cβ’), 32.5 (CH2; CγGln, Cγ’Gln), 28.7 (CH2; CβAhx), 27.8 (CH2; CβGln, Cβ’Gln), 25.8 (CH2; 
CγAhx), 24.8 (CH2; CδAhx), 22.6 (CH3; -COCH3), 12.0 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C148H161N24O22S2Na: 2715 [M-H+Na]+; found: 2715. 
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9.3.3 Two-Armed Diketopiperazine Receptor Precursor 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200 mg (76.3 µmol, 1 eq) of the diketopiperazine receptor precursor 15 were 
dissolved in CH2Cl2 (10 ml) followed by addition of 0.6 ml (3.82 mmol, 50 eq) TAEA which 
caused the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 
min and then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5). The aq. 
phases were washed once with CH2Cl2 and the org. phases were washed and dried over 
Na2SO4 to yield the corresponding diamine, after filtration and removal of all volatiles under 
reduced pressure.  
The diamine was dissolved in dry CH2Cl2 (2.5 ml) followed by addition of 26 µl (152.7 
µmol, 2 eq) iPr2NEt. The solution was cooled with an ice bath before a mixture of 116 mg 
(305.5 µmol, 4 eq) HCTU in DMF (0.5 ml), 26 µl (152.7 µmol, 2 eq) iPr2NEt and 127 mg 
(305.5 µmol, 4eq) Fmoc-Cys(Acm)-OH in CH2Cl2 (2.5 ml), was added and stirred at r.t. for 1 
h. The reaction mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) 
and CH2Cl2. The aq. phases were extracted again with CH2Cl2. The org. phases were washed 
with brine and dried over Na2SO4. After filtration and evaporation of the solvent under 
reduced pressure, the crude product was purified by flash chromatography on silica gel 
(gradient of CH2Cl2/MeOH from 99.5:0.5 to 95:5 (v/v)) to afford 137 mg (46.2 µmol, 60%) of 
the Fmoc-protected diketopiperazine precursor 24. 
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C168H168N24O24S2: 2971.41 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.46. 
 
ESI-MS: m/z: calcd for C168H167N24O24S2Na: 2993 [M-H+Na]+; found: 2993. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 mg (46.2 µmol, 1 eq) of the diketopiperazine receptor precursor 24 were 
dissolved in CH2Cl2 (5 ml) followed by addition of 0.3 ml (2.31 mmol, 50 eq) TAEA which 
caused the formation of a precipitate after 2-5 min. The suspension was stirred at r.t. for 30 
min and then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5). The aq. 
phases were washed once with CH2Cl2 and the org. phases were washed with brine and 
dried over Na2SO4 to yield the corresponding diamine, after filtration and removal of all 
volatiles under reduced pressure.  
The diamine was dissolved in dry CH2Cl2 (5 ml) followed by addition of 19 µl (138.6 
µmol, 3 eq) Et3N and 13 µl (138.6 µmol, 3 eq) Ac2O. After stirring for 30 min, the reaction 
mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The 
aq. phases were extracted again with CH2Cl2. The org. phases were washed with brine and 
dried over Na2SO4. After filtration and evaporation of the solvent under reduced pressure, 
the crude product was purified by preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) and gel 
filtration (LH 20, CH2Cl2/MeOH, 90:10, v/v) to yield 70 mg (25.6 µmol, 55%) of the two-
armed diketopiperazine precursor 25. 
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C142H152N24O22S2: 2611.00 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.28. 
 
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.58 (s, 2H; -NHTrt), 8.51 (t, J = 6.3, 2H; -
NHAcm), 8.35 (d, J = 8.9 Hz, 4H; Hdye), 8.31 (m, 2H; -NHPro), 8.12 (m, 2H; -NHCys), 8.09 (m, 
2H; -NHGln), 7.95 (m, 2H; -NHTyr), 7.92 (d, J = 8.8 Hz, 4H; Hdye), 7.89 (d, J = 7.8 Hz, 2H; -
NHPhe), 7.83 (d, J = 9.0 Hz, 4H; Hdye), 7.29-7.12 (m, 40H, HPhe, HTrt), 7.10 (d, J = 8.1 Hz, 4H; 
HTyr), 6.91 (d, J = 9.0 Hz, 4H; Hdye), 6.79 (d, J = 8.1 Hz, 4H; HTyr), 4.46 (m, 2H; HαPhe), 4.44 
(m, 2H; HαCys), 4.38 (dd, J = 15.6, 8.6 Hz, 2H; HαTyr), 4.28 (m, 2H; Hα), 4.26 (m, 2H; 
CH2Acm), 4.19 (dd, J = 18.8, 7.6 Hz, 2H; HαGln), 4.12 (m, 2H; Hγ), 4.10 (m, 2H; CH2Acm), 4.06 
(m, 4H; -N-CH2-CH2-O-dye), 3.77 (m, 4H; -N-CH2-CH2-O-dye), 3.60 (m, 2H; Hδ), 3.53 (m, 4H; -
N-CH2-CH3dye), 3.14 (m, 2H; Hδ’), 3.00 (m, J = 10.7 Hz, 2H; HβPhe), 2.86 (m, 2H; HβTyr), 2.83 
(m, 2H; HβCys), 2.77 (m, 2H; Hβ’Tyr), 2.73 (m, 2H; Hβ’Phe), 2.53 (m, 2H; Hβ’Cys), 2.29 (m, 4H; 
HγGln, Hγ’Gln), 2.10 (m, 2H; Hβ), 1.84 (m, 2H; Hβ’), 1.85 (s, 3H; -COCH3), 1.78 (s, 3H; -
COCH3), 1.78 (m, 2H; HβGln), 1.69 (m, 2H; Hβ’Gln), 1.14 (t, J = 6.9 Hz, 6H; -N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 171.5/171.0/170.8/170.6/170.5/169.9/169.5 
(Cq; CO), 165.7 (Cq; Cε), 156.9 (Cq; Tyr), 156.2/151.6/146.9 (Cq; dye), 144.9 (Cq; Trt), 
142.8 (Cq; dye), 137.6 (Cq; Phe), 130.3 (CH; CHTyr), 129.3 (Cq; Tyr), 128.5/127.5 (CH; 
CHTrt), 126.4 (CH; CHPhe), 126.3/126.2/125.0/122.5 (CH; dye), 113.9 (CH; CHTyr), 111.7 (CH; 
dye), 69.2 (Cq; Trt), 65.1 (CH2; -N-CH2-CH2-O-dye), 58.1 (CH, Cα), 54.0 (CH; CαTyr), 53.9 (CH; 
CαPhe), 52.4 (CH; CαGln), 52.2 (CH; CαCys), 50.4 (CH2; Cδ, Cδ’), 49.1 (CH2; -N-CH2-CH2-O-dye), 
46.8 (CH; Cγ), 45.3 (CH2; -N-CH2-CH3dye), 39.5 (CH2, CH2Acm), 37.3 (CH2; CβPhe, Cβ’Phe), 37.1 
(CH2; CβTyr, Cβ’Tyr), 33.2 (CH2; Cβ, Cβ’), 32.7 (CH2; CγGln, Cγ’Gln), 32.3 (CH2; CβCys, Cβ’Cys), 
28.3 (CH2; CβGln, Cβ’Gln), 28.6 (CH3; -COCH3), 28.5 (CH3; -COCH3), 12.0 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C142H150N24O22S2Na: 2632 [M-2H+Na]+; found: 2632. 
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9.3.4 Macrocyclic diketopiperazine receptor prototype 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 mg (25.6 µmol, 1 eq) of the diketopiperazine receptor precursor 24 were 
dissolved in a 6:2.5:0.42 (v/v/v) mixture of CH2Cl2, MeOH and H2O (20 ml) followed by 
addition of 26 mg (102.5 µmol, 4 eq) I2 in a 8:1.5 (v/v) mixture of CH2Cl2 and MeOH (5 ml). 
After stirring for 1 h, the excess of I2 was quenched with a 1 M ascorbic acid. The mixture 
was then extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The aq. 
phases were extracted again with CH2Cl2. The org. phases were washed with brine and dried 
over Na2SO4. After filtration and evaporation of the solvent under reduced pressure, the 
crude product was purified by preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) and gel filtration 
(LH 20, CH2Cl2/MeOH, 90:10, v/v) to yield 40 mg (16.1 µmol, 63%) of the macrocyclic 
diketopiperazine prototype 26. 
 
C136H140N22O20S2: 2466.83 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.48. 
 
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.56 (s, 2H; -NHTrt), 8.36 (d, J = 8.9 Hz, 4H; 
Hdye), 8.15 (m, 2H; -NHGln), 8.12 (d, J = 7.7 Hz, 2H; -NHCys), 8.05 (m, 2H; -NHPhe), 7.93 (d, J 
= 8.9 Hz, 4H; Hdye), 7.90 (m, 2H; -NHTyr), 7.83 (d, J = 9.1 Hz, 4H; Hdye), 7.67 (m, 2H; -
NHPro), 7.29-7.12 (m, 40H, HPhe, HTrt), 7.08 (d, J = 8.5 Hz, 4H; HTyr), 6.89 (d, J = 9.2 Hz, 4H; 
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Hdye), 6.78 (d, J = 8.4 Hz, 4H; HTyr), 4.51 (m, 2H; HαCys), 4.48 (m, 2H; HαPhe), 4.44 (m, 2H; 
Hα), 4.21 (dd, J = 10.4, 5.5 Hz, 2H; HαTyr), 4.13 (m, 2H; Hγ), 4.04 (m, 4H; -N-CH2-CH2-O-
dye), 3.91 (m, 2H; HαGln), 3.77 (m, 4H; -N-CH2-CH2-O-dye), 3.60 (m, 2H; Hδ), 3.52 (m, 4H; -N-
CH2-CH3dye), 3.12 (m, 2H; Hδ’), 3.04 (m, 2H; HβTyr), 3.01 (m, 2H; HβPhe), 2.96 (m, 2H; HβCys), 
2.89 (m, 2H; Hβ’Tyr), 2.77 (m, 2H; Hβ’Phe), 2.69 (m, 2H; Hβ’Cys), 2.26 (m, 4H; HγGln, Hγ’Gln), 
2.18 (m, 2H; Hβ), 2.09 (m, 2H; Hβ’), 1.77 (m, 2H; HβGln, Hβ’Gln), 1.78 (s, 6H; -COCH3), 1.13 
(t, J = 6.9 Hz, 6H; -N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 171.8/171.3/171.0/170.7/170.2/169.7 (Cq; 
CO), 165.8 (Cq; Cε), 156.8 (Cq; Tyr), 156.2/151.6/146.9 (Cq; dye), 144.9 (Cq; Trt), 142.8 
(Cq; dye), 137.3 (Cq; Phe), 130.2 (Cq; Tyr), 130.1 (CH; CHTyr), 128.5/127.5 (CH; CHTrt), 
126.3 (CH; CHPhe), 126.1/125.0/122.5 (CH; dye), 114.1 (CH; CHTyr), 111.7 (CH; dye), 69.2 
(Cq; Trt), 65.2 (CH2; -N-CH2-CH2-O-dye), 58.3 (CH, Cα), 54.9 (CH; CαTyr), 53.9 (CH; CαPhe), 
53.6 (CH; CαGln), 51.7 (CH; CαCys), 50.5 (CH2; Cδ, Cδ’), 49.1 (CH2; -N-CH2-CH2-O-dye), 47.3 
(CH; Cγ), 45.3 (CH2; -N-CH2-CH3dye), 39.8 (CH2;CβCys, Cβ’Cys), 36.9 (CH2; CβPhe, Cβ’Phe), 35.2 
(CH2; CβTyr, Cβ’Tyr), 32.7 (CH2; Cβ, Cβ’), 32.4 (CH2; CγGln, Cγ’Gln), 27.3 (CH2; CβGln, Cβ’Gln), 22.4 
(CH3; -COCH3), 12.0 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C136H140N22O20S2: 2466 [M]+; found: 2466. 
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10 GENERAL FMOC-STRATEGY FOR THE SYNTHESIS OF SIDE-CHAIN DEPROTECTED 
PEPTIDES ONTO AMINO-FUNCTIONALIZED RESIN EXEMPLIFIED BY THE 
SYNTHESIS OF Ac-D-Val-D-Val-D-His-NH(CH2)5CONH-Resin 
 
 
 
 
 
 
 
10.1 Coupling onto Amino-Functionalized Resin 
 
7.0 g (7.70 mmol, 200-400 mesh, loading 1.1mmol g-1) amino methyl polystyrene 
resin were placed in a Merrifield vessel and washed three times with CH2Cl2 for 1 min. The 
resin was then suspended in the smallest amount dry CH2Cl2 (30 ml) to allow efficient 
shaking. 3.0 g (8.47 mmol, 1.1 eq) N-α-Fmoc-aminocaproic acid and 0.8 ml (14.63 mmol, 
1.9 eq) acetic acid, along with 3.1 g (23.1 mmol, 3 eq) HOBt in DMF (7 ml) were added and 
the mixture was shaken for 5 min before 3.6 ml (23.10 mmol, 3 eq) DIC were added. The 
mixture was shaken for 2 h and then washed three times with DMF and five times with 
CH2Cl2 for 1 min each. After this a few resin beads were sampled to a small glass tube for 
the Kaiser test (qualitative test for the presence or absence of free amino groups).[99] If the 
Kaiser test was positive (blue color) the Fmoc protecting groups were removed and the next 
amino acid was coupled. If the Kaiser test was negative (yellow color) the coupling was 
repeated. At the end, the loading of the resin was determined, by the quantitative Fmoc-
test, to be 0.41 mmol g-1.[71]  
 
 
10.2 Fmoc-Deprotection  
 
200 mg (82.0 µmol, 200-400 mesh, loading 0.41 mmol g-1) of the Fmoc-
functionalized resin was washed three times with DMF for 1 min. The deprotection was 
achieved by shaking the resin with a mixture of 20% (v/v) piperidine in DMF (10 ml), first for 
2 min and then for 10 min. After washing the resin three times with DMF and five times with 
CH2Cl2 1 min each, the Kaiser test was performed to ensure the successful Fmoc-
deprotection. Consecutive deprotection, then coupling and deprotection cycles employing 
128  Experimental Section 
 
152 mg (246.0 µmol, 3 eq) Fmoc-D-His(Trt)-OH, 83 mg (246.0 µmol, 3 eq) Fmoc-D-Val-OH, 
33 mg (246.0 µmol, 3 eq) HOBt and 40 µl (246.0 µmol, 3 eq) DIC yielded Fmoc-D-Val-D-Val-
D-His(Trt)-NH(CH2)5CONH-resin. After another Fmoc-test was done, the new loading of the 
resin post coupling was determined to be 0.33 mmol g-1. 
 
 
10.3 Acetylation of Free Amines 
 
After the final Fmoc-deprotection, the resin was suspended in dry CH2Cl2 (5 ml) and 
approx. 56 µl (410.0 µmol, 5 eq) Et3N, before 39 µl (410.0 µmol, 5 eq) Ac2O were added. 
The mixture was shaken for 1 h and then washed three times with DMF and five times with 
CH2Cl2 for 1 min each. The yellow color of the Kaiser test confirmed the completion of the 
reaction. 
 
 
10.4 Cleavage of the Side-Chain Protecting Groups 
 
Cleavage of the side-chain protecting groups was achieved by shaking the resin with 
a 1:1:0.1 (v/v/v) mixture of TFA/CH2Cl2/TIS (10 ml), first for 2 min and then again for 1 h. 
The resin was then washed three times with DMF, three times with CH2Cl2, three times with 
a 8:2 (v/v) mixture of CH2Cl2/Et3N and three times with CH2Cl2 for 1 min each. Ac-D-Val-D-
val-D-His-NH(CH2)5CO-NH-Resin was finally removed, dried in vacuo for at least 4 h and then 
stored at low temperature (4°C). 
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Using the same pathway, the following peptides were synthesized on amino methyl 
polystyrene resin which was functionalized with N-α-Fmoc-aminocaproic acid (200-400 mesh, 
loading 0.41 mmol g-1): 
 
Ac-L-Ala-L-Gln-L-Ala-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-D-Ala-L-Gln-L-Ala-NH(CH2)5CO-NH-Resin: loading 0.34 mmol g-1 
Ac-D-Gln-D-Ala-D-Leu-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-D-Gln-D-Phe-D-Val-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-L-Ala-L-Gln-D-Phe-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-D-Gln-D-Phe-D-Leu-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-D-Gln-D-Leu-D-Leu-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-L-Leu-L-Gln-D-Phe-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-D-Phe-D-Val-D-Gln-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g-1 
Ac-D-Lys-D-Pro-L-Pro-NH(CH2)5CO-NH-Resin: loading 0.35 mmol g-1 
Ac-L-Pro-L-Pro-D-Lys-NH(CH2)5CO-NH-Resin: loading 0.35 mmol g-1 
Ac-L-Ser-D-Pro-D-Pro-NH(CH2)5CO-NH-Resin: loading 0.36 mmol g-1 
Ac-D-Phe-L-Lys-D-Pro-NH(CH2)5CO-NH-Resin: loading 0.40 mmol g-1 
Ac-D-Ser-D-Lys-L-Lys-NH(CH2)5CO-NH-Resin: loading 0.41 mmol g-1 
Ac-D-Pro-L-Pro-D-Gln-NH(CH2)5CO-NH-Resin: loading 0.33 mmol g_1 
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11 SYNTHESIS OF THE SYMMETRIC CARBAZOLE TEMPLATE 
 
11.1 3,6-Dibromo-carbazole-9-acetic acid-ethyl ester 30 
 
 
 
 
 
 
 
 
A mixture of 10.0 g (30.77 mmol, 1.0 eq) 3,6-dibromocarbazole 28 and 8.6 g (61.54 
mmol, 2 eq) potassium carbonate was evacuated and flushed with nitrogen three times. 
After the addition of anhydrous DMF (170 ml), the yellow suspension was stirred for 3.5 h at 
65°C. 7.5 ml (67.69 mmol, 2.2 eq) ethyl bromoacetate 29 were then added and the mixture 
was allowed to stir at 60°C for 2 h. After cooling to r.t., water (170 ml) was added and a 
white precipitate was observed. After cooling in an ice bath, the suspension was filtered, 
washed with 1 l of cold water and dried overnight in vacuo. After recrystallisation of the 
precipitate from 190 ml of Hexane/Chloroforme (1:1, v/v), 10.5 g (25.54 mmol, 81 %) 3,6-
dibromocarbazolethylester 30 were obtained as a white solid. 
 
C16H13Br2NO2: 411.09 g/mol 
 
TLC: Pentane/EtOAc (7:1); Rf: 0.49. 
 
1H-NMR (500 MHz, CDCl3, 25°C): δ(ppm) = 8.14 (m, 2H; 4, 4’), 7.57 (d, J = 1.7 Hz, 1H; 2), 
7.55 (d, J = 1.7 Hz, 1H; 2’), 7.20 (d, J = 8.6 Hz, 2H; 1, 1’), 4.93 (s, 2H; -N-CH2-CO2-), 4.20 
(q, J = 7.1 Hz, 2H; CH3-CH2-CO2-), 1.22 (t, J = 7.1 Hz, 3H; CH3-CH2-CO2-). 
 
13C-NMR (125.6 MHz, CDCl3, 25°C): δ(ppm) = 167.9 (Cq; -CO2-), 139.6 (Cq; C3,3’), 129.5 
(CH; C2,2’), 124.0 (Cq; C5,5’), 123.6 (CH; C4,4’), 113.1 (Cq; C6,6’), 110.3 (CH; C1,1’), 60.1 (CH2; 
CH3-CH2-CO2-), 45.0 (CH2; -N-CH2-CO2-), 14.3 (CH3; CH3-CH2-CO2-). 
 
ESI-MS: m/z: calcd for C16H13Br2NO2Na: 434 [M+Na]+; found: 434. 
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11.2 N-tert-Boc Protected 3,6-bis(3-aminopropyl)-carbazole-9-acetic acid-ethyl 
ester 34 
 
 
 
 
 
5.7 g (36.26 mmol, 2.4 eq) tert-butyl N-allylcarbamante 32 were evacuated and 
flushed with argon three times. After cooling in an ice bath, 85.0 ml (42.30 mmol, 2.8 eq) of 
0.5 M solution of 9-BBN 31 in THF were added slowly and the mixture was allowed to stir 
overnight at r.t. Under argon, removal of the solvent under reduced pressure yielded a 
yellow oily residue 33. 
 
 
 
 
 
 
 
Under Argon, toluene (310 ml) and a 1 M solution of KOH (91 ml) were added to the 
oily residue 33. The mixture was degassed two times. 6.2 g (15.11 mmol, 1.0 eq) 3,6-
dibromo-carbazole-9-acetic acid-ethyl ester 30 were then added and the mixture was 
degassed two times. After the addition of 1.8 g (1.50 mmol, 10 mol %) Pd[PPh3]4 , the 
yellow solution was then degassed three times and allowed to stir at 120°C overnight. After 
cooling to r.t., the reaction mixture was washed with sat. NaHCO3-soln. and with brine and 
dried over Na2SO4. The aq. phase was slightly evaporated at reduced pressure to eliminate 
the toluene and then extracted with chloroform (3x150 ml) and the org. phases were dried 
over Na2SO4. After filtration of the toluene- and the chloroform-phases and removal of all 
volatiles under reduced pressure, flash chromatography (gradient of pentane/EtOAc from 5:1 
to 3:1 (v/v)) afforded 1.2 g (2.11 mmol, 14 %) of the N-tert-Boc protected 3,6-bis(3-
aminopropyl)-carbazole-9-acetic acid-ethyl ester 34 as a white solid. 
 
C32H45N3O6: 567.72 g/mol 
 
TLC: Pentane/EtOAc (3:1); Rf: 0.29. 
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1H-NMR (500 MHz, CDCl3, 25°C): δ(ppm) = 7.85 (s, 2H; 4, 4’), 7.26 (d, J = 1.7 Hz, 1H; 2), 
7.25 (d, J = 1.6 Hz, 1H; 2’), 7.21 (d, J = 8.6 Hz, 2H; 1, 1’), 4.93 (s, 2H; -N-CH2-CO2-), 4.19 
(q, J = 7.1 Hz, 2H; CH3-CH2-CO2-), 3.19 (t, J = 7.0 Hz, 4H; -CH2-CH2-CH2-NH-), 2.81 (t, J = 
7.5 Hz, 4H; -CH2-CH2-CH2-NH-), 1.90 (tt, J = 7.6, 7.2 Hz, 4H; -CH2-CH2-CH2-NH-), 1.45 (s, 
18H; CH3Boc), 1.22 (t, J = 7.1 Hz, 3H; CH3-CH2-CO2-). 
 
13C-NMR (125.6 MHz, CDCl3, 25°C): δ(ppm) = 168.6 (Cq; -CO2-), 156.1 (Cq; COBoc), 139.5 
(Cq; C5,5’), 132.7 (Cq; C3,3’), 126.5 (CH; C2,2’), 123.2 (Cq; C6,6’), 119.8 (CH; C4,4’), 108.2 (CH; 
C1,1’), 79.3 (Cq; CBoc), 61.6 (CH2; CH3-CH2-CO2-), 44.9 (CH2; -N-CH2-CO2-), 40.4 (CH2; -CH2-
CH2-CH2-NH-), 33.1 (CH2; -CH2-CH2-CH2-NH-), 32.5 (CH2; -CH2-CH2-CH2-NH-), 28.5 (CH3; 
CBoc), 14.2 (CH3; CH3-CH2-CO2-). 
 
ESI-MS: m/z: calcd for C32H45N3O6Na: 590 [M+Na]+; found: 590. 
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12 SYNTHESIS OF TWO-ARMED CARBAZOLE RECEPTOR PROTOTYPES 
 
12.1 Dye-Marked Carbazole Precursor 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
500 mg (880.7 µmol, 2 eq) of the N-tert-Boc protected 3,6-bis(3-aminopropyl)-
carbazole-9-acetic acid-ethyl ester 34 were dissolved in a 1:1 (v/v) mixture of THF and 
MeOH (3 ml). After the addition of 1.5 M NaOH (0.7 ml), the mixture was stirred for 4 h at 
r.t. The reaction mixture was then carefully acidified to pH 3 with 1 M HCl. CH2Cl2 and water 
were added and the mixture was extracted. The aq. phase was extracted again with CH2Cl2 
and the org. phases were washed with brine and dried over Na2SO4. Filtration and 
evaporation of the solvent under reduced pressure yielded a red solid which was mixed with 
364 mg (880.7 µmol, 2.0 eq) HCTU in DMF (0.5 ml), 151 µl (880.7 µmol, 2 eq) iPr2NEt and 
CH2Cl2 (2 ml). This mixture was stirred at r.t. for 1 min and added to a cold mixture of 138 
mg (440.4 µmol, 1 eq) of the Dye-NH2 37 and 151 µl (880.7 µmol, 2 eq) iPr2NEt in CH2Cl2 (2 
ml). The reaction mixture was stirred at r.t. for 2 h. The reaction mixture was extracted 
three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The aq. phases were 
extracted again with CH2Cl2. The org. phases were washed with brine and dried over Na2SO4. 
After filtration and evaporation of the solvent under reduced pressure the crude product was 
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purified by preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) to yield 247 mg (295.8 µmol, 67 %) 
of the dye-marked carbazole precursor 38. 
 
C46H58N8O7: 835.02 
 
TLC: MeOH/CH2Cl2 (5:95): 0.48. 
 
1H-NMR (500 MHz, 5% CD3OD in CDCl3, 25°C): δ(ppm) = 8.23 (d, J = 9.0 Hz, 2H; Hdye), 
7.86 (d, J = 8.9 Hz, 2H; Hdye), 7.79 (m, 2H; Hdye), 7.78 (s, 2H; H4,4’), 7.17 (d, J = 8.6 Hz, 2H; 
H2,2’), 7.08 (d, J = 8.2 Hz, 2H; H1,1’), 6.68 (d, J = 8.6 Hz, 2H; Hdye), 4.78 (s, 2H; -N-CH2-CO-
), 3.40 (m, 2H; -N-CH2-CH2-NH-dye), 3.33 (m, 2H; -N-CH2-CH2-NH-dye), 3.26 (q, J = 6.8 Hz, 
2H; -N-CH2-CH3dye), 3.03 (t, J = 6.7 Hz, 4H; -CH2-CH2-CH2-NH-), 2.73 (t, J = 7.4 Hz, 4H; -
CH2-CH2-CH2-NH-), 1.81 (tt, J = 7.5, 7.2 Hz, 4H; -CH2-CH2-CH2-NH-), 1.39 (s, 18H; CH3Boc), 
1.04 (t, J = 6.9 Hz, 3H; -N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, 5% CD3OD in CDCl3, 25°C): δ(ppm) = 169.5 (Cq; CO), 156.3 (Cq; 
COBoc), 155.4/152.2/147.1/142.9 (Cq; dye), 139.1 (Cq; C5,5’), 133.3 (Cq; C3,3’), 127.4 (CH; 
dye), 126.9 (CH; C2,2’), 124.8 (CH; dye), 123.3 (Cq; C6,6’), 122.0 (CH; dye), 119.9 (CH; C4,4’), 
112.1 (CH; dye), 108.3 (CH; C1,1’), 79.3 (Cq, CHBoc), 48.9 (CH2; -N-CH2-CH2-N-dye), 46.8 (CH2; 
-N-CH2-CO-), 45.5 (CH2; -N-CH2-CH3dye), 39.9 (CH2; -CH2-CH2-CH2-NH-), 37.0 (CH2; -N-CH2-
CH2-N-dye), 32.9 (CH2; -CH2-CH2-CH2-NH-), 32.2 (CH2; -CH2-CH2-CH2-NH-), 28.3 (CH3; CBoc), 
12.1 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C46H58N8O7: 835 [M]+; found: 835; calcd for C46H57N8O7Na: 857 [M-
H+Na]+; found: 857; calcd for C46H57N8O7K: 873 [M-H+K]+; found: 873. 
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12.2 General Fmoc-Strategy for the Synthesis of the Two-Armed Carbazole 
Receptors in Solution, Exemplified by the Synthesis of the Receptor 39 
 
 
 
 
 
 
 
12.2.1 First coupling 
 
150 mg (264.4 µmol, 1 eq) of the bis-N-Boc-protected carbazole precursor 34 were 
dissolved in a 1:3 (v/v) mixture of TFA and CH2Cl2 (2.2 ml) and allowed to stir at r.t. for 1 h. 
After the removal of all volatiles under reduced pressure, the residue was triturated with 
Et2O to yield a red solid which was isolated by decantation and dried in vacuo. The 
corresponding TFA-salt of 34 was then dissolved in dry CH2Cl2 (2.5 ml) followed by addition 
of 91 µl (528.8 µmol, 2 eq) iPr2NEt, ready for the next coupling. 
The solution was cooled with an ice bath before a mixture of 437 mg (1.06 mmol, 4 
eq) HCTU in DMF (2 ml), 91 µl (528.8 mmol, 2 eq) iPr2NEt and 610 mg (1.06 mmol, 4 eq) 
Fmoc-L-Tyr(dye)-OH 13 in CH2Cl2 (2.5 ml), was added and stirred at r.t. for 1 h. The 
reaction mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and 
CH2Cl2. The aq. phases were extracted again with CH2Cl2. The org. phases were washed with 
brine and dried over Na2SO4. After filtration and evaporation of the solvent under reduced 
pressure, the crude product was purified by flash chromatography on silica gel (gradient of 
CH2Cl2/MeOH from 99.5:0.5 to 98:2 (v/v)) to afford 227 mg (152.7 µmol, 60%) of the dye-
marked bis-N-Boc-protected receptor precursor. 
 
C82H95N13O13: 1486.71 
 
TLC: MeOH/CH2Cl2 (3:97); Rf: 0.62. 
 
ESI-MS: m/z: calcd for C82H95N13O13: 1486 [M]+; found: 1486, calcd for C82H94N13O13Na: 
1508 [M-H+Na]+; found: 1508. 
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12.2.2 Second coupling 
 
227 mg (152.7 µmol, 1 eq) of the dye-marked bis-N-Boc-protected receptor precursor 
were dissolved in MeOH (3 ml) and treated with a solution of 4 M HCl in dioxan (9.5 ml) at 
r.t. for 1 h. After removal of all volatiles under reduced pressure, the residue was triturated 
with Et2O to yield a red solid which was isolated by decantation and dried in vacuo. The 
corresponding HCl-salt was dissolved in dry CH2Cl2 (5 ml) with 52 µl (305.5 µmol, 2 eq) 
iPr2Net. 
This solution was cooled with an ice bath before a mixture of 253 mg (610.8 mmol, 4 
eq) HCTU in DMF (2 ml), 52 µl (305.5 mmol, 2 eq) iPr2NEt and 373 mg (610.8 mmol, 4eq) 
Fmoc-L-Gln(Trt)-OH in CH2Cl2 (5 ml), was added and stirred at r.t. for 1 h. The reaction 
mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The 
aq. phases were extracted again with CH2Cl2. The org. phases were washed with brine and 
dried over Na2SO4. Filtration and evaporation of the solvent at reduced pressure yielded the 
crude product which was triturated with MeOH to yield a red solid. The solid was isolated by 
filtration and dried in vacuo to obtain 376 mg (152.7 µmol, 100%) of the dye-marked bis-N-
Fmoc-protected receptor precursor. 
 
C150H143N17O18: 2471.84 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.19. 
 
ESI-MS: m/z: calcd for C150H143N17O18Na: 2494 [M+Na]+; found: 2494. 
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12.2.3 Third coupling 
 
376 mg (152.7 µmol, 1 eq) of the dye-marked bis-N-Fmoc-protected receptor 
precursor were dissolved in DMF (2 ml) followed by addition of 474 µl (4.58 mmol, 30 eq) 
diethylamine. The reaction mixture was stirred at r.t. for 30 min. After removal of DMF under 
reduced pressure, the crude product was co-evaporated three times with n-heptane. The 
residue was dried in vacuo and then dissolved in a mixture of dry CH2Cl2 (1 ml) and DMF (2 
ml) with 52 µl (305.5 µmol, 2 eq) iPr2NEt, ready for the last amino acid coupling. 
This solution was cooled with an ice bath before a mixture of 253 mg (610.8 mmol, 4 
eq) HCTU in DMF (2 ml), 52 µl (305.5 mmol, 2 eq) iPr2NEt and 236 mg (610.8 mmol, 4eq) 
Fmoc-L-Phe-OH in CH2Cl2 (1 ml), was added and stirred at r.t. for 1 h. The reaction mixture 
was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) and CH2Cl2. The aq. 
phases were extracted again with CH2Cl2. The org. phases were washed with brine and dried 
over Na2SO4. Filtration and evaporation of the solvent at reduced pressure yielded the crude 
product which was triturated with MeOH to yield a red solid. The solid was isolated by 
filtration and dried in vacuo to obtain 372 mg (134.5 µmol, 88%) of the dye-marked bis-N-
Fmoc-protected receptor precursor which contained two tripeptidic arms. 
 
C168H161N19O20: 2766.19 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.49. 
 
ESI-MS: m/z: calcd for C168H160N19O20Na: 2788 [M-H+Na]+; found: 2788. 
 
 
12.2.4 Acetylation 
 
After the final Fmoc-deprotection using 479 µmol (4.04 mmol, 30 eq) diethylamine in 
DMF (4 ml), the diamine was dissolved in a mixture of CH2Cl2 (6 ml) and DMF (6 ml) 
followed by the addition of 56 µl (403.9 µmol, 3 eq) Et3N and 38 µl (403.9 µmol, 3 eq) Ac2O. 
After stirring the mixture for 30 min, the reaction mixture was extracted three times with 0.1 
M Na-phosphate buffer (pH 5.5) and CH2Cl2. The aq. phases were extracted again with 
CH2Cl2. The org. phases were washed with brine and dried over Na2SO4. After filtration and 
evaporation of the solvent under reduced pressure the crude product was purified by 
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preparative-TLC (CH2Cl2/MeOH, 90:10, v/v) and gel filtration (LH 20, CH2Cl2/MeOH, 90:10, 
v/v) to yield 172 mg (71.5 µmol, 53%) of the two-armed carbazole receptor 39. 
 
C142H145N19O18: 2405.79 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.29. 
 
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.50 (s, 2H; -NHTrt), 8.29 (d, J = 9.1 Hz, 4H; 
Hdye), 8.13 (d, J = 7.7 Hz, 2H; -NHGln), 8.02 (d, J = 8.1 Hz, 2H; -NHTyr), 7.91 (m, 2H; -CH2-
CH2-CH2-NH-), 7.87 (d, J = 9.1 Hz, 4H; Hdye), 7.81 (s, 2H; H4,4’), 7.79 (m, 2H; -NHPhe), 7.76 
(d, J = 9.2 Hz, 4H; Hdye), 7.34 (m, 2H; H2,2’), 7.22-7.09 (m, 42H, HPhe, HTrt, H1,1’), 7.07 (d, J = 
8.6 Hz, 4H; HTyr), 6.79 (d, J = 9.3 Hz, 4H; Hdye), 6.73 (d, J = 8.6 Hz, 4H; HTyr), 5.18 (s, 2H; -
N-CH2-CO2-), 4.44 (m, 2H; HαTyr), 4.37 (dd, J = 14.3, 7.7 Hz, 2H; HαPhe), 4.15 (dd, J = 13.5, 
7.6 Hz, 2H; HαGln), 4.07 (q, J = 7.1 Hz, 2H; CH3-CH2-CO2-), 3.94 (m, 4H; -N-CH2-CH2-O-dye), 
3.64 (m, 4H; -N-CH2-CH2-O-dye), 3.42 (q, J = 7.0 Hz, 4H; -N-CH2-CH3dye), 3.04 (m, 2H; -CH2-
CH2-CH2-NH-), 2.94 (m, 2H; -CH2-CH2-CH2-NH-), 2.91 (m, 2H; HβPhe), 2.85 (m, 2H; HβTyr), 
2.73 (dd, J = 13.0, 7.8 Hz, 2H; Hβ’Tyr), 2.65 (dd, J = 13.9, 10.3 Hz, 2H; Hβ’Phe), 2.56 (m, 4H; 
-CH2-CH2-CH2-NH-), 2.25 (m, 4H; HγGln, Hγ’Gln), 1.77 (m, 2H; HβGln), 1.67 (m, 2H; Hβ’Gln), 
1.64 (s, 6H; -COCH3), 1.62 (m, 4H; -CH2-CH2-CH2-NH-), 1.14 (t, J = 7.1 Hz, 3H; CH3CH2-CO2-
), 1.05 (t, J = 6.9 Hz, 6H; -N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 172.1/171.9/171.3/170.9/169.8 (Cq; CO), 
169.3 (Cq; -CO2-), 157.3 (Cq; Tyr), 156.6/152.0/147.3 (Cq; dye), 145.3 (Cq; Trt), 143.2 (Cq; 
dye), 139.6 (Cq; C5,5’), 138.5 (Cq; Phe), 132.8 (Cq; C3,3’), 130.7 (CH; CHTyr), 130.2 (Cq; Tyr), 
129.6/128.4 (CH; CHPhe), 128.9/127.9 (CH; CHTrt), 126.7 (CH; dye), 126.5 (CH; C1,1’), 
125.4/122.9 (CH; dye), 122.7 (Cq; C6,6’), 120.0 (CH; C4,4’), 114.4 (CH; CHTyr), 112.1 (CH; 
dye), 109.4 (CH; C2,2’), 69.6 (Cq; Trt), 65.6 (CH2; -N-CH2-CH2-O-dye), 61.3 (CH3-CH2-CO2-), 
54.6 (CH; CαPhe), 54.5 (CH; CαTyr), 52.8 (CH; CαGln), 49.5 (CH2; -N-CH2-CH2-O-dye), 45.7 (CH2; 
-N-CH2-CH3dye), 44.5 (CH2; -N-CH2-CO2-), 38.7 (CH2; -CH2-CH2-CH2-NH-), 37.8 (CH2; CβPhe, 
Cβ’Phe), 37.5 (CH2; CβTyr, Cβ’Tyr), 33.0 (CH2; CγGln, Cγ’Gln), 32.9 (CH2; -CH2-CH2-CH2-NH-), 31.9 
(CH2; -CH2-CH2-CH2-NH-), 28.4 (CH2; CβGln, Cβ’Gln), 22.8 (CH3; -COCH3), 14.5 (CH3; CH3-CH2-
CO2-), 12.4 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C142H144N19O18Na: 2427 [M-H+Na]+; found: 2427. 
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12.2.5 Two-Armed Carbazole Receptor 40 
 
(40 was obtained in analogy to the procedures described in 12.2.1 – 12.2.4) 
 
 
 
 
 
 
 
First coupling: 200 mg (239.5 µmol, 1 eq) of receptor precursor 38 
14 ml of 4 M HCl in Dioxan 
Methanol (4 ml) 
   440 mg (958.0 µmol, 4 eq) Fmoc-L-Tyr(tBu)-OH 
   396 mg (958.0 µmol, 4 eq) HCTU in DMF (1 ml) 
   164 µl (958.0 µmol, 4 eq) iPr2Net 
   CH2Cl2 (2 ml) 
   Yield: 174 mg (114.9 µmol, 48%) 
 
C92H96N10O11: 1517.81 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.74. 
 
ESI-MS: m/z: calcd for C92H96N10O11Na: 1540 [M+Na]+; found: 1540. 
 
 
Second coupling: 859 µl (5.75 mmol, 50 eq) TAEA 
   CH2Cl2 (10 ml) and DMF (4 ml) 
   281 mg (459.7 µmol, 4 eq) Fmoc-L-Gln(Trt)-OH 
   190 mg (459.7 µmol, 4 eq) HCTU in DMF (1 ml) 
   79 µl (459.7 µmol, 4 eq) iPr2Net 
   CH2Cl2 (4 ml) 
   Yield: 259 mg (114.9 µmol, 100%) 
 
 
N
H
N
O
N
H
H
N
L-Tyr(tBu)
L-Tyr(tBu)
L-Gln(Trt)L-PheAc
L-Gln(Trt)L-PheAc
dye
40
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C140H140N14O15: 2258.69 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.35. 
 
ESI-MS: m/z: calcd for C140H140N14O15: 2258 [M]+; found: 2258, calcd for C140H139N14O15Na: 
2280 [M-H+Na]+; found: 2280, calcd for C140H139N14O15K: 2296 [M-H+K]+; found: 2296. 
 
 
Third coupling: 859 µl (5.75 mmol, 50 eq) TAEA 
   CH2Cl2 (10 ml) and DMF (4 ml) 
   178 mg (459.7 µmol, 4 eq) Fmoc-L-Phe-OH 
   190 mg (459.7 µmol, 4 eq) HCTU in DMF (1 ml) 
   79 µl (459.7 µmol, 4 eq) iPr2Net 
   CH2Cl2 (4 ml) 
   Yield: 204 mg (79.9 µmol, 70%) 
 
C158H158N16O17: 2553.04 
 
TLC: MeOH/CH2Cl2 (5:95); Rf: 0.15. 
 
ESI-MS: m/z: calcd for C158H156N16O17Na: 2574 [M-2H+Na]+; found: 2574. 
 
 
Acetylation:  597 µl (3.40 mmol, 50 eq) TAEA 
   CH2Cl2 (9 ml) and DMF (1 ml) 
   33 µl (239.7 µmol, 3 eq) Et3N 
   23 µl (239.7 µmol, 3 eq) Ac2O 
   CH2Cl2 (5 ml) 
Yield: 95 mg (43.4 µmol, 54%) of the two-armed carbazole 
receptor 40 
 
C132H142N16O15: 2192.64 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.73. 
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1H-NMR (500 MHz, 5% CD3OD in CDCl3, 25°C): δ(ppm) = 8.22 (d, J = 8.9 Hz, 2H; Hdye), 
7.85 (d, J = 8.6 Hz, 2H; Hdye), 7.82 (s, 2H; H4,4’), 7.79 (m, 2H; Hdye), 7.27-6.90 (m, 48H, 
HPhe, HTrt, HTyr, H1,1’, H2,2’), 6.78 (d, J = 8.3 Hz, 4H; HTyr), 6.71 (m, 2H; Hdye), 4.70 (s, 2H; -N-
CH2-CO-), 4.62 (m, 2H; HαTyr), 4.16 (dd, J = 10.9, 3.5 Hz, 2H; HαPhe), 4.02 (m, 2H; HαGln), 
3.41 (dd, J = 14.5, 3.8 Hz, 2H; HβTyr), 3.33 (m, 2H; -N-CH2-CH2-NH-dye), 3.28 (m, 2H; -N-
CH2-CH3dye), 3.26 (m, 2H; -N-CH2-CH2-NH-dye), 3.19 (m, 4H; -CH2-CH2-CH2-NH-), 3.05 (dd, J 
= 13.9, 2.9 Hz, 2H; HβPhe), 2.78 (m, 2H; Hβ’Tyr), 2.76 (m, 4H; -CH2-CH2-CH2-NH-), 2.63 (t, 
2H; Hβ’Phe), 2.04 (m, 2H; HγGln), 1.93 (m, 2H; HβGln), 1.89 (m, 4H; -CH2-CH2-CH2-NH-), 1.62 
(m, 2H; Hβ’Gln), 1.43 (s, 6H; -COCH3), 1.19 (m, 2H;Hγ’Gln), 1.17 (s, 18H; CH3tBu), 1.06 (t, 3H; 
-N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, 5% CD3OD in CDCl3, 25°C): δ(ppm) = 174.3/174.1/173.2/ 
171.4/171.3/169.7 (Cq; CO), 153.1 (Cq; Tyr), 146.8 (Cq; dye), 144.0 (Cq; Trt), 142.1 (Cq; 
dye), 139.0 (Cq; C5,5’), 136.5 (Cq; Phe), 133.8 (Cq; Tyr), 133.5 (Cq; C3,3’), 129.6 (CH; CHTyr), 
128.6/127.9 (CH; CHTrt), 128.5 (CH; CHPhe), 126.9 (CH; dye), 126.9 (CH; C2,2’), 124.9 (CH; 
dye), 124.4 (CH; CHTyr), 123.4 (Cq; C6,6’), 121.4 (CH, dye), 120.2 (CH; C4,4’), 112.9 (CH; 
dye), 108.1 (CH; C1,1’), 78.9 (Cq, CH3tBu), 70.3 (Cq; Trt), 56.9 (CH; CαPhe), 54.6 (CH; CαTyr), 
54.5 (CH; CαGln), 49.9 (CH2; -N-CH2-CH2-NH-dye), 46.8 (CH2; -N-CH2-CO-), 45.9 (CH2; -N-CH2-
CH3dye), 39.2 (CH2; -CH2-CH2-CH2-NH-), 36.9 (CH2; -N-CH2-CH2-NH-dye), 36.4 (CH2; CβPhe, 
Cβ’Phe), 36.1 (CH2; CβTyr, Cβ’Tyr), 33.0 (CH2; -CH2-CH2-CH2-NH-), 31.4 (CH2; CγGln, Cγ’Gln), 31.2 
(CH2; -CH2-CH2-CH2-NH-), 28.6 (CH3; CtBu), 25.5 (CH2; CβGln, Cβ’Gln), 22.4 (CH3; -COCH3), 12.2 
(CH3; -N-CH2-CH3dye). 
 
MS (MALDI-ToF): m/z: calcd for C132H143N16O15: 2193 [M+H]+; found: 2193, m/z: calcd for 
C132H143N16O15Na: 2216 [M+H+Na]+; found: 2216. 
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12.2.6 Two-Armed Carbazole Receptor 41 
 
(41 was obtained in analogy to the procedures described in 12.2.1 – 12.2.4) 
 
 
 
 
 
 
 
100 mg (41.6 µmol, 1.2 eq) of the carbazole receptor 39 were dissolved in a 1:1 
(v/v) mixture of THF and MeOH (10 ml), DMF was added until complete solubilization. After 
the addition of 150 µl (312.0 µmol, 9 eq) 2 M NaOH, the mixture was stirred for 1 h at r.t. 
The reaction mixture was extracted three times with 0.1 M Na-phosphate buffer (pH 5.5) 
and CH2Cl2. The aq. phases were extracted again with CH2Cl2. The org. phases were washed 
with brine and dried over Na2SO4. Filtration and evaporation of the solvent under reduced 
pressure yielded a red solid which was mixed with 286 mg (69.3 µmol, 2.0 eq) HCTU in DMF 
(1 ml), 12 µl (69.3 µmol, 2 eq) iPr2NEt and CH2Cl2 (2.5 ml). This mixture was stirred at r.t. 
for 1 min and added to a cold mixture of 26 mg (34.6 µmol, 1 eq) H2N-(CH2CH2O)≈16CH3 
(H2N-PEG750), which was before melted at 80°C in vacuo for 30 min, in order to remove 
traces of moisture, and 12 µl (69.3 µmol, 2eq) iPr2NEt in CH2Cl2 (2.5 ml). The reaction 
mixture was stirred at r.t. for 1 h, and then extracted three times with 0.1 M Na-phosphate 
buffer (pH 5.5) and CH2Cl2. The aq. phases were extracted again with CH2Cl2. The org. 
phases were washed with brine and dried over Na2SO4. After filtration and evaporation of the 
solvent under reduced pressure, the crude product was purified by preparative-TLC 
(CH2Cl2/MeOH, 90:10, v/v) to afford 75 mg (24.2 µmol, 70 %) of the dye-marked carbazole 
precursor 41. 
 
C173H208N20O33: 3095.62 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.52. 
 
 
 
 
N
H
N
O
N
H
H
N
L-Tyr(dye)
L-Tyr(dye)
L-Gln(Trt)L-PheAc
L-Gln(Trt)L-PheAc
PEG750
41
Experimental Section 
 
145
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.53 (s, 2H; -NHTrt), 8.34 (d, J = 8.9 Hz, 4H; 
Hdye), 8.31 (s, 1H; -NH-(CH2CH2O)≈16-CH3), 8.16 (d, J = 7.6 Hz, 2H; -NHGln), 8.06 (d, J = 8.1 
Hz, 2H; -NHPhe), 7.95 (m, 2H; -CH2-CH2-CH2-NH-), 7.91 (d, J = 8.9 Hz, 4H; Hdye), 7.84 (s, 
2H; H4,4’), 7.83 (m, 2H; -NHTyr), 7.79 (d, J = 9.0 Hz, 4H; Hdye), 7.36 (d, J = 8.2 Hz, 2H; H2,2’), 
7.22-7.11 (m, 42H, HPhe, HTrt, H1,1’), 7.10 (d, J = 8.5 Hz, 4H; HTyr), 6.83 (d, J = 9.2 Hz, 4H; 
Hdye), 6.76 (d, J = 8.4 Hz, 4H; HTyr), 4.93 (s, 2H; -N-CH2-CO-), 4.48 (m, 2H; HαPhe), 4.41 (dd, 
J = 14.2, 7.6 Hz, 2H; HαTyr), 4.19 (dd, J = 12.9, 7.3 Hz, 2H; HαGln), 3.97 (m, 4H; -N-CH2-
CH2-O-dye), 3.67 (m, 4H; -N-CH2-CH2-O-dye), 3.58-3.30 (m, 64H; -NH-(CH2CH2O)≈16-CH3), 3.47 
(m, 4H; -N-CH2-CH3dye), 3.22 (s, 3H; -NH-(CH2CH2O)≈16-CH3), 3.08 (m, 2H; -CH2-CH2-CH2-
NH-), 2.99 (m, 2H; -CH2-CH2-CH2-NH-), 2.94 (m, 2H; HβPhe), 2.89 (m, 2H; HβTyr), 2.77 (m, 
2H; Hβ’Tyr), 2.69 (m, 2H; Hβ’Phe), 2.60 (m, 4H; -CH2-CH2-CH2-NH-), 2.29 (m, 4H; HγGln, Hγ’Gln), 
1.81 (m, 2H; HβGln), 1.71 (m, 2H; Hβ’Gln), 1.69 (s, 6H; -COCH3), 1.66 (m, 4H; -CH2-CH2-CH2-
NH-), 1.08 (t, J = 6.8 Hz, 6H; -N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 171.7/171.5/170.9/170.5/169.4/167.6 (Cq; 
CO), 156.8 (Cq; Tyr), 156.2/151.6/146.8 (Cq; dye), 144.9 (Cq; Trt), 142.8 (Cq; dye), 139.4 
(Cq; C5,5’), 138.1 (Cq; Phe), 132.1 (Cq; C3,3’), 130.2 (CH; CHTyr), 129.7 (Cq; Tyr), 129.1/128.0 
(CH; CHPhe), 128.5/127.5 (CH; CHTrt), 126.3/126.2 (CH; dye), 126.1 (CH; C1,1’), 125.0/122.5 
(CH; dye), 122.2 (Cq; C6,6’), 119.3 (CH; C4,4’), 114.0 (CH; CHTyr), 111.6 (CH; dye), 109.0 (CH; 
C2,2’), 71.3/69.8/69.6(CH2; -NH-(CH2CH2O)≈16-CH3), 69.6 (Cq; Trt), 69.2/69.0 (CH2; -NH-
(CH2CH2)≈16-OCH3), 65.2 (CH2; -N-CH2-CH2-O-dye), 58.1 (CH3; -NH-(CH2CH2O)≈16-CH3), 54.2 
(CH; CαTyr), 54.1 (CH; CαPhe), 52.4 (CH; CαGln), 49.0 (CH2; -N-CH2-CH2-O-dye), 45.6 (CH2; -N-
CH2-CO-), 45.2 (CH2; -N-CH2-CH3dye), 38.7 (CH2; -NH-(CH2CH2O)≈16-CH3), 38.3 (CH2; -CH2-
CH2-CH2-NH-), 37.4 (CH2; CβPhe, Cβ’Phe), 37.1 (CH2; CβTyr, Cβ’Tyr), 32.6 (CH2; CγGln, Cγ’Gln), 32.5 
(CH2; -CH2-CH2-CH2-NH-), 31.5 (CH2; -CH2-CH2-CH2-NH-), 28.0 (CH2; CβGln, Cβ’Gln), 22.4 (CH3; 
-COCH3), 11.9 (CH3 ; -N-CH2-CH3dye). 
 
MS (MALDI-ToF): m/z: calcd for C173H207N20O33Na: 3117 [M-H+Na]+; found: 3117 
(distribution of peaks due to the polydispersity of the PEG). 
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12.2.7 Two-Armed Carbazole Receptor 42 
 
(42 was obtained in analogy to the procedures described in 12.2.1 – 12.2.4) 
 
 
 
 
 
 
 
First coupling: 300 mg (528.8 µmol, 1 eq) of receptor precursor 34 
1:3 (v/v) mixture of TFA and CH2Cl2 (4 ml) 
   1.22 mg (2.11 mmol, 4 eq) Fmoc-L-Tyr(dye)-OH 
   874 mg (2.11 mmol, 4 eq) HCTU in DMF (2 ml) 
   362 µl (2.11 mmol, 4 eq) iPr2Net 
   CH2Cl2 (10 ml) 
   Yield: 174 mg (373.3 µmol, 71%) 
 
C82H95N13O13: 1486.71 
 
TLC: MeOH/CH2Cl2 (3:97); Rf: 0.62. 
 
ESI-MS: m/z: calcd for C82H95N13O13: 1486 [M]+; found: 1486, calcd for C82H94N13O13Na: 
1508 [M-H+Na]+; found: 1508. 
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PEG coupling: 500 mg (336.3 µmol, 1.2 eq) of receptor precursor 60 
   21 ml of a 2 M solution of NaOH 
   1:1 (v/v) mixture of THF and MeOH (160 ml) 
   210 mg (280.6 µmol, 1 eq) H2N-PEG750 
   232 mg (560.5 µmol, 2 eq) HCTU in DMF (1 ml) 
   96 µl (560.5 µmol, 2 eq) iPr2Net 
   CH2Cl2 (15 ml) and DMF (15 ml) 
   Yield: 336 mg (154.4 µmol, 55%) 
 
C113H158N14O29: 2176.54 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.50. 
 
1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.35 (d, J = 8.9 Hz, 4H; Hdye), 8.30 (m, 1H; -
NH-(CH2CH2O)≈16-CH3), 7.92 (d, J = 8.9 Hz, 4H; Hdye), 7.90 (m, 2H; -CH2-CH2-CH2-NH-), 7.87 
(s, 2H; H4,4’), 7.82 (d, J = 9.1 Hz, 4H; Hdye), 7.38 (d, J = 8.4 Hz, 2H; H2,2’), 7.22 (d, J = 8.2 
Hz, 2H, H1,1’), 7.15 (d, J = 9.1 Hz, 4H; HTyr), 6.89 (d, J = 9.1 Hz, 4H; Hdye), 6.83 (m, 2H; -
NHTyr), 6.82 (d, J = 8.0 Hz, 4H; HTyr), 4.94 (s, 2H; -N-CH2-CO-), 4.10 (m, 2H; HαTyr), 4.07 
(m, 4H; -N-CH2-CH2-O-dye), 3.77 (m, 4H; -N-CH2-CH2-O-dye), 3.54 (m, 4H; -N-CH2-CH3dye), 
3.52-3.26 (m, 64H; -NH-(CH2CH2O)≈16-CH3), 3.22 (s, 3H; -NH-(CH2CH2O)≈16-CH3), 3.08 (m, 
4H; -CH2-CH2-CH2-NH-), 2.85 (dd, J = 13.5, 5.1 Hz, 2H; HβTyr), 2.69 (m, 2H; Hβ’Tyr), 2.65 (m, 
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4H; -CH2-CH2-CH2-NH-), 1.72 (m, 4H; -CH2-CH2-CH2-NH-), 1.29 (s, 18H; CH3Boc), 1.14 (t, J = 
6.9 Hz, 6H; -N-CH2-CH3dye). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 171.5/167.6 (Cq; CO), 156.8 (Cq; Tyr), 
156.2 (Cq; dye), 155.2 (Cq; COBoc), 151.6/146.9/142.8 (Cq; dye), 139.5 (Cq; C5,5’), 132.2 
(Cq; C3,3’), 130.4 (CH; CHTyr), 130.3 (Cq; Tyr), 126.2 (CH; C1,1’), 126.1/125.0/122.5 (CH; 
dye), 122.2 (Cq; C6,6’), 119.3 (CH; C4,4’), 114.0 (CH; CHTyr), 111.7 (CH; dye), 109.1 (CH; 
C2,2’), 71.3/69.8/69.6/69.5/69.0 (CH2; -NH-(CH2CH2O)≈16-CH3), 65.3 (CH2; -N-CH2-CH2-O-dye), 
58.1 (CH3; -NH-(CH2CH2O)≈16-CH3), 56.1 (CH; CαTyr), 49.2 (CH2; -N-CH2-CH2-O-dye), 46.0 
(CH2; -N-CH2-CO-), 45.3 (CH2; -N-CH2-CH3dye), 38.7 (CH2; -NH-(CH2CH2O)≈16-CH3), 38.2 (CH2; 
-CH2-CH2-CH2-NH-), 36.9 (CH2; CβTyr, Cβ’Tyr), 32.5 (CH2; -CH2-CH2-CH2-NH-), 31.7 (CH2; -CH2-
CH2-CH2-NH-), 28.2 (CH3; CBoc), 12.0 (CH3; -N-CH2-CH3dye). 
 
ESI-MS: m/z: calcd for C113H157N14O29Na: 2198 [M-H+Na]+; found: 2198 (distribution of 
peaks due to the polydispersity of the PEG). 
 
 
Second coupling: 136.7 mg (62.8 µmol, 1 eq) of 61 
4 ml of 4M HCl in Dioxan 
Methanol (2 ml) 
   150 mg (251.2 µmol, 4 eq) Fmoc-Asn(Trt)-OH 
   104 mg (251.2 µmol, 4 eq) HCTU in DMF (1 ml) 
   43 µl (251.2 µmol, 4 eq) iPr2Net 
   CH2Cl2 (5 ml) 
   Yield: 167.6 mg (53.5 µmol, 85%) 
 
C183H210N18O35: 3221.73 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.49 
 
ESI-MS: m/z: calcd for C183H209N18O35Na: 3243 [M-H+Na]+; found: 3243 (distribution of 
peaks due to the polydispersity of the PEG). 
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Third coupling: 148 mg (47.1 µmol, 1 eq) of receptor precursor 
146 µl (1.41 mmol, 30 eq) diethylamine 
   DMF (4 ml) 
   73 mg (188.8 µmol, 4 eq) Fmoc-L-Phe-OH 
   78 mg (188.8 µmol, 4 eq) HCTU in DMF (2 ml) 
   32 µl (188.8 µmol, 4 eq) iPr2Net 
   CH2Cl2 (5 ml) 
   Yield: 155 mg (45.3 µmol, 96%) 
 
C201H228N20O37: 3516.07 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.52. 
 
ESI-MS: m/z: calcd for C201H226N20O37Na: 3537 [M-2H+Na]+; found: 3537 (distribution of 
peaks due to the polydispersity of the PEG). 
 
 
Acetylation:  106 mg (31.0 µmol, 1 eq) of receptor precursor 
97 µl (931.1 µmol, 30 eq) diethylamine 
   DMF (4 ml) 
   13 µl (93.1 µmol, 3 eq) Et3N 
   9 µl (93.1 µmol, 3 eq) Ac2O 
   CH2Cl2 (4 ml) 
   Yield: 77 mg (25.1 µmol, 81%) of the two-armed carbazole  
receptor 42 
 
C175H212N20O35: 3155.67 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.46. 
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1H-NMR (500 MHz, DMSO, 25°C): δ(ppm) = 8.79 (s, 2H; -NHTrt), 8.39 (d, J = 8.2 Hz, 2H; -
NHAsn), 8.34 (d, J = 9.1 Hz, 4H; Hdye), 8.31 (s, 1H; -NH-(CH2CH2)16-OCH3), 8.07 (d, J = 7.7 
Hz, 2H; -NHTyr), 8.01 (d, J = 8.3 Hz, 2H; -NHPhe), 7.91 (d, J = 9.1 Hz, 4H; Hdye), 7.80 (d, J = 
9.3 Hz, 4H; Hdye), 7.79 (m, 2H; -CH2-CH2-CH2-NH-), 7.78 (m, 2H; H4,4’), 7.38 (d, J = 8.3 Hz, 
2H; H2,2’), 7.26-7.11 (m, 42H, HPhe, HTrt, H1,1’), 7.09 (d, J = 8.6 Hz, 4H; HTyr), 6.81 (d, J = 9.3 
Hz, 4H; Hdye), 6.72 (d, J = 8.6 Hz, 4H; HTyr), 4.96 (s, 2H; -N-CH2-CO-), 4.55 (m, 2H; HαAsn), 
4.52 (m, 2H; HαPhe), 4.32 (dd, J = 13.6, 8.4 Hz, 2H; HαTyr), 3.87 (m, 4H; -N-CH2-CH2-O-dye), 
3.60 (m, 4H; -N-CH2-CH2-O-dye), 3.52-3.30 (m, 64H; -NH-(CH2CH2)16-OCH3), 3.42 (m, 4H; -N-
CH2-CH3dye), 3.22 (s, 3H; -NH-(CH2CH2)16-OCH3), 3.02 (m, 2H; HβTyr), 2.93 (m, 2H; HβPhe), 
2.85 (m, 2H; -CH2-CH2-CH2-NH-), 2.79 (m, 2H; HβAsn), 2.72 (m, 2H; Hβ’Tyr), 2.68 (m, 2H; 
Hβ’Phe), 2.64 (m, 2H; -CH2-CH2-CH2-NH-), 2.61 (m, 2H; Hβ’Asn), 2.51 (m, 4H; -CH2-CH2-CH2-
NH-), 1.71 (s, 6H; -COCH3), 1.51 (m, 4H; -CH2-CH2-CH2-NH-), 1.09 (t, J = 6.9 Hz, 6H; -N-
CH2-CH3dye). 
 
13C-NMR (125.6 MHz, DMSO, 25°C): δ(ppm) = 171.4/170.5/170.2/169.7/169.0/167.6 (Cq; 
CO), 156.7 (Cq; Tyr), 156.2/151.5/146.8 (Cq; dye), 144.7 (Cq; Trt), 142.8 (Cq; dye), 139.4 
(Cq; C5,5’), 138.1 (Cq; Phe), 132.1 (Cq; C3,3’), 130.3 (Cq; Tyr), 130.1 (CH; CHTyr), 129.2/127.9 
(CH; CHPhe), 128.5/127.5 (CH; CHTrt), 126.3 (CH; C1,1’), 126.2/125.0/122.5 (CH; dye), 122.2 
(Cq; C6,6’), 119.3 (CH; C4,4’), 113.9 (CH; CHTyr), 111.6 (CH; dye), 109.0 (CH; C2,2’), 
71.3/69.8/69.6(CH2; -NH-(CH2CH2)16-OCH3), 69.6 (Cq; Trt), 69.4/69.0 (CH2; -NH-(CH2CH2)16-
OCH3), 65.1 (CH2; -N-CH2-CH2-O-dye), 58.1 (CH3; -NH-(CH2CH2)16-OCH3), 54.4 (CH; CαTyr), 
53.7 (CH; CαPhe), 49.7 (CH; CαAsn), 49.0 (CH2; -N-CH2-CH2-O-dye), 45.5 (CH2; -N-CH2-CO-), 
45.2 (CH2; -N-CH2-CH3dye), 38.8 (CH2; -NH-(CH2CH2)16-OCH3), 38.6 (CH2; CβAsn, Cβ’Asn), 38.3 
(CH2; -CH2-CH2-CH2-NH-), 37.9 (CH2; CβPhe, Cβ’Phe), 36.2 (CH2; CβTyr, Cβ’Tyr), 32.5 (CH2; -CH2-
CH2-CH2-NH-), 31.3 (CH2; -CH2-CH2-CH2-NH-), 22.4 (CH3; -COCH3), 11.9 (CH3; -N-CH2-
CH3dye). 
 
ESI-MS: m/z: calcd for C175H211N20O35Na: 3177 [M-H+Na]+; found: 3177 (distribution of 
peaks due to the polydispersity of the PEG). 
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13 GENERAL PROTOCOL FOR THE SYNTHESIS OF AN ENCODED COMBINATORIAL 
TWO-ARMED CARBAZOLE RECEPTOR LIBRARY USING POLYCHLORINATED 
AROMATICS AS TAG MOLECULES 
 
13.1 Splitting and Encoding of the Resin 
 
5.2 g (2.26 mmol, loading 0.43 mmol g-1) Tentagel S functionalized with N-tert-Boc 
protected carbazole template 44[77] were placed in 150 ml Merrifield vessel and washed 
three times with CH2Cl2. Cleavage of the Boc protecting group was achieved by shaking the 
resin with a 30% (v/v) mixture of TFA/CH2Cl2 for 30 min. The resin was then washed three 
times with CH2Cl2, five times with a 30% (v/v) mixture of iPr2NEt/ CH2Cl2 and then three 
times with CH2Cl2 for 1 min each. Finally, the resin was removed and dried for at least 2 h. 
Subsequently, the resin was split into fifteen equal portions of 350 mg (0.15 mmol) each and 
placed into fifteen 25 ml Merrifield shaking vessels. The resin was then suspended in dry 
CH2Cl2 (5 ml). 2 mol% of each tag were dissolved in 1 ml DMF and added separately into the 
fifteen reaction vessels along with 20 mg (0.15 mmol, 1 eq) HOBt, per tag, in 0.5 ml DMF. 
The mixtures were shaken for at least 5 min to ensure an equal distribution of the tags. After 
the addition of 35 µl (0.23 mmol, 1.5 eq) DIC, per tag, to each reaction vessel the mixture 
was shaken immediately and the reaction allowed to proceed overnight. The fifteen portions 
of resin were then washed once with DMF and three times with CH2Cl2 for 1 min each. 
 
 
13.2 Check of Successful Encoding 
 
In order to check the success of the tag coupling, three beads from each of the 
fifteen vessels were isolated in micropipette. The beads were washed two times with DMF, 
then 1.5 µl DMF was added and the micropipettes were sealed. The tag alcohols were 
released by photolysis using a UV lamp (366 nm) for 2 h and analyzed by EC-GC analysis. If 
EC-GC detection of the tags could be achieved, the resin was ready for coupling, if not, the 
tag coupling process was repeated. 
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13.3 Synthesis of the Two Peptidic Arms 
 
After checking the success of the first encoding process, the coupling of the fifteen 
amino acids was performed with 3 eq of each amino acid, 61 mg (0.45 mmol, 3 eq) HOBt in 
0.5 ml DMF and 69 µl (0.45 mmol, 3 eq) DIC following the general procedure for Fmoc-
synthesis (for the amount of each amino acid for each step, see Chapter 13.7, experimental 
section). After washing the beads three times with DMF and five times with CH2Cl2 for 1 min 
each, the resin portions were recombined in a 150 ml Merrifield vessel. The Fmoc-protecting 
group was removed as described in the general procedures for Fmoc-synthesis (see Chapter 
10.2, experimental section). The resin was then dried for at least 2 h after the last CH2Cl2 
wash and split into fifteen equal portions again. 
Splitting, encoding of the resin and coupling of each amino acid cycles were repeated 
using the protocol described above until the two tripeptidic arms were assembled.  
 
 
13.4 Synthesis of the Side-Chain Deprotected Carbazole Receptor Library 
 
Fmoc-deprotection and acetylation of 1.0 g (0.43 mmol) protected receptor-resin was 
achieved following the procedure described in Chapter 10 (experimental section). 
Cleavage of the side-chain protecting groups was achieved by shaking 410 mg of 
acetylated protected receptor-resin with a 95:2.5:2.5 (v/v/v) mixture of TFA/H2O/TIS (10 ml) 
first for 5 min, 15 min and then again 45 min. The resin was then washed ten times with 
CH2Cl2, ten times with a 30% (v/v) mixture of Et3N/CH2Cl2 and finally twenty times with 
CH2Cl2 for 1 min each. The resin was dried in vacuo and then stored at low temperature 
(4°C). 
 
 
13.5 Synthesis of the Tetrapeptide Two-Armed Carbazole Library 
 
After the amino acid coupling at the third position, Fmoc-deprotection of 3.1 g (1.33 
mmol) protected receptor-resin was achieved and the resin dried for at least 2 h. 
Subsequently, the resin was split into fifteen equal portions of 207 mg (0.09 mmol) each and 
placed into fifteen 25 ml Merrifield shaking vessels. The resin was then suspended in dry 
CH2Cl2 (5 ml). 2 mol% of each tag were dissolved in 1 ml DMF and added separately into the 
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fifteen reaction vessels along with 12 mg (0.09 mmol, 1 eq) HOBt, per tag, in 0.5 ml DMF. 
The mixtures were shaken for at least 5 min to ensure an equal distribution of the tags. After 
the addition of 21 µl (0.13 mmol, 1.5 eq) DIC, per tag, to each reaction vessel the mixture 
was agitated immediately and the reaction allowed to proceed overnight. The fifteen portions 
of resin were then washed once with DMF and three times with CH2Cl2 for 1 min each. 
Encoding of the resin and checking for successful encoding was performed as described in 
Chapter 13.2. 
The coupling of the fifteen amino acids was performed with 3 eq of each amino acid, 
41 mg (0.26 mmol, 3 eq) HOBt in 0.5 ml DMF and 42 µl (0.26 mmol, 3 eq) DIC following the 
general procedure for Fmoc-synthesis (for the amount of each amino acid for each step, see 
Chapter 13.7, experimental section). After washing the beads three times with DMF and five 
times with CH2Cl2 for 1 min each, the resin portions were recombined in a 150 ml Merrifield 
vessel. 
Fmoc-deprotection and acetylation of 1.7 g (0.73 mmol) protected receptor-resin was 
achieved following the procedure described in Chapter 10 (experimental section). Cleavage 
of the side-chain protecting groups was achieved by shaking 800 mg of acetyl protected 
receptor-resin with a 95:2.5:2.5 (v/v/v) mixture of TFA/H2O/TIS (10 ml) first for 5 min, 15 
min and then again 45 min. The resin was then washed ten times with CH2Cl2, ten times with 
a 30% (v/v) mixture of Et3N/ CH2Cl2 and finally twenty times with CH2Cl2 for 1 min each. The 
resin was dried in vacuo and then stored at low temperature (4°C). 
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13.6 Tags Used for the Described Library 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Oxidatively (A) and Photolabile (B) Cleavage Tag Molecules 
 
1st step: (CH2)12-Cl5 (2.03 mg, 3.01 µmol) = tag No 1 in step 1 (T1) 
  (CH2)11-Cl5 (1.99 mg, 3.01 µmol) = tag No 2 in step 1 (T2) 
  (CH2)10-Cl5 (1.95 mg, 3.01 µmol) = tag No 3 in step 1 (T3) 
  (CH2)9-Cl5 (1.90 mg, 3.01 µmol) = tag No 4 in step 1 (T4) 
 
2nd step: (CH2)12-2,4,5-Cl3 (1.82 mg, 3.01 µmol) = tag No 5 in step 2 (T5) 
  (CH2)12-2,4,6-Cl3 (1.82 mg, 3.01 µmol) = tag No 6 in step 2 (T6) 
 (CH2)11-2,4,5-Cl3 (1.78 mg, 3.01 µmol) = tag No 7 in step 2 (T7) 
  (CH2)11-2,4,6-Cl5 (1.78 mg, 3.01 µmol) = tag No 8 in step 2 (T8) 
 
3rd step: (CH2)10-2,4,5-Cl3 (1.74 mg, 3.01 µmol) = tag No 9 in step 3 (T9) 
  (CH2)10-2,4,6-Cl3 (1.74 mg, 3.01 µmol) = tag No 10 in step 3 (T10) 
 (CH2)9-2,4,5-Cl3 (1.69 mg, 3.01 µmol) = tag No 11 in step 3 (T11) 
  (CH2)9-2,4,6-Cl5 (1.69 mg, 3.01 µmol) = tag No 12 in step 3 (T12) 
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4th step: (CH2)8-2,4,5-Cl3 (0.98 mg, 1.78 µmol) = tag No 13 in step 4 (T13) 
  (CH2)8-2,4,6-Cl3 (0.98 mg, 1.78 µmol) = tag No 14 in step 4 (T14) 
 (CH2)7-2,4,5-Cl3 (0.95 mg, 1.78 µmol) = tag No 15 in step 4 (T15) 
  (CH2)7-2,4,6-Cl5 (0.95 mg, 1.78 µmol) = tag No 16 in step 4 (T16) 
 
 
13.7 Encoding Scheme and Amounts of Amino Acids Used 
 
Step 1: M.W. 0.45 mmol Tag M.W.: Charge Code 
Fmoc-Gly 297.31 134 mg T1 673.79 2 mol% 0001 
Fmoc-D-Ala 311.34 140 mg T2 660.77 “ 0010 
Fmoc-L-Val 339.39 152 mg T3 646.74 “ 0100 
Fmoc-D-Pro 337.38 152 mg T4 632.72 “ 1000 
Fmoc-L-Phe 387.44 174 mg T1 + T2  “ 0011 
Fmoc-D-Tyr(tBu) 459.54 206 mg T2 + T3  “ 0110 
Fmoc-L-Ser(tBu) 383.44 172 mg T3 + T4  “ 1100 
Fmoc-D-Thr(tBu) 397.5 178 mg T1 + T3  “ 0101 
Fmoc-L-Glu(OtBu) 425.48 191 mg T2 + T4  “ 1010 
Fmoc-D-Asp(OtBu)  411.46 185 mg T1 + T4  “ 1001 
Fmoc-L-Gln(Trt) 610.71 275 mg T1 + T2 + T3  “ 0111 
Fmoc-D-Asn(Trt) 596.68 268 mg T2 + T3 + T4  “ 1110 
Fmoc-L-Lys(Boc) 468.55 210 mg T1 + T2 + T4  “ 1011 
Fmoc-D-His(Trt) 619.72 278 mg T1 + T3 + T4  “ 1101 
Fmoc-L-Arg(Pbf) 648.78 292 mg T1 + T2 + T3 + T4  “ 1111 
Step 2: M.W. 0.45 mmol Tag M.W.: Charge Code 
Fmoc-Gly 297.31 134 mg T5 604.90 2 mol% 0001 
Fmoc-L-Ala 311.34 140 mg T6 604.90 “ 0010 
Fmoc-D-Val 339.39 152 mg T7 590.88 “ 0100 
Fmoc-L-Pro 337.38 152 mg T8 590.88 “ 1000 
Fmoc-D-Phe 387.44 174 mg T5 + T6  “ 0011 
Fmoc-L-Tyr(tBu) 459.54 206 mg T6 + T7  “ 0110 
Fmoc-D-Ser(tBu) 383.44 172 mg T7 + T8  “ 1100 
Fmoc-L-Thr(tBu) 397.5 178 mg T5 + T7  “ 0101 
Fmoc-D-Glu(OtBu) 425.48 191 mg T6 + T8  “ 1010 
Fmoc-L-Asp(OtBu)  411.46 185 mg T5 + T8  “ 1001 
Fmoc-D-Gln(Trt) 610.71 275 mg T5 + T6 + T7  “ 0111 
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Fmoc-L-Asn(Trt) 596.68 268 mg T6 + T7 + T8  “ 1110 
Fmoc-D-Lys(Boc) 468.55 210 mg T5 + T6 + T8  “ 1011 
Fmoc-L-His(Trt) 619.72 278 mg T5 + T7 + T8  “ 1101 
Fmoc-D-Arg(Pbf) 648.78 292 mg T5 + T6 + T7 + T8  “ 1111 
Step 3: M.W. 0.45 mmol Tag M.W.: Charge Code 
Fmoc-Gly 297.31 134 mg T9 576.85 2 mol% 0001 
Fmoc-D-Ala 311.34 140 mg T10 576.85 “ 0010 
Fmoc-L-Val 339.39 152 mg T11 562.85 “ 0100 
Fmoc-D-Pro 337.38 152 mg T12 562.85 “ 1000 
Fmoc-L-Phe 387.44 174 mg T9 + T10  “ 0011 
Fmoc-D-Tyr(tBu) 459.54 206 mg T10 + T11  “ 0110 
Fmoc-L-Ser(tBu) 383.44 172 mg T11 + T12  “ 1100 
Fmoc-D-Thr(tBu) 397.5 178 mg T9 + T11  “ 0101 
Fmoc-L-Glu(OtBu) 425.48 191 mg T10 + T12  “ 1010 
Fmoc-D-Asp(OtBu)  411.46 185 mg T9 + T12  “ 1001 
Fmoc-L-Gln(Trt) 610.71 275 mg T9 + T10 + T11  “ 0111 
Fmoc-D-Asn(Trt) 596.68 268 mg T10 + T11 + T12  “ 1110 
Fmoc-L-Lys(Boc) 468.55 210 mg T9 + T10 + T12  “ 1011 
Fmoc-D-His(Trt) 619.72 278 mg T9 + T11 + T12  “ 1101 
Fmoc-L-Arg(Pbf) 648.78 292 mg T9 + T10 + T11 + T12  “ 1111 
Step 4: M.W. 0.26 mmol Tag M.W.: Charge Code 
Fmoc-Gly 297.31 79 mg T13 548.80 2 mol% 0001 
Fmoc-L-Ala 311.34 83 mg T14 548.80 “ 0010 
Fmoc-D-Val 339.39 91 mg T15 534.80 “ 0100 
Fmoc-L-Pro 337.38 90 mg T16 534.80 “ 1000 
Fmoc-D-Phe 387.44 103 mg T13 + T14  “ 0011 
Fmoc-L-Tyr(tBu) 459.54 122 mg T14 + T15  “ 0110 
Fmoc-D-Ser(tBu) 383.44 102 mg T15 + T16  “ 1100 
Fmoc-L-Thr(tBu) 397.5 105 mg T13 + T15  “ 0101 
Fmoc-D-Glu(OtBu) 425.48 112 mg T14 + T16  “ 1010 
Fmoc-L-Asp(OtBu)  411.46 109 mg T13 + T16  “ 1001 
Fmoc-D-Gln(Trt) 610.71 163 mg T13 + T14 + T15  “ 0111 
Fmoc-L-Asn(Trt) 596.68 159 mg T14 + T15 + T16  “ 1110 
Fmoc-D-Lys(Boc) 468.55 124 mg T13 + T14 + T16  “ 1011 
Fmoc-L-His(Trt) 619.72 165 mg T13 + T15 + T16  “ 1101 
Fmoc-D-Arg(Pbf) 648.78 173 mg T13 + T14 + T15 + T16  “ 1111 
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14 SYNTHESIS OF THE PEGYLATED TRIPEPTIDES IN SOLUTION PHASE AND ON SOLID 
SUPPORT 
 
14.1 Synthesis of the Peptide-PEG Conjugate 2 in Solution Phase 
 
 
 
 
 
 
 
14.1.1 General Fmoc-Strategy for the Synthesis of Peptides onto Hydroxy-
Functionalized Resin Exemplified by the Synthesis of Ac-D-Val-D-
Val–OH 52 
 
 
 
 
 
2.5 g (2.50 mmol, 100-200 mesh, loading 1 mmol g-1) alkoxy-benzyl alkohol resin 
(Wang resin) were placed in a 25 ml Merrifiel vessel and washed three times with CH2Cl2 for 
1 min each. The resin was then suspended in smallest amount of dry CH2Cl2 to allow efficient 
shaking (15 ml). 2.5 g (7.50 mmol, 3 eq) Fmoc-D-Val-OH, 1.0 g (7.50 mmol, 3 eq) HOBt 
dissolved in the smallest amount possible of dry DMF (3 ml) and 30 mg (0.1 eq relative to 
the resin loading) DMAP were added and the mixture was shaken 5 min before 1.2 ml (7.50 
mmol, 3 eq) DIC were added. The mixture was shaken for 2 h and then washed three times 
with DMF and five times with CH2Cl2 for 1 min each. Semiquantitative Fmoc-test was used to 
determine the loading after the coupling.[71] If the value obtained was less than 70% the first 
residue attachment procedure was repeated. For the Fmoc-deprotection the resin was 
washed three times with DMF for 1 min each. The deprotection was achieved by shaking the 
resin with a mixture of 20% (v/v) piperidine in DMF (30 ml), first for 2 min and then for 10 
min. After washing the resin three times with DMF and five times with CH2Cl2, 1 min each, 
the resin was ready for the next coupling. Both the amino acid coupling and the Fmoc-
deprotection were closely monitored by the Kaiser test for free amines.[99] Consecutive 
coupling without DMAP and deprotection cycle employing 2.5 g (7.50 mmol, 3 eq) Fmoc-D-
Val-OH yielded H-D-Val-D-val-resin. The resin was suspended in 15 ml dry CH2Cl2 and 1.8 ml 
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(12.50 mmol, 5 eq) Et3N, before 1.2 ml (12.50 mmol, 5 eq) Ac2O were added. The mixture 
was allowed to shake for 1 h and then washed three times with DMF and five times with 
CH2Cl2 1 min each. The Kaiser test was performed to ensure the success of acetylation. 
Cleavage of the side-chain protected peptide from the solid support was achieved by treating 
the resin two times with a 95:2.5:2.5 (v/v/v) mixture of TFA/H2O/TIS (30 ml) at r.t. for 1 h 
each. The resin was then washed three times with CH2Cl2 (30 ml). After removal of the 
solvent, the oily residue was triturated with Et2O to yield a white solid which was isolated by 
decantation followed by removal of all volatiles in vacuo. 514 mg (1.99 mmol, 80%) Ac-D-
Val-D-Val-OH 52 were obtained without further purification. 
 
C12H22N2O4: 258.31 g/mol 
 
1H-NMR (500 MHz, CD3OD, 25°C): δ(ppm) = 4.34 (d, J = 5.7 Hz, 1H; HαD-Val), 4.25 (d, J = 
7.7 Hz, 1H; HαD-Val), 2.20 (dsept, J = 6.8, 5.8 Hz, 1H; HβD-Val), 2.03 (septd, J = 7.7, 6.8 Hz, 
1H; HβD-Val), 2.00 (s, 3H; -COCH3), 1.02-0.97 (m, 12H; HγD-Val). 
 
13C-NMR (125.6 MHz, CD3OD, 25°C): δ(ppm) = 173.1/172.6/171.9 (Cq; CO), 58.9 (CH; CαD-
Val), 57.5 (CH; CαD-Val), 30.3/30.3 (CH; CβD-Val), 20.9 (CH3; -COCH3), 18.3/18.1/17.4/16.9 
(CH3; CγD-Val). 
 
ESI-MS: m/z: calcd for C12H22N2O4Na: 281 [M+Na]+; found: 281, calcd for C24H44N4O8Na: 
539 [2M+Na]+; found: 539, calcd for C12H21N2O4Na: 257 [M-H]-; found: 257, calcd for 
C24H43N2O4: 515 [2M-H]-; found: 515. 
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14.1.2 Synthesis of PEG-Chain Functionalized Fmoc-D-His(Trt) 
 
 
 
 
 
 
 
1.5 g (2.42 mmol, 1.2 eq) Fmoc-D-His(Trt)-OH were preactivated with 898 mg (3.02 
mmol, 1.5 eq) DEPBT and 685 µl (4.03 mmol, 2 eq) iPr2NEt dissolved in a 1:1 (v/v) mixture 
of THF/CH2Cl2 (14 ml) for 1 min at r.t. and then added to a solution of dry CH2Cl2 (28 ml) 
containing 1.5 g (2.02 mmol, 1 eq) H2N-(OCH2CH2)≈16-OCH3 which was before melted at 
80°C in vacuo for 30 min, in order to remove traces of moisture. The reaction mixture was 
allowed to stir at r.t. for 3 h. After removal of the solvent under reduced pressure, the 
residue was purified by flash chromatography on silica gel (gradient of CH2Cl2/MeOH from 
99.5:0.5 to 98:2 (v/v)) to afford 2.6 g (1.91 mmol, 95%) Fmoc-D-His(Trt)-NH-(CH2CH2O)≈16-
CH3 53 as a white oil. 
 
C73H100N4O19: 1336.59 g/mol. 
 
TLC: MeOH/CH2Cl2 (10:90); Rf: 0.56. 
 
1H-NMR (500 MHz, CD3OD, 25°C): δ(ppm) = 7.76 (d, J = 7.6 Hz, 2H; HFmoc), 7.58 (d, J = 
7.5 Hz, 2H; HFmoc), 7.34 (m, 2H; HFmoc), 7.33 (s, 1H; HImi), 7.28-7.20/7.06-7.01 (m, 17H; 
HTrt/HFmoc), 6.75 (s, 1H; HImi), 4.41 (dd, J = 4.9, 9.1 Hz, 1H; HαD-His), 4.21 (m, J = 7.2 Hz, 
2H; CH2Fmoc), 4.07 (t, J = 7.1 Hz, 1H; CHFmoc), 3.59-3.51 (m, 64H; -NH-(CH2-CH2O)≈16-CH3), 
3.29 (s, 3H; -NH-(CH2-CH2O)≈16-CH3), 3.03 (dd, J = 4.8, 14.8 Hz, 1H; HβD-His), 2.84 (dd, J = 
9.2, 14.7 Hz, 1H; Hβ’D-His). 
 
13C-NMR (125.6 MHz, CD3OD, 25°C): δ(ppm) = 172.5 (Cq; CO), 156.6 (Cq; -CO2-), 
143.9/143.8 (Cq; CFmoc), 142.2 (Cq; CTrt), 141.2/141.1 (Cq; CFmoc), 138.0 (CH; CHImi), 136.6 
(Cq; CImi), 129.5/128.1/128.0 (CH; CHTrt), 127.6/127.0/125.1/119.8 (CH; CHFmoc), 119.7 (CH; 
CHImi), 75.4 (Cq; CTrt), 71.6/70.2/70.0/69.9/60.1 (CH2; -NH-(CH2-CH2O)≈16-CH3), 66.7 (CH2; 
CH2Fmoc), 57.8 (CH3; -NH-(CH2-CH2O)≈16-CH3), 55.18 (CH; CαD-His), 47.0 (CH; CHFmoc), 
39.3/39.1 (CH2; -NH-(CH2-CH2O)≈16-CH3) 30.8 (CH2; CβD-His, Cβ’D-His). 
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ESI-MS: m/z: calcd for C73H100N4O19Na: 1359 [M+Na]+; found 1359 (distribution of peaks 
due to the polydispersity of the PEG). 
 
 
14.1.3 Coupling of 52 and Side-Chain Deprotection 
 
 
 
 
 
 
1.8 g (1.30 mmol, 1 eq) Fmoc-D-His(Trt)-NH-(CH2CH2O)≈16-CH3 53 were dissolved in 
acetonitrile (64 ml) followed by addition of 4.1 ml (39.10 mmol, 30 eq) diethylamine and 
allowed to stir at r.t. for 1 h. After removal of all volatiles under reduced pressure, the oily 
residue was co-evaporated 3 times with n-heptane to yield the corresponding amine as a 
white oil, which was dissolved in CH2Cl2 (18 ml). 403 mg (1.56 mmol, 1.2 eq) Ac-D-Val-D-Val-
OH 52 were preactivated with 583 mg (1.95 mmol, 1.5 eq) DEPBT and 445 µl (2.60 mmol, 2 
eq) iPr2NEt dissolved in a 1:1 (v/v) mixture of THF/CH2Cl2 (12.5 ml) for 1 min at r.t. and then 
added to the solution. The reaction mixture was allowed to stir at r.t. for 4 h. After removal 
of the solvent under reduced pressure, the residue was purified by flash chromatography on 
silica gel (gradient of CH2Cl2/MeOH/Et3N from 99.5:0.5:0.1 to 96:4:0.1 (v/v/v)) to afford 1.57 
g (1.14 mmol, 88 %) Ac-D-Val-D-Val-D-His(Trt)-NH-(CH2CH2O)≈16-CH3 54 as a white oil. 
1.6 g (1.14 mmol) of the protected pegylated tripeptide 54 were dissolved in a 1:5 
(v/v) mixture of TFA/CH2Cl2 (78.5 ml) and allowed to stir at r.t. for 1 h. After removal of all 
volatiles under reduced pressure, the oily residue was triturated with cold Et2O to yield a 
white solid which was isolated by decantation followed by removal of all residual volatiles 
under reduced pressure. The TFA-salt peptide was treated with ion-exchange 
chromatography (Dowex® 1x2-400, H2O) affording 921 mg (827.2 µmol, 71%) of the 
desalted pegylated tripeptide 2, as a colorless sticky oil. 
 
C51H96N6O20: 1113.34 g/mol. 
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1H-NMR (500 MHz, CD3OD, 25°C): δ(ppm) = 7.29 (s, 1H; HImi), 6.56 (s, 1H; HImi), 4.26 (dd, 
J = 1.5, 7.8 Hz, 1H; HαD-His), 3.85 (d, J = 3.8 Hz, 1H; HαD-Val), 3.84 (d, J = 3.7 Hz, 1H; HαD-
Val), 3.31-2.94 (m, 64H; -NH-(CH2-CH2O)≈16-CH3), 3.04 (s, 3H; -NH-(CH2-CH2O)≈16-CH3), 2.73 
(dd, J = 6.2, 14.9 Hz, 1H; HβD-His), 2.63 (dd, J = 7.9, 14.8 Hz, 1H; Hβ’D-His), 1.74-1.69 (m, 
2H; HβD-Val), 1.68 (s, 3H; -COCH3), 0.62-0.57 (m, 12H; HγD-Val). 
 
13C-NMR (125.6 MHz, CD3OD, 25°C): δ(ppm) = 173.9/173.4/173.1/173.0 (Cq; CO), 136.3 
(CH; CHImi), 72.9/71.5/71.3/71.3/70.4 (CH2; -NH-(CH2-CH2O)≈16-CH3), 60.5/60.2 (CH; CαD-
Val), 59.1 (CH2; -NH-(CH2-CH2O)≈16-CH3), 54.7 (CH; CαD-His), 40.4 (CH2; -NH-(CH2-CH2O)≈16-
CH3), 31.9 (CH; CβD-Val), 31.6 (CH; CβD-Val), 30.4 (CH2; CβD-His, Cβ’D-His), 22.4 (CH3; -COCH3), 
19.8/19.7/18.9/18.8 (CH3; CγD-Val). 
 
ESI-MS: m/z: calcd for C51H96N6O20Na: 1136 [M+Na]+; found 1136 (distribution of peaks 
due to the polydispersity of the PEG). 
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14.2 General Fmoc-Strategy for the Synthesis of Peptides onto Tentagel PAP 
Resin, Exemplified by the Synthesis of Ac-D-Val-D-Val-D-His-NH-
(CH2CH2O)≈73-H 55 
 
 
 
 
 
 
 
14.2.1 Coupling onto Tentagel PAP Resin 
 
2.5 g (600.0 µmol, loading 0.24 mmol g-1) of the Tentagel PAP resin were placed in a 
clean dry Merrifield vessel and washed three times with CH2Cl2 for 1 min. The resin was then 
suspended in smallest amount dry CH2Cl2 to allow efficient shaking (15 ml). 740 mg (1.20 
mmol, 2 eq) Fmoc-D-His(Trt)-OH along with 497 mg (1.20 mmol, 2 eq) HCTU in DMF (2 ml) 
were added and the mixture was shaken for 5 min before 412 µl (2.40 mmol, 4 eq) iPr2NEt 
were added. The mixture was shaken for 2 h and then washed three times with DMF and 
five times with CH2Cl2 for 1 min each. The amino acid coupling was monitored by the Kaiser 
test. 
 
 
14.2.2 Fmoc-Deprotection 
 
The Fmoc-functionalized resin was washed three times with DMF (1 min) for 1 min 
each. The deprotection was achieved by shaking the resin with a mixture of 20% (v/v) 
piperidine in DMF (20 ml, v/v) first for 2 min and then for 10 min. After washing the resin 
three times with DMF (5 ml) and five times with CH2Cl2 (5 ml) for 1min each, the Kaiser test 
was performed to ensure the successful Fmoc-deprotection. Consecutive coupling and 
deprotection cycles employing 407 mg (1.20 mmol, 2 eq) Fmoc-D-Val-OH yielded H-D-Val-D-
Val-D-His(Trt)-PEG-resin. 
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14.2.3 Acetylation of Free Amines 
 
The resin was suspended in 15 ml dry CH2Cl2 and 412 µl (3.00 mmol, 5 eq) Et3N, 
before 287 µl (3.00 mmol, 5 eq) Ac2O were added. The mixture was allowed to shake at r.t. 
for 1 h and then washed three times with DMF (5 ml) and five times with CH2Cl2 (5 ml) for 1 
min each. 
 
 
14.2.4 Removal of Peptide from Tentagel PAP Resin 
 
The solid-supported peptide on Tentagel PAP resin was first dried in vacuo and 
treated with a 99:1 (v/v) mixture of TFA/TMSBr (30 ml) at r.t. for 6 h. Following filtration, 
the resin was then washed once with the cleavage mixture (30 ml), TFA (30 ml) and three 
times with CH2Cl2 (15 ml). Filtrates were combined and after removal of the solvent, the oily 
residue was triturated with Et2O to yield a white solid which was isolated by decantation 
followed by removal of all residual volatiles under reduced pressure. The TFA-salt of the 
peptide was treated with ion-exchange chromatography (Dowex® 1x2-400, H2O) affording, 
after concentration of the fractions, 1.6 g (451.5 µmol, 75%) of the desalted pegylated 
tripeptide 55, as a colorless sticky oil. 
 
C164H322N6O77: 3610.31 g/mol. 
 
1H-NMR (500 MHz, CD3OD, 25°C): δ(ppm) = 8.90 (s, 1H; HImi), 7.43 (s, 1H; HImi), 4.66 (ψt, 
J = 6.6 Hz, 1H; HαD-His), 4.17 (d, J = 7.6 Hz, 1H; HαD-Val), 4.10 (d, J = 7.5 Hz, 1H; HαD-Val), 
3.82-3.76/3.72-3.55/3.54-3.47/3.25 (m, 292H; -NH-(CH2-CH2O)≈73-H), 3.23 (dd, J = 6.5, 
14.9 Hz, 1H; HβD-His), 3.12 (dd, J = 6.3, 15.1 Hz, 1H; Hβ’D-His), 2.08-2.02 (m, 2H; HβD-Val), 
2.01 (s, 3H; -COCH3), 0.99-0.93 (m, 12H; HγD-Val). 
 
13C-NMR (125.6 MHz, CD3OD, 25°C): δ(ppm) = 174.4/173.7/173.6/171.7 (Cq; CO), 135.9 
(CH; CHImi), 130.5 (Cq; CImi), 119.1 (CH; CHImi), 74.0/71.7/71.5/70.6/62.5 (CH2; -NH-(CH2-
CH2O)≈73-H), 60.5/60.8 (CH; CαD-Val), 53.8 (CH; CαD-His), 40.7 (CH2; -NH-(OCH2-CH2O)≈73-H), 
31.9/31.9 (CH; CβD-Val), 28.6 (CH2; CβD-His, Cβ’D-His), 22.7 (CH3; -COCH3), 20.1/20.0/19.3/19.2 
(CH3; CγD-Val). 
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ESI-MS: m/z: calcd for C164H321N6O77: 3609 [M-H]+; found 3609 (distribution of peaks due to 
the polydispersity of the PEG). 
 
 
14.3 Synthesis of Ac-Lys-Lys-Lys-NH-(CH2CH2O)≈19-H 56 
 
(56 was obtained in analogy to the procedure described in 14.2) 
 
 
 
 
 
C58H117N7O23: 1280.58 g/mol. 
 
1H-NMR (500 MHz, CD3OD, 25°C): δ(ppm) = 4.38-4.25 (m, 3H; HαLys), 3.85-3.40/3.39-3.19 
(m, 76H; -NH-(CH2-CH2O)≈19-H), 2.98 (m, 6H; HεLys), 2.00 (s, 3H; -COCH3), 1.84 (m, 3H; 
HβLys), 1.74 (m, 3H; Hβ’Lys), 1.70 (m, 6H; HδLys), 1.49 (m, 6H; HγLys). 
 
13C-NMR (125.6 MHz, CD3OD, 25°C): δ(ppm) = 170.9/170.8/170.6 (Cq; CO), 
70.7/68.6/68.2/68.0/67.5/59.2 (CH2; -NH-(CH2-CH2O)≈19-H), 52.0/51.6/51.5 (CH; CαLys), 46.9 
(CH2; -NH-(CH2-CH2O)≈19-H), 37.8/37.6/37.3 (CH2; CεLys), 29.8/29.5/29.3 (CH2; CβLys, Cβ’Lys), 
25.2/25.2/25.0 (CH2; CδLys), 20.9/20.8/20.7 (CH2; CγLys), 19.5 (CH3; -COCH3). 
 
ESI-MS: m/z: calcd for C58H117N7O23: 1280 [M]+; found 1280 (distribution of peaks due to 
the polydispersity of the PEG). 
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14.4 Synthesis of Ac-Val-Val-Gly-NH-(CH2CH2O)≈19-H 57 
 
(57 was obtained in analogy to the procedure described in 14.2) 
 
 
 
 
 
 
C52H102N4O23: 1151.38 g/mol. 
 
1H-NMR (500 MHz, CD3OD, 25°C): δ(ppm) = 4.16 (d, J = 7.7 Hz, 1H; HαVal), 4.07 (d, J = 
7.6 Hz, 1H; HαVal), 3.91 (ψd, J = 16.7 Hz, 1H; HαGly), 3.77 (ψd, J = 16.7 Hz, 1H; HαGly), 
3.72-3.39/3.37-3.24 (m, 76H; -NH-(CH2-CH2O)≈19-H), 2.14-2.02 (m, 2H; HβVal), 1.99 (s, 3H; -
COCH3), 0.99-0.94 (m, 12H; HγVal). 
 
13C-NMR (125.6 MHz, CD3OD, 25°C): δ(ppm) = 174.2/174.0/173.5/171.4 (Cq; CO), 
73.6/71.6/71.5/71.5/71.4/71.3/70.4/62.2 (CH2; -NH-(OCH2-CH2)≈19-OH), 60.9/60.4 (CH; 
CαVal), 49.6 (CH2; -NH-(CH2-CH2O)≈19-H), 43.4 (CH; CαGly), 40.4 (CH2; -NH-(CH2-CH2O)≈19-H), 
31.7/31.5 (CH; CβVal), 22.4 (CH3; -COCH3), 19.8/19.7/19.0/18.9 (CH3; CγVal). 
 
ESI-MS: m/z: calcd for C52H102N4O23Na: 1174 [M+Na]+; found 1174 (d distribution of peaks 
due to the polydispersity of the PEG). 
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D. Listing of the Sequences Found in the Screenings of 
the Peptide Libraries 
 
Sequences found in the screening of the side-chain deprotected tripeptide library Ac-AA3-
AA2-AA1-NH(CH2)5CONH-PS with macrocyclic diketopiperazine receptors 17a, 17b, 20, 23 
and 26. 
 
Macrocyclic diketopiperazine receptor 17a: 
 
50 µmol in CHCl3, 4 days 
 
   AA3   AA2   AA1  
Ac   L-Ser   L-Pro   L-Pro 
Ac   L-Ser   D-Pro   D-Pro 
Ac   D-Gln   D-Pro   D-Pro 
Ac   D-His   D-Phe   D-Pro 
Ac   L-Phe   L-Leu   L-Asn 
 
50 µmol in CHCl3, 7 days 
 
   AA3   AA2   AA1  
Ac   Gly   D-Lys   D-Pro 
Ac   Gly   D-Val   D-Gln 
Ac   L-Val   L-Phe   L-Gln 
Ac   L-Phe   D-Phe   L-Lys 
Ac   D-Pro   L-Pro   L-Lys 
Ac   L-Pro   D-Pro   D-Lys 
Ac   L-Thr   L-Pro   D-Lys 
Ac   D-Gln   L-Pro   D-Lys 
Ac   L-Pro   D-Lys   D-Lys 
Ac   L-Ser   D-Ala   D-Lys 
Ac   L-Ala   D-His   D-Lys 
Ac   L-Arg   D-His   D-Lys 
Ac   L-Val   L-Asn   D-Lys 
Ac   L-Arg   L-Asn   L-Lys 
Ac   D-Lys   L-Ala   L-Arg 
Ac   D-Glu   D-Arg   D-Glu 
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Macrocyclic diketopiperazine receptor 17b: 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1 
Ac   D-Arg   D-Thr   D-Phe 
Ac   D-Phe   D-Thr   D-Gln 
Ac   D-Phe   L-Phe   L-Lys 
Ac   D-Phe   L-Lys   L-Phe 
Ac   D-Phe   L-Lys   D-Pro 
Ac   L-Pro   D-Phe   L-Lys 
Ac   L-Leu   D-Lys   L-Pro 
Ac   D-Lys   L-Pro   L-Val 
Ac   D-Lys   L-Pro   L-Lys 
Ac   L-Lys   L-Pro   L-Pro 
Ac   D-Pro   D-Lys   D-Pro 
Ac   D-Pro   D-Pro   L-Gln 
Ac   D-Pro   L-Pro   D-Gln 
Ac   D-Gln   L-Pro   D-Pro 
Ac   D-Ala   L-Pro   D-Pro 
Ac   D-Ser   D-Gln   D-Pro 
Ac   D-Ser   D-Lys   L-Lys 
Ac   D-Ser   D-Lys   D-Lys 
Ac   D-Arg   D-Ser   L-Gln 
Ac   D-His   L-Arg   L-Lys 
 
 
Macrocyclic diketopiperazine receptor 20 
 
50 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   L-Asp   L-Glu   L-Gln 
Ac   D-Asp   L-Pro   L-Gln 
Ac   D-Thr   L-Pro   L-Lys 
Ac   D-Pro   D-Lys   L-Pro 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-Lys   D-Pro   L-Pro  4x 
Ac   D-Thr   D-Pro   D-Pro 
Ac   L-Ala   L-Arg   L-Pro 
Ac   L-Leu   L-Pro   D-Pro 
Ac   L-Lys   D-Pro   D-Pro 
Ac   L-Lys   L-Pro   L-Pro 
Ac   L-Lys   D-Pro   D-Phe 
Ac   L-Pro   L-Pro   D-Pro 
Ac   L-Thr   D-Pro   L-Pro 
Ac   L-Thr   L-Pro   D-Pro 
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Macrocyclic diketopiperazine receptor 23 
 
30 µM in CHCl3 
 
   AA3   AA2   AA1 
Ac   L-Ala   L-Asp   D-Phe 
Ac   L-Ala   L-Asp   L-Lys 
Ac   D-Ala   L-Asp   L-Ala 
Ac   D-Gln   D-Phe   D-Val 
Ac   D-Gln   D-Phe   D-Thr 
Ac   D-Gln   D-Lys   D-Phe 
Ac   D-Gln   D-Leu   D-Phe 
Ac   D-Gln   D-Leu   L-Gln 
 
100 µM in CHCl3, 2 days 
 
   AA3   AA2   AA1  
Ac   D-Ala   L-Gln   L-Ala 
Ac   D-Gln   D-Leu   D-Leu 
Ac   D-Gln   D-Ala   D-Phe 
Ac   D-Gln   D-Ala   D-Leu  3x 
Ac   L-Leu   L-Gln   D-Ala 
 
100 µM in CHCl3, 3 days 
 
   AA3   AA2   AA1  
Ac   D-Ala   L-Gln   L-Ala 
Ac   L-Ala   L-Gln   L-Ala  3x 
Ac   L-Ala   L-Gln   D-Ala 
Ac   D-Gln   D-Val   D-Val 
Ac   D-Gln   D-Phe   D-Val 
Ac   D-Gln   D-Phe   D-Leu 
Ac   D-Gln   D-Ala   D-Leu 
Ac   L-Ala   L-Gln   D-Leu 
Ac   L-Arg   L-Gln   L-Leu 
Ac   L-Leu   L-Arg   D-Ser 
Ac   Gly   L-Gln   L-Ala 
Ac   Gly   L-Gln   D-Ala 
Ac   Gly   L-Gln   D-Phe 
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Macrocyclic diketopiperazine receptor 26 
 
100 µM in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-His   L-Lys   L-Gln 
Ac   D-Arg   L-Lys   D-Gln 
Ac   L-Arg   D-Gln   D-Leu 
Ac   L-Arg   D-Gln   L-Leu 
Ac   L-Arg   L-Pro   D-Gln 
Ac   D-Arg   D-Pro   D-Gln 
Ac   D-Arg   L-Ser   D-Gln 
Ac   L-Gln   L-Arg   D-Gln 
Ac   D-Thr   L-Gln   L-Arg 
Ac   D-Arg   L-Thr   L-Arg 
Ac   D-His   L-Ser   L-Arg 
Ac   D-Pro   L-Leu   L-Arg  2x 
Ac   L-Ser   D-Arg   L-Arg 
Ac   D-Ser   Gly   D-Arg 
 
50 µM in CHCl3 
 
   AA3   AA2   AA1 
Ac   L-Thr   D-Gln   D-Arg 
Ac   L-Lys   L-His   D-Gln 
Ac   D-Val   D-Ala   D-Gln 
Ac   L-Thr   L-Pro   D-Gln 
Ac   D-Thr   L-Asn   D-Gln 
Ac   D-Leu   D-Asn   L-Gln 
Ac   D-Gln   L-Asn   L-Gln 
Ac   D-Arg   L-Pro   L-Gln 
Ac   L-Arg   L-Arg   L-Gln 
Ac   D-Pro   D-Arg   L-Gln 
Ac   D-Gln   D-Arg   D-Pro 
Ac   D-Phe   L-Arg   L-Pro 
Ac   D-Arg   D-Asn   L-Pro 
Ac   L-Gln   L-Leu   L-Asn 
 
100 µM in CHCl3, 2 days 
 
   AA3   AA2   AA1  
Ac   L-Ser   L-Pro   L-Pro 
Ac   D-Thr   L-Pro   L-Pro 
Ac   L-Phe   D-Pro   D-Pro 
Ac   D-Glu   D-Pro   D-Pro 
Ac   D-Pro   L-Pro   D-Gln 
Ac   D-Pro   L-His   D-Gln 
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100 µM in CHCl3, 3 days 
 
   AA3   AA2   AA1  
Ac   L-Phe   L-Ser   D-Gln 
Ac   L-Thr   D-Pro   D-Gln 
Ac   D-Pro   L-Pro   L-Gln  2x 
Ac   L-Arg   L-Pro   L-Gln 
Ac   D-Pro   L-His   L-Gln 
Ac   D-Thr   L-His   L-Gln 
Ac   D-Thr   L-His   D-Gln 
Ac   L-Lys   D-Val   D-Gln 
Ac   D-Pro   L-Arg   L-Pro 
Ac   D-Asp   L-Pro   L-Pro 
 
100 µM in CHCl3, 4 days 
 
   AA3   AA2   AA1  
Ac   L-Phe   L-Val   L-Gln 
Ac   L-Arg   D-Ala   D-Gln 
Ac   Gly   L-His   D-Gln 
Ac   D-Lys   L-His   D-Gln 
Ac   D-Gln   L-His   L-Arg 
Ac   L-Thr   D-Lys   L-Arg 
Ac   L-Asn   L-Ala   L-Arg 
Ac   D-Phe   L-Ala   L-Arg 
Ac   D-Val   L-Pro   L-Arg 
Ac   D-Val   D-Pro   L-Arg 
Ac   L-Asn   D-Arg   D-Val 
Ac   L-Phe   D-Arg   D-Asn 
Ac   L-Lys   D-Arg   L-Pro 
Ac   L-Thr   D-Arg   D-Pro 
 
50 µM in CHCl3, 2 days 
 
   AA3   AA2   AA1  
Ac   L-Ser   L-Pro   L-Pro 
Ac   D-Thr   L-Pro   L-Pro 
 
50 µM in CHCl3, 3 days 
 
   AA3   AA2   AA1  
Ac   L-Thr   L-Pro   L-Gln 
Ac   D-Pro   L-Pro   L-Gln 
Ac   D-Pro   L-Pro   L-Asn 
Ac   L-Pro   D-Pro   D-Val 
Ac   L-Pro   L-His   L-Gln 
Ac   L-Pro   D-Gln   D-Ala 
Ac   L-Asp   D-Pro   D-Pro 
Ac   D-Pro   L-Pro   D-Pro  2x 
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50 µM in CHCl3, 4 days 
 
   AA3   AA2   AA1  
Ac   D-Asn   L-Phe   L-Phe 
Ac   D-Arg   L-Val   L-Arg 
Ac   D-Arg   D-Pro   L-Arg 
Ac   D-Arg   L-Gln   L-Phe 
Ac   D-Arg   D-Val   L-Gln 
Ac   L-Arg   D-Arg   L-Gln 
Ac   D-Thr   D-Pro   D-Gln 
Ac   D-Pro   D-Asn   D-Gln 
Ac   D-Pro   D-Arg   D-Gln 
Ac   L-Leu   D-Val   D-Gln 
Ac   D-His   D-Arg   D-Val 
Ac   L-Gln   D-Phe   L-Phe 
 
 
Sequences found in the assays of the side-chain deprotected tripeptide library and open-
chain diketopiperazine receptors 16, 22 and 25. 
 
Open-chain diketopiperazine receptor 16: 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-Gln   D-Ala   D-Val 
Ac   D-Gln   D-Phe   D-Ser 
Ac   D-Ala   L-Gln   L-Ser  2x 
Ac   Gly   L-Gln   L-Ser  2x 
Ac   L-Ala   L-Gln   D-Ser 
Ac   L-Leu   L-Gln   D-Ala 
Ac   L-Ala   L-Gln   L-Ala 
Ac   D-Ala   D-Phe   D-Gln  5x 
 
 
Open-chain diketopiperazine receptor 22: 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1 
Ac   D-Gln   D-Val   D-Val  3x 
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Open-chain diketopiperazine receptor 25: 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-Val   D-Val   D-His 
Ac   L-Arg   L-Leu   D-Gln 
Ac   L-Ala   L-Gln   D-Thr  2x 
Ac   D-Ala   L-Gln   Gly 
Ac   Gly   L-Gln   Gly 
Ac   L-Ala   L-Ser   L-Leu 
Ac   D-Asn   L-Asn   L-Gln 
Ac   D-Val   D-Gln   L-Asn 
Ac   Gly   L-Val   D-Phe 
 
50 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-Gln   D-Phe   D-Val  3x 
Ac   D-Gln   D-Val   D-Leu 
Ac   L-Leu   L-Gln   D-Ser 
Ac   L-Val   L-Ala   D-Asn 
Ac   Gly   D-Asn   D-Leu 
 
100 µmol in CHCl3, 2 days 
 
   AA3   AA2   AA1  
Ac   D-Pro   L-Gln   D-Pro 
Ac   D-Pro   D-Gln   D-Pro 
Ac   L-Pro   D-Leu   D-Asn 
Ac   L-Phe   D-Pro   D-Asn 
Ac   L-Ala   L-Asn   L-Phe 
Ac   D-Phe   L-Pro   L-Leu 
Ac   L-Pro   D-Pro   D-Pro 
 
100 µmol in CHCl3, 3 days 
 
   AA3   AA2   AA1  
Ac   L-Ala   L-Gln   D-Thr 
Ac   L-Ala   L-Gln   D-Ala 
Ac   L-Pro   D-Pro   D-Pro 
 
100 µmol in CHCl3, 4 days 
 
   AA3   AA2   AA1  
Ac   D-Asp   D-Phe   D-Val  2x 
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50 µmol in CHCl3, 2 days 
 
   AA3   AA2   AA1  
Ac   L-Gln   L-Pro   L-Pro 
Ac   D-Ala   L-Pro   L-Gln 
Ac   L-Pro   D-Pro   L-Gln 
Ac   D-Pro   L-Pro   D-Gln 
Ac   L-Thr   L-Pro   L-Pro 
 
50 µmol in CHCl3, 3 days 
 
   AA3   AA2   AA1  
Ac   L-Ala   L-Gln   D-Leu 
Ac   L-Ala   L-Gln   D-Ser 
Ac   L-Asp   D-Pro   D-Pro 
Ac   L-Phe   D-Pro   D-Pro 
Ac   D-Pro   L-Pro   D-Pro 
Ac   L-Pro   L-Pro   L-Gln 
 
50 µmol in CHCl3, 4 days 
 
   AA3   AA2   AA1  
Ac   L-Ala   L-Gln   D-Ser 
Ac   L-Ala   L-Gln   D-Ala 
 
 
Sequences found in the screening of the side-chain deprotected tripeptide library Ac-AA3-
AA2-AA1-NH(CH2)5CONH-PS with two-armed carbazole receptors 39 - 42. 
 
Two-armed carbazole receptor 39: 
 
50 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-Gln   D-Phe   D-Val 
Ac   D-Gln   D-Leu   D-Leu 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-Gln   D-Val   D-Phe 
Ac   D-Gln   D-Phe   D-Val  2x 
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Two-armed carbazole receptor 40: 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   L-Ala   L-Gln   D-Ala  2x 
Ac   D-Gln   D-Phe   D-Ala 
Ac   L-Ala   L-Ala   Gly 
Ac   D-Val   D-Leu   D-Leu 
 
50 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   L-Ala   L-Gln   D-Ala  3x 
Ac   D-Val   D-Ala   D-His 
Ac   D-Val   D-Leu   D-His 
 
1 mmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-His   L-Gln   D-Phe 
Ac   L-Ala   L-Gln   D-Ala 
Ac   D-Val   D-Leu   D-His 
Ac   D-Gln   D-Leu   D-Val 
Ac   D-Gln   D-Val   D-Leu 
 
 
Two-armed carbazole receptor 41: 
 
100 µmol in CHCl3, 2 days 
 
   AA3   AA2   AA1  
Ac   D-Ala   D-Val   D-His 
Ac   D-Val   D-Leu   D-His 
Ac   D-Val   D-Val   D-His  2x 
Ac   D-Val   D-Phe   D-His  2x 
Ac   D-Ala   D-Phe   D-His 
Ac   D-Leu   D-Phe   D-His 
Ac   D-Phe   D-Val   D-His  3x 
Ac   D-His   D-Ala   D-Val  2x 
Ac   D-Ala   D-Phe   D-His 
Ac   D-Gln   D-Phe   D-Phe  2x 
Ac   D-Gln   D-Phe   D-Val  3x 
Ac   D-Gln   D-Phe   D-Leu 
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50 µmol in CHCl3, 2 days 
 
   AA3   AA2   AA1  
Ac   D-Val   D-Ala   D-His 
Ac   D-Phe   D-Phe   D-His 
Ac   D-Phe   D-Val   D-His 
Ac   D-Gln   D-Phe   D-Val  2x 
Ac   D-Gln   D-Phe   D-Leu 
Ac   D-Gln   D-Val   D-Leu  2x 
Ac   D-Val   D-Ala   L-Ser 
 
50 µmol in CHCl3, 5 days 
 
   AA3   AA2   AA1  
Ac   D-Val   D-Leu   D-His 
Ac   D-Val   D-Val   D-His 
Ac   D-Gln   D-Phe   D-Val 
Ac   D-Gln   D-Val   D-Leu 
Ac   D-Gln   D-Ala   D-Val 
Ac   L-Val   L-Gln   D-Thr 
Ac   L-Val   L-Gln   D-Val  3x 
Ac   L-Ala   L-Gln   D-Ala  2x 
Ac   L-His   L-Gln   L-Ala 
Ac   L-Gln   L-Ser   D-Ser 
 
 
Two-armed carbazole receptor 42: 
 
100 µmol in CHCl3 
 
   AA3   AA2   AA1  
Ac   D-Val   D-Ala   D-His 
Ac   D-Val   D-Val   D-His 
Ac   D-Val   D-Phe   D-His 
Ac   D-Phe   D-Val   D-His 
Ac   D-Phe   D-Phe   D-His 
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